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 Résumé pour un grand public 
OGT (O-GlcNAc transferase) est une enzyme polyvalente et unique : elle peut non 
seulement fixer un sucre sur certaines protéines cellulaires (c’est la glycosylation; une 
modification de protéines, qui est la fonction normale d’OGT) mais elle est également 
capable de couper une protéine en deux. OGT est donc aussi une protéase ! 
 
La seule protéine connue, coupée par OGT s’appelle HCF-1, qui est un important régulateur 
de la division cellulaire. HCF-1 peut agir sur des gènes cibles (HCF-1 est donc un régulateur 
transcriptionnel) et assurer la progression du cycle cellulaire afin que la cellule se divise en 
deux cellules saines avec un noyau chacune. En effet, si OGT ne coupe pas HCF-1 en deux, 
HCF-1 ne peut pas effectuer correctement ses fonctions et par la suite, la cellule, au lieu de 
se diviser, devient une seule cellule –éventuellement cancéreuse– avec deux noyaux. C'est 
pourquoi, l’étude des mécanismes qui permettent à OGT de couper HCF-1 sans erreurs est 
fondamentale pour comprendre comment l’intégrité des cellules humaines est maintenue. 
 
Dans cette thèse, j’ai identifié les prérequis de la protéine HCF-1 qui permettent à OGT 
d’effectuer sa fonction de protéase. Curieusement, parmi des centaines d'acides aminés de 
HCF-1, j’en ai identifié un seul – un glutamate – qui est crucial pour la coupure. De plus, j’ai 
identifié d’autres éléments dans la protéine HCF-1 qui promeuvent une coupure efficace. En 
effet, OGT s’attache à ces éléments de HCF-1 et favorise leur glycosylation. Donc, OGT 
garantit la maturation d’HCF-1 au travers de différents mécanismes et assure l’intégrité 
cellulaire. 
 
  
   
 Abstract 
Post-translational protein modifications are crucial for many fundamental cellular and 
extracellular processes and greatly contribute to the complexity of organisms. Human HCF-1 
is a transcriptional co-regulator that undergoes complex protein maturation involving 
reversible and irreversible post-translational modifications. Upon synthesis as a large 
precursor protein, HCF-1 undergoes extensive reversible glycosylation with β-N-
acetylglucosamine giving rise to O-linked-β-N-acetylglucosamine (O-GlcNAc) modified 
serines and threonines. HCF-1 also undergoes irreversible site-specific proteolysis, which is 
important for one of HCF-1’s major functions — the regulation of the cell-division cycle. HCF-
1 O-GlcNAcylation and site-specific proteolysis are both catalyzed by a single enzyme with 
an unusual dual enzymatic activity, the O-GlcNAc transferase (OGT). HCF-1 is cleaved by 
OGT at any of six highly conserved 26 amino acid repeated sequences (HCF-1PRO 
repeats), but the mechanisms and the substrate requirements for OGT-mediated cleavage 
are not understood. In the present work, I characterized substrate requirements for OGT-
mediated cleavage and O-GlcNAcylation of HCF-1. I identified key elements within the HCF-
1PRO-repeat sequence that are important for proteolysis. Remarkably, an invariant single 
amino acid side-chain within the HCF-1PRO-repeat sequence displays particular OGT-binding 
properties and is essential for proteolysis. Additionally, I characterized substrate 
requirements for proteolysis outside of the HCF-1PRO repeat and identified a novel, highly O-
GlcNAcylated OGT-binding sequence that enhances cleavage of the first HCF-1PRO repeat. 
These results link OGT association and its O-GlcNAcylation activities to HCF-1PRO-repeat 
proteolysis. 
   
 Résumé 
La modification post-traductionnelle des protéines est cruciale pour plusieurs processus 
cellulaires et extra-cellulaires fondamentaux et contribue significativement à la complexité 
des organismes. HCF-1 chez l’humain est un co-régulateur transcriptionnel qui subit une 
maturation protéique complexe, impliquant des modifications post-traductionnelles 
réversibles et irréversibles. Après la synthèse de la protéine comme précurseur, HCF-1 subit 
une glycosylation extensive et réversible avec β-N-acetylglucosamine qui résulte en sérines 
et thréonines modifiées par O-linked-β-N-acetylglucosamine (O-GlcNAc). HCF-1 subit 
également une protéolyse irréversible et site-spécifique, importante pour une des fonctions 
majeures d’HCF1 – la régulation du cycle cellulaire. L’O-GlcNAcylation et la protéolyse 
d’HCF-1 sont toutes deux catalysées par une seule enzyme avec une peu commune double 
activité enzymatique, l’O-GlcNAc transférase (OGT). HCF-1 est clivée par OGT sur six 
séquences de répétition ultra-conservées (nommées HCF-1PRO répétitions), chacune 
consistant en 26 acides aminés. Les mécanismes et les substrats requis pour le clivage 
effectué par OGT ne sont pas compris. Dans le travail présenté ici, j’ai caractérisé les 
substrats requis pour le clivage et l’O-GlcNAcylation d’HCF-1 effectués par OGT. J’ai 
identifié des éléments clefs dans la séquence de l’HCF-1PRO répétition qui sont importants 
pour la protéolyse. De manière remarquable, un seul chaîne d’acide aminé invariant dans la 
séquence de l’HCF-1PRO répétition présente des propriétés de liaison à OGT particulières et 
est absolument essentiel pour la protéolyse. J’ai également caractérisé les substrats requis 
pour la protéolyse en dehors de l’HCF-1PRO répétition et identifié une nouvelle séquence de 
liaison à OGT très O-GlcNAcylatée qui augmente le clivage de la première HCF-1PRO 
répétition. Ces résultats lient l’association d’OGT et ses activités d’O-GlcNAcylation à la 
protéolyse d’HCF-1PRO répétition. 
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Chapter I : 
Introduction 
The availability of the human genome sequence has transformed biomedical research over 
the past decade. The analysis of the human genome has led to the identification of 
approximately 20,000 protein-coding genes. At first sight, the number of human genes 
seemed surprisingly low, given that similar numbers have been identified in organisms with 
much lower complexity, such as in the mustard weed Arabidopsis thaliana (approximately 
25,000 protein-coding genes) or in the roundworm Caenorhabditis elegans (around 20,000 
protein-coding genes). How can we assess and explain the complexity of an organism then, 
if not based on its gene count? In fact, nature has emerged with a plethora of mechanisms 
beyond the genetic code that have allowed organisms to acquire complexity and adaptability 
during evolution. One of these mechanisms — post-translational modification — is the major 
theme of this thesis. 
I.1 The human proteome is complex 
Each cell in the human body, with few exceptions, contains genetic material and the proteins 
encoded by these genes are the major players in cellular functions. The entire set of proteins 
synthesized in a cell, in a tissue or in an organism at a certain time is called the proteome. 
Unlike the genome, the makeup of a proteome can vary dramatically from cell to cell, as a 
result of controlled gene transcription patterns, alternative splicing and post-translational 
modifications. These mechanisms increase immensely the complexity of the human 
proteome. Some of these mechanisms, such as post-translational modification, carry 
biological information that is not accessible through genomic or transcriptomic approaches. 
To study protein structure and function as well as protein–protein interactions, a variety of 
techniques is available: 
• Genetic tools that allow the study of protein function, e.g. by mutational analyses. 
• Proteomics, the large-scale analysis of proteins using mass spectrometry approaches 
that allow the study of proteins and their modifications at the quantitative level. 
• X-ray crystallography, nuclear magnetic resonance (NMR) and single-particle 
electron cryo-electron microscopy (cryo-EM) are powerful techniques to study the 
structure of proteins, which can unravel how proteins interact with each other at 
atomic resolution. 
CHAPTER I 
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• Molecular dynamics, the computational modeling of biomolecular systems, which 
enable the prediction of structures and related energetics, and are especially valuable 
for molecules that are unstable and difficult to isolate. 
 
Thus, a combination of the abovementioned techniques allows the investigation of protein 
post-translational modifications. 
I.2 Post-translational modifications 
Protein activity and function are regulated at numerous levels of control, including 
transcription, mRNA processing, and translation. However, once a protein is folded into its 
tertiary structure, changes in activity and function may still be required. Nature has emerged 
with a sophisticated mechanism by which the structure and function of proteins can be 
changed rapidly in response to changes of the environment or internal conditions. These can 
occur, for example, during the development of an organism. 
Post-translational modification (PTM) is a biochemical mechanism by which amino 
acid residues of a protein are covalently modified. PTMs greatly enhance the informational 
complexity of an organism by allowing amino acid properties to be altered in response to 
internal or external conditions. More than 200 different types of PTMs have been identified to 
date (Minguez et al., 2012), with an ever-increasing number. PTMs are found in all life 
kingdoms (Beltrao et al., 2013), in Archaea, protists, bacteria and eukaryotes, demonstrating 
their ubiquitous usefulness.  
I.2.1 The different forms of PTMs 
PTMs can, in general, be categorized into reversible and irreversible (or at least not known to 
be reversible) modifications. Reversible modifications are more adaptable than irreversible 
modifications because they can be added or removed according to the needs of the 
organism. In this section, focus is given on the characteristics of reversible modifications. 
Particular emphasis on two different types of modifications, irreversible site-specific 
proteolysis and reversible O-linked glycosylation is given in sections I.3 and I.5, respectively. 
Among the most abundant experimentally observed reversible PTMs are 
phosphorylation, N-linked glycosylation, acetylation and O-linked glycosylation (Khoury et al., 
2011; Figure I-1). The most prevalent type of PTM is serine and threonine phosphorylation, 
but this number probably also reflects the large amount of phosphorylation studies 
conducted. Protein phosphorylation is a very adaptable modification due to its highly dynamic 
nature. An individual protein substrate can be phosphorylated or unphosphorylated, so that 
the population of substrate molecules contains a mixture of both molecular states. Therefore, 
the relative stoichiometry of the phosphorylated state at the steady state carries information 
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about the relative activities of the enzymes responsible for phosphorylation or 
dephosphorylation (Prabakaran et al., 2012). 
PTMs can influence protein activity, stability, interactions or localization. It is 
important to point out that PTMs do not only work in isolation but also in coordination 
(between PTMs of the same type or of different types), which creates a combinatorial 
increase of the number of possible molecular states of a protein. One well-studied example 
of a protein harboring many sites for different types of PTMs is the transcription factor p53. 
P53 exerts anti-proliferative effects in response to various types of cellular stress, including 
DNA damage (Brooks and Gu, 2003). Upon DNA damage, this protein can be modified at 
more than 20 different sites. Thus, an enormous amount of different combinations of these 
modifications is possible, so that the protein’s behavior can be altered in many ways. 
 
 
Figure I-1: Occurrence of experimentally detected post-translational modifications (PTMs), as 
curated from SwissProt by Khoury et al. (2011). (*) interchain with G-Cter in ubiquitin. 
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I.2.2 Cross-talk between PTMs 
The term “cross-talk” has been widely used to describe interplay, i.e. the dependency of two 
PTMs of different types on one another. Positive crosstalk has been defined as a condition in 
which one PTM serves as a signal for the addition or the removal of a second PTM or for the 
recognition by another protein that carries out a second modification. Negative crosstalk 
refers to direct competition for modification of a single residue in a protein, or to masking by 
one modification of a recognition site for a second one (Hunter, 2007). This concerted action 
of PTMs can occur not only on a single protein, but also between different proteins. These 
large PTM networks, usually studied by computational proteomic approaches, thus reveal the 
complexity of this interplay of protein modifications and their respective functions. 
 A well-described example for cross-talk between different types of PTMs is the N-
terminal tail of Histone H3 (Figure I-2). Histone modifications influence each other in a 
context-dependent manner to facilitate or repress transcription. 
 
 
Figure I-2: Cross-talk between PTMs of the N-terminal tail of histone H3.     
This scheme illustrates some of the possible modifications of the first 20 amino acids at the N-
terminus of histone H3. Blue and red lines show activating and inhibiting effects on the addition of 
neighboring modifications. Acetylation and methylation of lysine 4 (H3K4) and lysine 9 (H3K9) are 
mutually exclusive reactions. P, phosphoryl-; Me, methyl-, Ac, acetyl group. Figure adapted from 
Alberts (2008). 
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I.2.3 Evolution and conservation of PTMs 
To date, we know the functional role of only a small fraction of PTMs. Among the few well-
characterized modifications are phosphorylation and acetylation. Large-scale identification of 
these PTMs across multiple species, using new mass spectrometry methods, has enabled 
studies of the evolutionary conservation of the post-translationally modified residues and 
their functions. Phosphorylation and acetylation appear to be very ancient modifications and 
it has been suggested that their origins might be related to energy sensing, which have since 
then been coopted to other functions (reviewed in Beltrao et al., 2013). 
Evolutionary studies have implied that many PTM sites are unlikely to play a 
biological role and some might change position while retaining function (Beltrao et al., 2013; 
personal communication at the Gordon Conference “Post-translational modification 
Networks”, Hong Kong, 2013). Many PTM sites, such as phosphorylation sites, are weakly 
constrained and are often not conserved (Beltrao et al., 2013). Thus, the study of the 
biological importance and function of a specific PTM in a protein appears to be very 
challenging. 
I.3 Proteolysis 
Proteolysis is the cleavage of proteins by proteolytic enzymes, also called proteases. 
Proteases are a class of enzymes that hydrolyze peptide bonds in proteins. Like other 
enzymes, proteases accelerate the reaction by stabilizing the transition state (the highest 
energy point in a chemical transformation), and thus lower the activation energy for the 
reaction to occur. The active site of a protease plays a crucial role for the stabilization of the 
transition state. The active site is a region in the enzyme in which usually the primary 
substrate-binding site is localized and catalysis occurs. It acts like a template or mold for the 
substrate and binds specifically to the amino-acid residues next to the scissile bond. 
I.3.1 Human proteases 
In humans, there are more than 600 proteases, representing approximately 2% of the human 
genome (Turk et al., 2012). These proteases differ from each other remarkably in a number 
of characteristics, such as in their size, localization or specificity. To gain an overview, 
proteases are grouped into families, based on their catalytic mechanism. There are five 
mammalian protease families: aspartyl, cysteine, metallo-, serine and threonine proteases. 
During peptide cleavage, a tetrahedral intermediate is formed. The tetrahedral intermediate 
is the configuration that the substrate should have in the transition state before being 
transformed into the product; it is thus a prerequisite for peptide-bond cleavage in all types of 
proteases (Turk, 2006; Drag and Salvesen, 2010; Turk et al., 2012; Figure I-3). 
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Figure I-3: The two major proteolysis mechanisms of mammalian proteases.    
Top: A peptide bond can be hydrolyzed via two different mechanisms: Serine (Ser), cysteine (Cys) 
and threonine (Thr) proteases (on the left) stabilize a tetrahedral intermediate that involves a stable 
covalent bond to the enzyme's catalytic nucleophile (Nuc), whereas metalloproteases and aspartate 
(Asp) proteases (on the right) use a non-covalent acid–base mechanism. In covalent catalysis, the 
nucleophile of the catalytic site is part of an amino acid (usually a histidine) and in general acid–base 
catalysis, the nucleophile is an activated water molecule. Aspartate or glutamate residues, as well as 
zinc can serve as acids and bases for these classes of proteases. The arrows indicate the donation of 
a proton (H+) that leads to the release of the product C-terminal of the scissile bond. Bottom: 
Schematic representation of a peptide substrate that binds to a protease. Subsites (numbered S1-Sn) 
are surfaces in the protease that are able to accommodate a single side-chain of a substrate. The 
substrate residues they accommodate are numbered P1-Pn. Beginning from the sites on each side of 
the scissile bond, the amino acid positions are non-primed towards the N-terminus, and primed 
towards the C-terminus. Figure modified from Turk (2006). 
 
 
 
  
Protease
S5 S4 S3 S2 S1 S1 S2 S3’ ’ ’ ’
P1P2P3P4P5 P1’ P2’ P3’ P4’
S4
C-terminusPrimed positionsNon−primed positions
Scissile bond
N-terminus
Covalent catalysis
Ser, Cys, Thr protease
General acid−base catalysis
Asp, metalloprotease
C
O
NH
H+
Base −
O−
C NHNuc
H+
Base −
O−
C NHOHAcid
Acid
Peptide bond
Hydrogen bond
Covalent bond
Extension of substrate
polypeptide chain
Tetrahedral
intermediates
CHAPTER I 
 7 
In principal, there are two major routes of proteolysis: Complete proteolysis by the 
ubiquitin-proteasome system and by the lysosome, which degrade proteins into their amino 
acid building blocks, ultimately leading to the destruction of proteins (Caballero et al.). In 
addition to protein degradation related to protein turnover, a second type of proteolysis can 
occur, which is referred to as limited proteolysis, proteolytic processing or site-specific 
proteolysis (Goulet and Nepveu, 2004). Site-specific proteolysis, as this type of proteolysis is 
referred to in this work, occurs when proteins are functionally modified, in many cases 
activated or inactivated, by highly specific proteases that make a small number of cuts, often 
only one. 
I.3.2 Protease signaling 
Proteases have traditionally not been considered as signaling molecules, but this view has 
changed dramatically, as the role of site-specific proteolysis in a number of fundamental 
biological processes, for example in development (Schroeter et al., 1998; Yoshida et al., 
1996), metabolism (Brown and Goldstein, 1997), immune response (Hailfinger et al., 2011), 
apoptosis (Patel et al., 1996) or in cell cycle progression (Goulet and Nepveu, 2004; Julien 
and Herr, 2003) became apparent. The blood coagulation cascade is one of the pioneering 
examples, demonstrating how site-specific proteolysis regulates an entire cellular process 
(Davie and Ratnoff, 1964; Macfarlane, 1964). In blood coagulation, the activating signal is 
passed through a pathway by the sequential activation of protease zymogens (inactive 
enzyme precursors). Another example for protease signaling is apoptosis, programmed cell 
death, mediated by caspases, which are proteases synthesized as zymogens (procaspases). 
When activated by specific signals, the caspase cascade causes cell death to eliminate cells 
that are damaged or have become superfluous, leading, for example, to the sculpting of the 
shapes of body parts in the course of development (Berg et al., 2002). 
In contrast to other cellular signaling pathways involving reversible PTMs, such as 
kinase signaling, site-specific proteolysis is, in principle, irreversible. This unidirectional 
process is responsible to transmit important signals rapidly, such as in caspase-mediated 
apoptosis or blood coagulation, described above. Moreover, unidirectional signaling is 
particularly important in cellular processes, such as the cell cycle. 
I.3.3 Site-specific proteolysis in cell-cycle progression 
Proteases provide numerous ways of regulating cellular processes throughout the body. The 
mammalian cell-division cycle can be divided into four main phases, the G1-, S-, G2- and M-
phases (Figure I-4 A). The passage from one phase to the next is tightly regulated to ensure 
that a cell only proceeds to the next phase when cell-cycle processes in the previous phase 
were completed properly and when environmental conditions are favorable. Two examples of 
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proteins regulated by site-specific proteolysis to control cell-cycle progression are the 
trithorax group mixed-lineage leukemia (MLL) family of proteins (Hsieh et al., 2003; 
Yokoyama et al., 2004) and the herpes simplex virus (HSV) host cell factor 1 (HCF-1) (Kristie 
et al., 1995; Wilson et al., 1993; Wilson et al., 1995b; Julien and Herr, 2003), which are both 
synthesized as large precursor proteins and then undergo proteolytic processing to form non-
covalently self-associated heterodimers. 
MLL (schematically depicted in Figure I-4 B bottom) is cleaved by a threonine 
protease called Taspase1 (Hsieh et al., 2003) that undergoes autoproteolysis to generate an 
N-terminal reactive threonine, which is utilized to cleave MLL into its native dimeric form. 
MLL cleavage by Taspase1 is required to activate its SET domain for full histone 
methyltransferase activity. Additionally, MLL proteolysis is also required to promote 
progression through the cell cycle by regulation of genes expressed at the G1/S boundary 
(Takeda et al., 2006). 
HCF-1 (schematically depicted in Figure I-4 B top) is cleaved by the 
glycosyltransferase O-GlcNAc transferase (OGT; Capotosti et al., 2011), which, to date, is 
not grouped into any of the above-mentioned protease families, as it does not display 
homologies with known proteases (Capotosti and Herr, unpublished results) and its 
mechanism of cleavage has remained largely unknown (see I.6 and I.7.). Nevertheless, it is 
known that HCF-1 site-specific proteolysis promotes cell-cycle progression through M phase 
(Julien and Herr, 2003). Interestingly, it has been shown that HCF-1 and MLL interact with 
each other (Yokoyama et al., 2004) and that HCF-1 and members of the MLL family form 
multi-protein complexes to regulate G1/S-phase passage (Tyagi et al., 2007; Tyagi and Herr, 
2009). Another intriguing point is that MLL and HCF-1 are both cleaved by the same 
Taspase1 protease in Drosophila (Capotosti et al., 2007) but adopted different proteolysis 
mechanisms in vertebrates. 
Hence, although MLL and HCF-1 display many parallels regarding their activation and 
function, their proteolytic maturation pathways are very different in vertebrates, underscored 
by their respective protease recognition sequences, which are strikingly distinct (Figure I-4 
B). Protease mechanisms thus show great versatility to tightly control fundamental biological 
processes, such as the cell-division cycle. 
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Figure I-4: Human HCF-1 and MLL undergo proteolytic maturation to regulate the cell cycle.   
(A) Schematic representation of the different phases of the mammalian cell-division cycle. (B) 
Schematic representation of the human HCF-1 and MLL proteins (not to scale). HCF-1 contains a 
Kelch domain, a region enriched in basic (Basic) or acidic (Acidic) residues, a pair of fibronectin type 
2-like repeats (Fn3) and a nuclear localization signal (NLS). HCF-1 is cleaved by OGT at any of six 
centrally-located 26 amino acid-repeated sequences, called HCF-1PRO-repeats (HCF-1PRO). MLL 
contains an AT hook (binds to the minor groove of AT-rich DNA), an snRNP (small nuclear ribonucleic 
protein) homology domain, a DNA methyltransferase (DNMT) domain, plant homology domain (PHD) 
fingers, a Bromo domain, an HCF-1 binding motif (HBM), an N- (FYRN) and C- (FYRD) terminal FY-
rich self-association domains, a transcriptional activation (TA) domain, and a Su(var)3-9, enchancer-
of-zeste, trithorax (SET) domain. MLL is cleaved by Taspase1 at the Taspase cleavage sites CS1 and 
CS2. The HCF-1 and MLL protease recognition sequences are shown below their respective protein 
schematics. The arrowheads mark the cleaved peptide bonds. 
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I.4 Glycosylation 
Protein glycosylation is the covalent attachment of carbohydrates to amino acids of proteins, 
giving rise to glycoproteins. A large variety of glycoproteins has been described and found in 
essentially all living organisms, ranging from eubacteria to eukaryotes (Spiro, 2002). 
Glycosylation represents one of the most abundant forms of PTMs (Figure I-1), which can 
be, reversible or irreversible depending on the type of glycosylation. Many glycoproteins are 
soluble proteins, which are secreted from cells, as well as membrane-bound proteins (Berg 
et al., 2002). It has been suggested that the attachment of sugar residues onto proteins is 
one of the most complicated co- or posttranslational modifications that a protein can undergo 
(Spiro, 2002). In fact, there exists a large variety of glycans (monosaccharides linked via 
glycosidic bond to each other) that can be attached, either to the amide nitrogen atom in the 
side chain of asparagine (N-linked glycosylation) or to the oxygen atom in the side chains of 
serine or threonine (O-linked glycosylation) (Dalziel et al., 2014; see Figure I-5 A for 
schematics of different glycans). 
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Figure I-5: Mammalian glycan biosynthetic pathways.         
(A) Schematic representation of a variety of classes of glycans (CS: chondroitin sulphate; HA: 
hyaluronan; HAS: hyaluronan synthase; HS: heparin and heparin sulphate; KS: keratin sulphate; GM 
and GD: mono- and disialylated glycosphingolipids, respectively; OM: oligomannose). (B) Biosynthetic 
pathways of glycans in the endoplasmic reticulum (ER) and Golgi apparatus. Monosaccharide 
abbreviations: Gal: galactose; Glu: glucose; GlcA: glucuronic acid; GlcN: glucosamine; GlcNAc: N-
Acetylglucosamine; Fuc: fucose; SA: sialic acid; Xyl: xylose. From Dalziel et al. (2014). Reprinted with 
permission from AAAS. 
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I.4.1 N-linked glycosylation 
All N-linked oligosaccharides have in common a pentasaccharide core consisting of three 
mannose and two N-acetylglucosamine (GlcNAc) residues (Berg et al., 2002). Additional 
sugars are attached to this core to form the great variety of oligosaccharide patterns found in 
glycoproteins. In eukaryotes, N-glycosylation begins as a co-translational event in the 
endoplasmic reticulum (Figure I-5 B), where preassembled blocks of 14 sugars (including 
two GlcNAc, nine mannose and three glucose moieties) are first added to the nascent 
polypeptide chain. After removal of some of the glucose and mannose moieties, the protein 
is transferred to the Golgi apparatus where the glycans lose a variable number of mannose 
residues and acquire a more complex structure. The glycans are classified as “high” or “oligo” 
mannose, and as “hybrid” or “complex” (UniProt Consortium, 2015). 
I.4.2 O-linked glycosylation 
O-linked glycosylation of secreted and membrane-bound proteins takes place in the cis-Golgi 
compartment after N-glycosylation and folding of the protein (Figure I-5 B). The most 
common type of O-glycosylation in secreted and membrane-bound mammalian proteins is 
the addition of reducing terminal N-acetylgalactosamine (GalNAc). The terminal GalNAc 
residue can be further extended with galactose and/or GlcNAc resulting in eight common 
core structures, which are often further decorated with the addition of up to three sialic acid 
residues (UniProt Consortium, 2015). 
 One type of O-linked glycosylation is the addition of a single N-Acetylglucosamine 
(GlcNAc) moiety to serine or threonine residues of internal cellular proteins (O-
GlcNAcylation; Torres and Hart, 1984). In contrast to other types of O-linked glycosylation, 
this modification is reversible and highly dynamic (Wells and Hart, 2003). O-GlcNAcylated 
proteins have been found in a number of eukaryotes including plants and filamentous fungi, 
but not in S. cerevisiae or S. pombe (UniProt Consortium, 2015). Interestingly, O-
GlcNAcylated proteins can also be found in many viruses that infect eukaryotic cells (Hart et 
al., 2011). Because of the major importance of this type of modification for the present work, 
an entire section (I.5) is devoted to this topic. 
I.4.3 Biological role of glycans 
Glycans exert their biological influence in three ways (Dalziel et al., 2014): First, they have 
protective and stabilizing functions for glycoproteins. For instance, they maintain their 
solubility and ensure the correct folding of extracellular domains. Second, they can be targets 
for recognition by glycan-binding proteins, such as lectins. Third, they can alter the properties 
of the protein to which they are attached, e.g., growth factors can be modulated by the extent 
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and type of their glycosylation. Recognition by glycan-binding proteins appears to be of 
particular importance in cellular communication and cell trafficking, which is crucial for 
multicellular organisms, for example during development. In human pathologies, glycans play 
an important role in host-microbe interactions. They can be targets for exogenous pathogens 
that make use of glycans during early steps in their invasion. In fact, research focused on 
therapeutic strategies to target protein-glycan interactions is increasingly gaining attention 
(Dalziel et al., 2014). 
I.5 O-GlcNAcylation 
O-GlcNAcylation is the monoaddition of β-N-acetylglucosamine (GlcNAc) to the hydroxyl 
groups of serines or threonines of proteins in the form of O-linked- β-N-acetylglucosamine 
(O-GlcNAc). O-GlcNAcylation is a reversible PTM that was discovered just 30 years ago 
(Torres and Hart, 1984). It is the only type of glycosylation that occurs in the nucleus and in 
the cytosol and is catalyzed in animals by a single enzyme, the O-GlcNAc transferase 
(OGT). Unlike glycosylation of secreted proteins, as described in I.4, O-GlcNAc is not 
elongated or further modified. There is also a single enzyme that can remove the O-linked 
sugar moiety, called O-GlcNAcase (OGA). The addition and removal of O-GlcNAc is highly 
dynamic and sometimes referred to as O-GlcNAc cycling (Hart et al., 2007). O-GlcNAcylation 
is generally considered to be more similar to protein phosphorylation than to classical 
glycosylation in terms of dynamics, localization and function. To date, more than 600 O-
GlcNAcylated proteins have been identified, which are involved in almost all types of cellular 
processes, such as in cell-cycle regulation and division (Slawson et al., 2005; Sakabe and 
Hart, 2010; Olivier-Van Stichelen, 2012 #171), transcription (Jackson and Tjian, 1988), 
translation (Zhu et al., 2015), metabolism (Ruan et al., 2012), chromatin remodeling 
(reviewed in Hanover et al., 2012) and development (Gambetta and Muller, 2014).  
I.5.1 Cross-talk between O-GlcNAcylation and other PTMs 
As explained in I.2.2, PTMs of different types can influence each other, what is commonly 
referred to as cross-talk. Two types of O-GlcNAc cross-talk — with protein phosphorylation, 
and with protein ubiquitination, respectively — are described here. 
Serines and threonines do not only represent sites for O-GlcNAcylation, but also for 
phosphorylation, and cross-talk between these two PTMs by direct competition for 
modification sites (Figure I-6) has been described for a number of proteins, including the 
oncoprotein c-Myc (Kamemura et al., 2002) and the C-terminal domain of RNA polymerase II 
(Kelly et al., 1993; Comer and Hart, 2001). Occupancies of adjacent sites in proteins by O-
GlcNAc and O-phosphate can influence each other as well, as was shown for the tumor 
suppressor p53 (Yang et al., 2006). One method to establish the existence of cross-talk 
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between these two modifications is the inhibition of specific kinases, such as GSK-3. 
Inhibition of GSK-3 causes increased O-GlcNAcylation of many proteins (Wang et al., 2007), 
suggesting that GSK-3 phosphorylation and O-GlcNAcylation influence each other. 
Interestingly, the enzymes responsible for the modifications, OGT and GSK-3, are also 
reciprocally regulated. It has been shown that GSK-3 regulates OGT activity by OGT 
phosphorylation (Kaasik et al., 2013), demonstrating that O-GlcNAcylation and 
phosphorylation influence each other not only at the substrate level, but also at the enzyme 
level. The role and outcome of the cross-talk between O-GlcNAcylation and phosphorylation 
may vary from substrate to substrate ranging from, for example, circadian proteins (Kaasik et 
al., 2013) to cell-cycle-control proteins (Wang et al., 2010b). It is also important to point out, 
however, that O-GlcNAcylation and phosphorylation are usually substoichiometric, 
suggesting that only particular pools of a protein are cross-regulated (Hunter, 2007). Thus, 
the physiological importance of cross-talk between these two modifications should be 
evaluated carefully. 
A number of studies proposed cross-talk between O-GlcNAcylation and ubiquitination 
(reviewed in Ruan et al., 2013). Most of these studies suggest indirect cross-talk via the well-
established reciprocal regulation between phosphorylation and ubiquitination (Hunter, 2007). 
For example, O-GlcNAcylation of p53 inhibits phosphorylation and thereby reduces p53 
ubiquitination and degradation (Yang et al., 2006). More direct cross-talk between O-
GlcNAcylation and ubiquitination was observed via the deubiquitinase BRCA1-Associated 
Protein 1 (BAP1), which is involved in the promotion of protein stability. O-GlcNAcylation of 
specific proteins can lead to the recruitment of BAP1, which deubiquitinates the protein and 
thereby leads to increased protein stability. One example is the O-GlcNAcylation of the 
transcription factor PGC-1α, which is stabilized in this manner to control gluconeogenesis 
(Ruan et al., 2012). 
 
Figure I-6: Cross-talk between O-GlcNAcylation and O-phosphorylation.      
Schematic representation of O-GlcNAc and O-phosphate protein modifications. Whereas O-
GlcNAcylation is regulated by a single enzyme (OGT) that attaches N-acetylglucosamine (GlcNAc) to 
the target protein and a single enzyme (OGA) that can remove it, phosphorylation is regulated by a 
multitude of kinases and phosphatases. Figure adapted from Hart et al. (2011). 
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I.5.2 The role of O-GlcNAc in transcription 
OGT is not only found in the cytoplasm, but also in the nucleus (Torres and Hart, 1984) 
where O-GlcNAcylation occurs on nuclear and chromatin-associated proteins (Kelly and 
Hart, 1989). Remarkably, a plethora of transcription regulating proteins are O-GlcNAcylated, 
such as p53, RNA polymerase II, TFIIA, and HCF-1 (reviewed in Slawson and Hart, 2011), 
whereas several studies also reported histones to be modified (Fujiki et al., 2011; Sakabe et 
al., 2010). In the past, O-GlcNAcylation has been associated with transcriptional repression 
(Yang et al., 2002). But the majority of recent studies proposed an important role in 
transcriptional activation in mammalian cells. Both OGT and O-GlcNAcylated proteins have 
been detected at transcription start-sites (Ranuncolo et al., 2012) of promoters of actively 
transcribed genes (Deplus et al., 2013; Vella et al., 2013). The mechanism by which OGT 
influences transcription is not completely understood, but it seems that O-GlcNAcylation of 
specific target substrates is required. Among the proteins that are known to interact 
abundantly with OGT at active promoters are the ten-eleven translocation (TET) enzymes 
(Deplus et al., 2013; Vella et al., 2013) and HCF-1 (Deplus et al., 2013; Dey et al., 2012; 
reviewed in Gambetta and Muller , 2015). 
I.5.3 UDP-GlcNAc and the role of O-GlcNAc in metabolism 
OGT uses the high-energy nucleotide sugar UDP-GlcNAc to transfer the GlcNAc moiety onto 
its O-GlcNAcylation target substrates. Cellular UDP-GlcNAc concentrations fluctuate 
because de novo UDP-GlcNAc synthesis occurs through a broad-range nutrient-sensing 
pathway: the Hexosamine Biosynthetic Pathway (HBP; Marshall et al., 1991; Figure I-7). The 
HBP integrates glucose, amino acid, fatty acid, and nucleotide metabolism. As O-
GlcNAcylation by OGT depends on UDP-GlcNAc concentrations (Hart et al., 2007), this PTM 
is widely believed to reflect the intracellular metabolic status. Indeed, O-GlcNAc responds to 
cellular stimuli including insulin, nutrients and cellular stress (Vosseller et al., 2002; Zachara 
et al., 2004). Moreover, O-GlcNAcylation regulates metabolic processes, such as 
transcription during gluconeogenesis (Ruan et al., 2012), glucose production in the liver 
(Zhang et al., 2014) or lipogenesis via stabilization of the carbohydrate responsive element-
binding protein (ChREBP; Guinez et al., 2011). To conclude, protein O-GlcNAcylation and 
metabolism seem to be deeply interwoven via the HBP. Nevertheless, it is also worth noting 
that O-GlcNAcylation has been found to be crucial for processes independent of metabolism, 
such as for development (Gambetta et al., 2009; Gambetta and Muller, 2014). Given that O-
GlcNAcylation plays a role for key metabolic processes, it is not surprising that aberrant O-
GlcNAcylation has been linked to a spectrum of human diseases, including cancer, diabetes, 
cardiovascular, and Alzheimer’s diseases (reviewed in Hart et al., 2011).  
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Figure I-7: The Hexosamine Biosynthetic Pathway (HBP) and its end product UDP-GlcNAc.       
(A) Schematic depicting the major steps of the HBP. Glucose (Glc) taken up by the cell or being 
cleaved from glycogen, enters the HBP and gets activated by a number of metabolic enzymes of the 
glucose metabolism. Glutamine fructose-6-phosphate amidotransferase (GFAT) catalyzes the addition 
of a nitrogen atom from the amino acid glutamine onto the sugar, which gets subsequently acetylated, 
using AcetylCoA, which is a cofactor of fatty acid metabolism. Finally, UDP-GlcNAc is generated, 
using the high-energy nucleotide UTP of the nucleotide metabolism. (B) Chemical structure of the 
endproduct of the HBP, UDP-GlcNAc, color-coded according to the scheme in (A). 
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I.5.4 Functional mechanisms of O-GlcNAcylation 
Despite the identification of a plethora of O-GlcNAcylated proteins, relevant for many 
fundamental cellular processes, the molecular mechanism by which O-GlcNAc modulates 
protein structure and function is largely unknown. In general, O-GlcNAc modified residues 
are found on unstructured protein domains and tend to cluster (personal communication with 
Dr. Tony Hunter, The Salk Institute, USA and Trinidad et al., 2012). Apart from its role in 
cross-talk with phosphorylation and ubiquitination, described above, O-GlcNAcylation has 
been described to affect protein enzymatic activity (Yang et al., 2006), protein-protein 
interactions (Roos et al., 1997), or protein aggregation (Gambetta and Muller, 2014). More 
recently, a role for O-GlcNAc in protein stabilization of the transcription factor Sp1 during and 
after translation has been reported (Zhu et al., 2015). Hence, it is difficult to predict how O-
GlcNAc affects the molecular properties of a target protein. 
I.5.5 O-GlcNAc identification on proteins 
If O-GlcNAc modified proteins are so abundant, why has this modification remained relatively 
unrecognized for so long? A general answer to this question is that O-GlcNAc identification 
and detection methods have been limited. First, unlike O-phosphate, O-GlcNAc is uncharged 
and a single O-GlcNAc modified residue does not usually cause an apparent mobility shift on 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). Only highly O-
GlcNAcylated proteins, such as the nuclear pore protein Nup62 or HCF-1, under certain 
conditions, cause visible shifts on SDS-PAGE. Second, O-GlcNAc is often lost during protein 
isolation due to the removal of the moiety by OGA and other enzymes during cell lysis. Third, 
O-GlcNAc is difficult to detect using mass spectrometry analysis because it often occurs at 
substoichiometric levels and falls off the polypeptide during the ionization process. Recent 
advances in mass spectrometry, especially detection using the novel electron transfer 
dissociation (ETD) and higher energy collisional dissociation (HCD) techniques, make it now 
possible to identify O-GlcNAc on polypeptides with high reliability. Moreover, the recent 
development of monoclonal antibodies has also improved the ability to specifically detect O-
GlcNAcylated proteins. 
I.6 OGT 
O-GlcNAc transferase (OGT) is the glycosyltransferase that catalyzes the addition of GlcNAc 
to serines or threonines of nuclear and cytoplasmic proteins. The enzyme is highly 
conserved in eukaryotes from protozoa to fungi, plants and animals but, interestingly, a 
related gene in yeast has not been identified. An OGT homolog exists also in bacteria, but 
there are fundamental structural differences to eukaryotic OGT, particularly in the protein 
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domains that constitute the active site (Lazarus et al., 2011). OGT belongs to the GT-B 
superfamily of glycosyltransferases (Gtfs), but is strikingly different from the other members 
of this family in terms of cellular localization and biological functions. OGT contains two 
distinct regions, a superhelical tetratricopeptide repeat (TPR) domain (Lubas et al., 1997) 
and a globular catalytic domain. There are three isoforms of OGT, differing mainly in the 
number of their N-terminal TPRs (Hanover et al., 2003). The longest form contains 13.5 
TPRs and is called ncOGT for nucleocytoplasmic OGT (Figure I-8 A), another form contains 
only nine TPRs and harbors a mitochondrial target sequence (mOGT), while the shortest 
form has only 2.5 TPRs (sOGT). The physiological roles of mOGT and sOGT are not well 
understood, but a catalytic activity for mOGT has been demonstrated (Love et al., 2003). 
I.6.1 Structure of human OGT 
The human TPR domain contains 13.5 tandemly arrayed TPRs, which are themselves each 
degenerate 34-amino acid motifs (Jinek et al., 2004) that fold into paired anti-parallel α-
helices and can be found in a variety of proteins, such as protein phosphatase 5 (PP5) and 
aryl-hydrocarbon-interacting-protein-like 1 (AIPL1). TPRs have been suggested to mediate 
protein-protein interactions and intracellular localization (D'Andrea and Regan, 2003). A 
crystal structure (Figure I-8 B) of the human OGT catalytic domain and the last 4.5 TPRs 
(OGT 4.5) revealed that the catalytic domain is divided into three distinct sub-domains, called 
N-Cat and C-Cat connected to each other by a third domain, Int-D for Intervening domain 
(Lazarus et al., 2011). The catalytic domain is connected to the TPR domain via a flexible 
helix. Whereas OGT uses the cofactor UDP-GlcNAc (I.5.3) to catalyze the sugar transfer to 
the O-GlcNAcylation substrate, in crystallization conditions, UDP-GlcNAc gets hydrolyzed 
and results in UDP and GlcNAc, and the latter then dissociates from OGT. Therefore, only 
UDP is visible in this crystal structure, which binds in a pocket in the C-Cat domain, near the 
interface with the N-Cat domain. 
 Because the first two TPR units of this crystal structure overlap with the last two TPR 
units of the previously crystallized human TPR domain (Jinek et al., 2004), it is possible to 
obtain a structural model of full-length human OGT by homology modeling (Zoete 2011, 
unpublished results; Figure I-8 C). This model clearly shows the bipartite structure of OGT: 
The superhelical TPR domain and the globular catalytic domain are structurally — and likely 
also functionally — different from each other. 
I.6.2 Substrate specificity of OGT 
OGT O-GlcNAcylates a multitude of substrates, but a consensus sequence has not been 
identified to date. The prediction of O-GlcNAcylation sites by means of bioinformatics tools, 
analogous to phosphorylation site prediction, has therefore not been very successful. 
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Nevertheless, it seems that OGT displays sequence preference for proline or β-branched 
amino acids (e.g. valine or threonine) flanking the glycoside acceptor residue (Lazarus et al., 
2011; Lubas et al., 1997). The reason behind this could be that OGT prefers residues, which 
enforce an extended conformation surrounding the acceptor residue. 
A crystal structure of OGT 4.5 in complex with UDP and a 14-mer peptide substrate 
of casein kinase II (CK-II) (Lazarus et al., 2011) showed that the CK-II peptide binds in a cleft 
between the TPR domain and the catalytic domain, and forms contacts to residues in the 
catalytic domain and to UDP via its amide backbone. Moreover, the cleft is filled with ordered 
water molecules, which suggests that this adaptable interface can bind to a range of 
substrates containing different amino acids with different side-chain sizes and polarities, 
partially explaining how OGT can bind to so many different substrates without a consensus 
motif. It has also been suggested that OGT targets its substrates via its TPR domain, but 
how specificity may be achieved is still unclear. A possibility is the formation of multi-protein 
complexes, in which OGT can bind to adapter proteins that will recruit OGT to its O-
GlcNAcylation targets. More generally, available TPR-ligand protein structures of other TPR 
containing proteins indicate that binding specificity cannot be attributed to a single property. 
Rather, specificity could be achieved by a combination of factors, such as hydrophobic 
pockets, residue type, charge and electrostatics between the TPRs and the ligand (Zeytuni et 
al., 2012). 
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Figure I-8: Structure of human OGT.            
(A) Schematic of the full-length human nucleocytoplasmic OGT (ncOGT) domain architecture (not to 
scale). The tetratricopeptide repeat (TPR) domain with 13.5 repeats is colored blue. The catalytic 
domain is divided in three sub-domains, the N-terminal domain (N-Cat, purple), the intervening domain 
(Int-D, green) and the C-terminal domain (C-Cat, red). (B) Crystal structure (PDB code 3PE3, (Lazarus 
et al., 2011)) of human OGT with 4.5 TPRs (OGT 4.5) in complex with UDP. Color-coding as in the 
scheme in (A). (C) Surface representation of human ncOGT in complex with UDP, modeled after the 
two structures in Jinek et al. (2004) and Lazarus et al. (2011) (PDB codes 1W3B and 3PE3, 
respectively) by Dr. Vincent Zoete. The entire catalytic domain is colored in beige and the TPR domain 
is colored in blue. 
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I.6.3 Mechanism of O-GlcNAcylation 
The mechanism of the glycosyltransferase reaction by OGT is not fully understood. OGT is 
proposed to use an “ordered bi-bi” mechanism (Figure I-9; Lazarus et al., 2012). In enzyme 
kinetics, “bi-bi” according to the Cleland notation (Cleland, 1967), stands for a multisubstrate 
enzyme reaction involving two substrates (first bi) and two products (second bi). UDP-
GlcNAc is proposed to bind first in the catalytic domain, followed by the peptide with the 
glycoside acceptor residue. The glycosyltransferase reaction causes UDP-GlcNAc 
hydrolysis, which yields the leaving group UDP that remains transiently bound to the catalytic 
domain. The GlcNAc moiety is transferred to the peptide (glycopeptide), which is 
subsequently released from the complex. In the last step, the leaving group UDP also 
dissociates from OGT, setting the stage for a new reaction cycle. Thus, UDP-GlcNAc is a 
cosubstrate, but is referred to in this work by the more general term “cofactor”. 
 There have been numerous attempts in the past to identify a so-called general 
catalytic base in OGT that could play a key role in the glycosyltransferase mechanism. The 
catalytic base would be needed to accept the proton from the serine or threonine acceptor 
hydroxyl. The GlcNAc moiety could then be transferred to the reactive serine or threonine, 
following the break of the bond between GlcNAc and UDP (the bond between the anomeric 
carbon atom and the phosphate). Genetic analysis, however, showed that substitution of the 
basic amino acids in close proximity to the acceptor residue by other amino acids did not 
inhibit the reaction completely. Based on new OGT structures, the best candidates His 558 
and His 498 in the OGT catalytic domain seem to be too far away to execute this function 
(Lazarus et al., 2012; Schimpl et al., 2012). It has been proposed that interactions between 
UDP-GlcNAc and the protein substrate facilitate catalysis (active substrate participation; 
Lazarus et al., 2012). Indeed, in the resolved structural complex, the contact interface 
between UDP-GlcNAc and the peptide substrate is extensive. Another proposal is that the α-
phosphate of UDP-GlcNAc (Figure I-7 B) might act as a general base (Schimpl et al., 2012). 
 
 
Figure I-9: Proposed ordered bi-bi kinetic mechanism for OGT O-GlcNAcylation.   
From left to right: OGT binds first the cofactor UDP-GlcNAc, and then the acceptor peptide. After the 
glycosyl reaction has occurred, the O-GlcNAcylated peptide and UDP get sequentially released and a 
new reaction cycle can begin. Schematic modified from Lazarus et al. (2012). 
  
OGT OGT
UDP−GlcNAc peptide glycopeptide UDP
OGT UDP−GlcNAc pep
pepocylg−cANclG−PDUTGO
OGT UDP
OGT
OGT
OGT
OGT
PDUTGO
Ternary substrate complex
Ternary product complex
CHAPTER I 
 22 
I.7 HCF-1 
HCF-1 is a transcriptional co-regulator, and evolutionary conserved in animals. It was first 
discovered as a human host-cell factor for herpes simplex virus (HSV) infection, in which 
HCF-1 is required to stabilize the formation of the VP16 induced-complex, a multiprotein 
transcriptional complex, which activates HSV immediate-early gene transcription (Figure 
I-10; Gerster and Roeder, 1988; Wysocka and Herr, 2003). Subsequent studies have shown 
that HCF-1 is an important regulator of cell proliferation and chromatin modification states 
(Goto et al., 1997; Wysocka et al., 2003). To become fully active, HCF-1 must undergo 
maturation via post-translational modification, which is the subject of this study.  
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Figure I-10: The VP16 induced complex (VIC) and the viral life cycle of Herpes simplex virus 
(HSV).               
(A) The VIC upon HSV infection. The viral protein VP16 binds to HCF-1 and is primed for association 
with Oct-1 on ‘TAATGARAT’ regulatory elements present in each immediate-early (IE) gene promoter. 
Oct-1 associates with DNA via the DNA-binding domain POU (Herr et al., 1988). (B) Schematic 
representation of the HSV life cycle. The nature of the infected cell dictates the course of infection. 
Upon primary infection, HSV enters the lytic cycle, which leads to subsequent infection of neurons. In 
lytic infection, the VIC activates transcription of HSV IE genes, resulting in a cascade of gene 
transcription, in which early and late genes are transcribed. During latent infection, there is little viral 
gene transcription. Nevertheless, the virus can be reactivated by stimuli such as stress or UV 
exposure, which causes renewed episodes of lytic infection at the site of primary infection. 
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I.7.1 HCF-1 serves as a binding platform for proteins involved in transcription 
A schematic of the human full-length HCF-1 pre-mature protein is shown in Figure I-11 A. 
HCF-1 is processed at a series of six centrally-located 26-amino-acid repeats, called HCF-
1PRO repeats (HCF-1PRO) (Wilson et al., 1993; Kristie et al., 1995; Wilson et al., 1995b) to 
generate two subunits called HCF-1N and HCF-1C, which remain self-associated. HCF-1 
contains several distinguishing regions including (from N-to-C termini): (i) a Kelch domain, a 
protein interaction domain named after of its similarity to the Drosophila protein Kelch, (ii) a 
SAS1N “self-association” element for association with the C-terminal HCF-1 subunit, (iii) 
regions with overall basic (called Basic) and acidic (called Acidic) character, separated by the 
HCF-1PRO repeats, (iv) a SAS1C element containing two fibronectin type 3 (Fn3) repeats 
involved in HCF-1 self-association with the N-terminal subunit (Park et al., 2012), and (v) a 
carboxyterminal nuclear localization signal (NLS).  HCF-1 does not bind DNA by itself, but it 
can bind to chromatin via association of its conserved Kelch domain with DNA binding 
proteins, such as transcription factors (Wysocka et al., 2001b). One important cellular 
function of HCF-1 is the coordination of the passage through the cell cycle (Goto et al., 1997; 
Julien and Herr, 2003) by association with transcriptional activators or repressors, for 
example the E2F transcription factor family (Tyagi et al., 2007) and several histone modifying 
enzymes, such as the mixed lineage leukemia (MLL) histone methyltransferase (Yokoyama 
et al., 2004) or Sin3 histone deacetylase (Wysocka et al., 2003). Although HCF-1 can 
selectively interact with transcription activating or repressing enzymes, chromatin 
immunoprecipitation of HCF-1 complexes revealed that it is present at approximately 5,000 
active promoters in HeLa cells (Michaud et al., 2013). 
HCF-1 not only interacts with transcriptional regulators, but also with a number of 
post-translational modification enzymes, involved in chromatin regulation, such as the 
deubiquitinase BAP1 (Machida et al., 2009; Misaghi et al., 2009; Yu et al., 2010), the protein 
phosphatase PP1 (Ajuh et al., 2000) or the glycosyltransferase OGT (Wysocka et al., 2003). 
Thus, HCF-1 acts as a binding platform for a variety of proteins involved in the control of 
transcription or in the control of chromatin states. The direct functional outcome of these 
interactions probably depends largely on the choice of HCF-1 binding-partner proteins in 
these protein complexes. 
I.7.2 HCF-1 proteolytic processing is important for proper cell-cycle progression  
HCF-1 is a protein that is both proteolytically processed and O-GlcNAcylated by the 
glycosyltransferase OGT (Capotosti et al., 2011). O-GlcNAcylation can be detected 
predominantly on HCF-1N (Capotosti et al., 2011; Daou et al., 2011), whereas proteolysis 
occurs at any of the six HCF-1PRO repeats. The resulting heterogeneous collection of N- and 
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C-terminal subunits remains stably, but non-covalently self-associated (Wilson et al., 1995b) 
and regulates different phases of the cell-division cycle (Julien and Herr, 2003; Figure I-11 
B). While HCF-1N is required for G1-to-S-phase transition via association with E2F 
transcription factors and MLL proteins (Tyagi et al., 2007; Tyagi and Herr, 2009), HCF-1C is 
important for proper M-phase progression via an unknown mechanism. Intriguingly, 
proteolytic processing is necessary to activate the functions of the C-terminal subunit during 
M phase, whereas the N-terminal subunit remains functional in the absence of proteolytic 
processing (Julien and Herr, 2003). A defect in proteolytic processing results in cytokinesis 
defects and cells that cannot properly exit from the M phase and thus contain two (or more 
nuclei), which is commonly referred to as “binucleation phenotype”. Binucleated cells are 
common in cancerous cells, such as HeLa cells, and are therefore a hallmark for cancer, 
suggesting that HCF-1 function is important to inhibit cancer progression. 
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Figure I-11: HCF-1 maturation and regulation of the human cell-division cycle.      
(A) Schematic representation of the human HCF-1 protein (the different domains are described in the 
text). Upon synthesis, HCF-1 undergoes proteolysis (depicted as scissors) and O-GlcNAcylation 
(depicted as blue squares) catalyzed by OGT. This maturation process results in hyperglycosylated N-
terminal subunits (HCF-1N) and hypoglycosylated C-terminal subunits (HCF-1C), which remain stably 
but non-covalently associated via self-association elements (SAS1N and SAS1C). The different 
subunits regulate distinct phases of the cell-division cycle: HCF-1N regulates G1 to S-phase 
progression and HCF-1C regulates the passage through M phase. 
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I.7.3 OGT catalyzes site-specific proteolysis of the HCF-1PRO repeats 
The human HCF-1 protein contains six HCF-1PRO repeats that are not only highly conserved 
in vertebrate species, but also nearly identical within the HCF-1 protein (Figure I-12 A and B). 
The HCF-1PRO repeats each contain 26 amino acid residues, of which a core sequence of 20 
residues displays a remarkably high conservation between species and a high identity 
between the six repeats (Wilson et al., 1993; Kristie et al., 1995) . A stretch of 21 out of 26 
residues is recognized and cleaved by OGT (Wilson et al., 1995b; Capotosti et al., 2011). 
This sequence was further divided into two sub-regions of particular importance for cleavage: 
A cleavage region consisting of seven amino acids surrounding the cleavage site at 
glutamate at position 10 (E10) and a threonine region, consisting of a stretch of threonine 
residues C-terminal of the cleavage region (Capotosti et al., 2011). Recently, the HCF-1PRO-
repeat cleavage products have been examined in vitro by mass spectrometry and the scissile 
bond mapped between cysteine 9 (C9) and E10 of the repeat (Lazarus et al., 2013; see 
Chapter II and Appendix). Interestingly, the glutamate at the cleavage site (E10) forms in 
vitro an N-terminal pyroglutamate (an uncommon amino acid derivative; the cyclic lactam of 
glutamic acid) after cleavage. The physiological role of N-terminal pyroglutamate of HCF-1 
polypeptides, if any, is not understood. 
The discovery that the glycosyltransferase OGT contains proteolytic activity was 
unexpected. OGT, as mentioned in I.3.3, has not been grouped into any of the known 
protease families yet, as OGT’s catalytic mechanism for proteolysis has until recently been 
unknown. Furthermore, to date, HCF-1 has remained the only known substrate for OGT-
mediated proteolysis. The HCF-1PRO repeats represent an unusually large sequence required 
for proteolysis, and it had therefore been proposed that the underlying catalytic mechanism 
for cleavage would be unusual (Wilson et al., 1995b; Capotosti et al., 2007). This hypothesis 
is underscored by the fact that, in a screen of over 1000 compounds to inhibit the proteolytic 
activity of HCF-1, only one compound was found, and it showed effective inhibition only at 
very high concentrations (Capotosti, Bogyo and Herr, unpublished results). Interestingly, it 
has been shown that a general inhibitor of O-GlcNAcylation, alloxan, inhibits HCF-1 
proteolysis and the cofactor for O-GlcNAcylation, UDP-GlcNAc, is required for proteolytic 
activity (Capotosti et al., 2011). It has thus been suggested that OGT’s O-GlcNAcylation 
activity is important for HCF-1 proteolysis. 
 OGT has a bipartite protein structure (see I.6.1) and the HCF-1PRO repeats display a 
bipartite sequence architecture. This analogy is intriguing and suggested that OGT interacts 
with the HCF-1PRO-repeat threonine region via its TPR domain to promote binding, whereas 
the OGT catalytic domain interacts with the HCF-1PRO-repeat cleavage region to promote 
proteolysis (Capotosti et al., 2011; Figure I-12 C). Indeed, consecutive alanine substitutions 
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of four conserved threonines within the threonine region disrupted OGT–HCF-1 interactions 
in co-immunoprecipitation assays (Capotosti et al., 2011), supporting the abovementioned 
model.  
 
Figure I-12: The HCF-1PRO repeats and the proposed bipartite interaction with OGT.                  
(A) Schematic representation of the human HCF-1 protein. (B) Sequence alignment of the six human 
HCF-1PRO repeats. The arrowhead indicates the cleaved peptide bond between cysteine at position 9 
(C9) and glutamic acid at position (E10). The cleavage region and the threonine region have been 
defined as described in the text. (C) HCF-1PRO-repeat sequence conservation represented as 
WebLogo, modified from (Capotosti et al., 2011). Alignment of all HCF-1PRO repeats from six different 
species, human, mouse, Xenopus tropicalis, X. laevis, Fugu rubripes, and Danio rerio. (C) Proposed 
bipartite interaction mode of the OGT catalytic domain with the HCF-1PRO-repeat cleavage region and 
of the OGT TPR domain with the HCF-1PRO-repeat threonine region (not to scale). OGT model as in 
Figure I-8 C. 
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I.7.4 Functional versatility of OGT–HCF-1 interactions 
OGT displays functional versatility regarding its substrate HCF-1. First, HCF-1 is one of the 
main nuclear OGT-binding partners and found to interact with OGT in a number of unbiased 
OGT interaction assays (Deplus et al., 2013). Indeed, approximately 50% of nuclear OGT is 
associated with HCF-1 (Daou et al., 2011), and Wilson et al. (1995b) showed that cleavage 
occurs predominantly in the nucleus. OGT and HCF-1 co-occupy active promoters (Dey et 
al., 2012), and form multiprotein complexes together, for example, with BAP1 and PGC-1α 
(Ruan et al., 2012) to control gluconeogenesis. 
Second, O-GlcNAcylation of HCF-1 is extensive within the N-terminal subunit and 
modified sites in this subunit have been mapped by mass spectrometry (Wang et al., 2010b; 
Capotosti et al., 2011; Myers et al., 2013). Yet, the role of HCF-1 O-GlcNAcylation, if any, for 
HCF-1 proteolysis or for its cellular function is still unknown. 
Third, it has been shown that HCF-1 proteolysis per se is not sufficient to activate 
HCF-1 functions during the cell cycle because a replacement of the HCF-1PRO repeats by 
Taspase1 cleavage sites leads to effective proteolysis, and yet an HCF-1 mutant 
binucleation phenotype. It thus seems that OGT mediates HCF-1 maturation in a way that 
allows HCF-1 to regulate proper cell-cycle progression through the activation of HCF-1C 
(Capotosti et al., 2011). Moreover, OGT — like HCF-1 — plays important roles for cell-cycle 
progression during M phase and G2/M-phase transition (Slawson et al., 2005; Fong et al., 
2012; Sakabe and Hart, 2010; Wang et al., 2010b). Thus, HCF-1–OGT interactions are 
abundant and may regulate a variety of cellular processes. 
I.7.5 Evolution of HCF-1 site-specific proteolysis 
From insects to humans, HCF proteins undergo proteolytic maturation using different 
mechanisms (Capotosti et al., 2007; Figure I-13). Interestingly, as mentioned earlier in 
section I.3.3, it has been shown that Drosophila HCF is cleaved by Taspase1, the protease 
that cleaves MLL (Capotosti et al., 2007), whereas vertebrate HCF-1 proteins are cleaved by 
OGT. In fact, only vertebrate HCF-1 proteins contain HCF-1PRO repeats, while retaining a 
vestigial, non-functional, invertebrate Taspase1 site, suggesting that there has been a switch 
during evolution, from Taspase1-mediated HCF cleavage to OGT-mediated HCF cleavage 
(Capotosti et al., 2007). It thus appears that MLL and HCF-1 proteolytic maturation pathways 
have diverged during evolution with the emergence of vertebrates (Capotosti et al., 2007). 
The reason for this is unclear but it is thought that the HCF-1PRO repeats, which all lie on one 
large exon and can nowhere else be found, were integrated into the vertebrate genome by a 
viral transposition event.  
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Figure I-13: The HCF protein family in vertebrates and invertebrates.       
Conserved protein domains are shown in the same color code. HCF proteins in insects contain 
functional Taspase1 cleavage sites and undergo proteolytic maturation via Taspase1-mediated 
cleavage. Vertebrate HCF-1 proteins contain HCF-1PRO repeats and undergo proteolytic maturation 
via OGT-mediated cleavage, while retaining a vestigial, non-functional, invertebrate Taspase1 site. 
Hs: Homo sapiens, Mm: Mus musculus, Fr: Fugu rubripes, Dm: Drosophila melanogaster, Ce: 
Caenorhabditis elegans, Sm: Schmidtea mediterranea, Nv: Nematostella vectensis, Aq: 
Amphimedeon queenslandica. Figure by courtesy of Diego Gonzales, Viviane Praz and Shilpi 
Minocha (former and present members of the Herr laboratory). 
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I.7.6 HCF-1 in human disease 
HCF-1 is an important regulator of cell division and proliferation (see above) but also appears 
to have important roles in differentiation and development (Herr laboratory, unpublished 
results). Apart from the role of the HCF-1 protein in human HSV infection (Figure I-10), the 
HCF-1 protein and the gene (HCFC1) have been implicated in a number of human diseases. 
HCF-1 levels correlate with proliferative capacity, and the highest levels are found in 
rapidly dividing cells such as transformed cell lines (Wysocka et al., 2001b). It has thus been 
proposed that differentially regulated HCF-1 could play a role in the development of cancer. 
Indeed, HCF-1 over-expression has been associated with human cancer (Glinsky et al., 
2005). Three routes via which HCF-1 could be involved in cancer are the interactions with 
BAP1, E2F1 or Thanatos-associated protein 11 (THAP11). BAP1 is a putative tumor 
suppressor in renal carcinoma. The ability of BAP1 to regulate cell proliferation seems to be 
mediated, at least in part, via interaction with HCF-1 and E2F family members and disruption 
of BAP1–HCF-1 interactions have been shown to impair BAP1’s ability to suppress cell 
proliferation (Pena-Llopis et al., 2012; Carbone et al., 2013). HCF-1–E2F1 association has 
been implicated in E2F1-induced apoptosis, and a potential role of HCF-1 in oncogenesis but 
also tumor suppression has been proposed (Tyagi and Herr, 2009). Another study has 
involved HCF-1 in human colorectal cancer. In a colorectal cancer cell line, HCF-1–THAP11 
interactions are important to regulate transcription and cell growth (Parker et al., 2012).  
 HCFC1 resides on the human X chromosome. Missense mutations in the HCF-1 
Kelch domain have been associated with an X-linked cobalamin disorder, probably by 
transcriptional dysregulation of genes involved in cobalamin metabolism (Yu et al., 2013). 
Furthermore, HCF-1 is implicated in nonsyndromic intellectual disability, a form of mental 
retardation inherited in an X-linked manner. This disease is caused by a regulatory mutation 
in the HCFC1 gene within its 5’ untranslated region (UTR) and within the sequence encoding 
the Kelch domain (Huang et al., 2012). 
 The role of HCF-1 maturation in disease is not understood, but it is clear that HCF-1 
proteolysis is required to regulate the cell cycle and to maintain cell integrity to avoid the 
formation of potentially cancerous cells. It may therefore only be time before human 
mutations are shown to affect HCF-1 proteolytic processing. 
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I.8 Conclusions 
There are, in principle, two types of post-translational modifications (PTMs) that enhance the 
complexity of an organism: Reversible modifications, being highly adaptable, and irreversible 
modifications, enabling the transmission of important cellular signals or the destruction of 
proteins. The human HCF-1 protein is an important regulator of the cell-division cycle and is 
subject to both reversible and irreversible PTMs. Interestingly, there is a single enzyme, the 
O-GlcNAc transferase (OGT), which catalyzes both types of PTMs of HCF-1: Site-specific 
proteolysis and O-GlcNAcylation. The catalytic mechanism for OGT-mediated HCF-1 
proteolysis is not understood and the mechanism for OGT O-GlcNAcylation remains unclear.  
Whereas site-specific proteolysis is required to activate HCF-1 functions during the 
cell-division cycle and thereby ensures the maintenance of cell integrity, the role of O-
GlcNAcylation for proteolysis or for HCF-1 cellular functions is unknown. To date, HCF-1 is 
the only protein identified as a substrate for OGT’s proteolytic activity, but the substrate 
requirements remain ill-defined.  
I.9 Thesis scope 
The objective of this thesis is the identification of HCF-1 substrate requirements for OGT-
mediated proteolytic processing, with the long-term goal to shed light on the OGT cleavage 
mechanism. 
 
My specific goals in this thesis are: 
 
1. To understand how OGT induces cleavage of the HCF-1PRO repeat by an analysis of 
substrate requirements within this sequence (Chapter II).  
 
2. To identify and characterize potential HCF-1 elements outside of the  
HCF-1PRO repeat that may influence or regulate proteolysis (Chapter III). 
 
3. To investigate the potential role of HCF-1 O-GlcNAcylation in HCF-1 proteolysis, 
comprising an analysis of O-GlcNAcylated HCF-1 sequences (Chapter IV). 
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Chapter II :  
HCF-1
PRO
-repeat requirements for 
OGT-mediated proteolysis 
Introduction 
The human HCF-1PRO repeats (Figure I-12 B) represent unusually large protease recognition 
sequences and the mechanism by which OGT cleaves them has remained obscure. 
Capotosti et al. (2011) identified key elements required for OGT-mediated cleavage: (i) 
ncOGT (Figure I-8), (ii) a sequence of 21 amino acids within the HCF-1PRO repeat comprising 
the cleavage and threonine regions, and (iii) the donor for O-GlcNAcylation, UDP-GlcNAc 
(Figure I-7). Within the HCF-1PRO repeat, the glutamate at position 10 (E10) was proposed to 
associate with the OGT catalytic center for cleavage due to its particular OGT-association 
properties: an E10A mutation causes enhancement of HCF-1–OGT binding with respect to 
wild-type E10 (Capotosti et al., 2011). In addition, the model of a bipartite interaction 
between OGT and the HCF-1PRO repeat (Figure I-12 C) is intriguing and laid the foundation 
for further investigations.  
In this chapter, I present a mutational analysis of the HCF-1PRO repeat and 
characterize interactions with OGT that promote HCF-1 proteolysis. One part of this project 
was developed in collaboration with Dr. Vaibhav Kapuria (postdoc in the Herr laboratory) and 
the laboratory of Dr. Suzanne Walker (Harvard Medical School, Boston, USA) and Dr. David 
Vocadlo (Simon Fraser University, Canada). Our publication “HCF-1 is cleaved in the active 
site of O-GlcNAc transferase” (Lazarus et al., 2013) is attached in the Appendix of this thesis 
(or accessible in Pubmed, PMID: 24311690). Other parts of the project were developed in 
collaboration with Dr. Vincent Zoete and Dr. Ute Roehrig (both at Swiss Institute of 
Bioinformatics, Lausanne, Switzerland). 
Results 
The results in this chapter can be summarized in six main conclusions: (i) intact UDP-GlcNAc 
is required for HCF-1PRO-repeat cleavage, (ii) the E10 side-chain is essential for HCF-1PRO-
repeat cleavage, (iii) the HCF-1PRO repeat adopts the conformation of an O-GlcNAcylation 
substrate in the OGT active site, (iv) the E10 side-chain strains interactions in the OGT–
UDP-GlcNAc–HCF-1PRO-repeat complex, (v) the HCF-1PRO-repeat cleavage and threonine 
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regions are separated from each other by a flexible linker, called Hinge region and (vi) the 
threonine region is important for HCF-1PRO-repeat–OGT association . 
II.1 HCF-1PRO-repeat proteolysis requires OGT and intact UDP-GlcNAc 
The six HCF-1PRO repeats in the human HCF-1 protein represent functionally equal cleavage 
sites for OGT. To study OGT-mediated HCF-1 proteolysis in vitro, Capotosti et al. (2011) 
designed a small GST-fusion HCF-1 precursor construct called HCF-1rep1 that comprises 
HCF-1 residues 867-1071, spanning the first HCF-1PRO repeat (Figure II-1). This construct 
contains a small portion of the HCF-1 Basic region containing several identified O-
GlcNAcylation sites (Capotosti et al., 2011) and an uncharacterized stretch of amino acids 
surrounding HCF-1PRO repeat 1. HCF-1rep1 also holds a C-terminal six-fold His-tag for 
protein purification. As in vitro transcription and translation of this construct resulted — next 
to the synthesis of the protein of interest — in a number of protein degradation products and 
premature truncated proteins (data not shown), I synthesized the HCF-1rep1 substrate in E. 
coli and purified the translated protein by Nickel-affinity chromatography. The bacterial 
synthesis and purification of the substrate allowed the study of HCF-1PRO-repeat proteolysis 
without the presence of UDP-GlcNAc or OGT, as is the case in in vitro transcription and 
translation systems (e.g. rabbit reticulocyte lysate). 
To establish an in vitro HCF-1–OGT cleavage assay with bacterially purified HCF-1 
substrates and OGT enzyme, I titrated human ncOGT (from here on called OGT unless 
stated otherwise; Figure II-2 A) or UDP-GlcNAc (Figure II-2 B) against fixed concentrations 
(3 µM) of the GST–HCF-1rep1 substrate. The reaction was incubated in cleavage buffer 
(Capotosti et al., 2011) for 16 h at 37°C and the resulting reaction products were resolved by 
SDS-PAGE, followed by immunoblotting. Antibodies directed towards the N-terminal GST-
tag were used to detect the uncleaved precursor protein as well as the N-terminal cleavage 
product. The intensities of the protein bands on the immunoblots were analyzed and the 
cleavage efficiencies (percentage of cleaved fragment to total GST–HCF-1rep1 protein in 
one sample) quantified. These titration experiments revealed that, for optimal cleavage 
conditions, OGT concentrations of 600 nM (Figure II-2 A) and UDP-GlcNAc concentrations of 
0.1 mM (Figure II-2 B) were required. In this in vitro cleavage assay system, maximum 
cleavage of only 40-50% could be observed. In all subsequent experiments presented in this 
study, I used 600 nM OGT and 1 mM UDP-GlcNAc, unless stated otherwise, to reach the 
highest cleavage efficiency possible. The reaction products from the titration experiments 
described above (Figure II-2 A and B) were also examined for O-GlcNAcylation by 
immunoblot using an antibody directed towards O-GlcNAc modified serines or threonines 
(data not shown). O-GlcNAcylation of uncleaved HCF-1rep1 protein and N-terminal cleavage 
products occurred at low concentrations of OGT (76 nM) and UDP-GlcNAc (1 µM), 
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respectively. The α-O-GlcNAc antibody used is, even at low concentrations, highly sensitive, 
and thus saturation of the antibody signal is reached in the majority of HCF-1rep1 cleavage 
reactions. For this reason, quantification of HCF-1rep1 O-GlcNAcylation is not shown. 
The experiments above show that both OGT and UDP-GlcNAc are required for HCF-
1PRO-repeat proteolysis, consistent with previously obtained results (Capotosti et al., 2011). 
Next, I investigated whether HCF-1rep1 could still be cleaved when the cofactor UDP-
GlcNAc in the in vitro cleavage assay was substituted by the nucleotide UDP or by an analog 
called UDP-5SGlcNAc, a kind gift of Dr. David Vocadlo. UDP-5SGlcNAc is an OGT O-
GlcNAcylation inhibitor (Ki= 8 µM; Gloster et al., 2011), whose sugar ring contains a sulfur 
atom in place of the endocyclic ring oxygen of GlcNAc, as shown in Figure II-3. UDP-
5SGlcNAc does not alter the structure of the OGT catalytic domain and binds to OGT in a 
manner almost identical to UDP-GlcNAc (Lazarus et al., 2012). The OGT-binding affinity of 
UDP-5SGlcNAc lies in the same range as the one of UDP-GlcNAc (Gloster et al., 2011 and 
Schimpl et al., 2012; summarized in Table II-1). Thus equal concentrations of both cofactors 
were used. Substituting UDP-GlcNAc by UDP (data not shown) or by UDP-5SGlcNAc 
(experiment performed by Dr. Vaibhav Kapuria; Figure S3 B and C in Lazarus et al., 2013) in 
the in vitro cleavage assay inhibited HCF-1PRO-repeat cleavage, suggesting that HCF-1PRO-
repeat cleavage requires intact UDP-GlcNAc. Intriguingly, not only proteolysis, but also O-
GlcNAcylation was inhibited in the presence of UDP or UDP-5SGlcNAc, respectively (data 
not shown), suggesting that the sugar ring of UDP-GlcNAc plays a crucial role for both HCF-
1PRO-repeat proteolysis and HCF-1rep1 O-GlcNAcylation. 
 
 
Figure II-1: Structure of HCF-1 proteins.        
Full-length human HCF-1 and the GST–HCF-1rep1 (HCF-1rep1) construct used to study HCF-1PRO-
repeat cleavage in vitro. The HCF-1PRO repeat 1 (rep1) sequence with the cleavage region and 
threonine region is illustrated. The highly conserved sequence of 20 amino acids (core sequence 
Kristie et al., 1995) is shaded gray. The red arrowhead indicates the cleaved peptide bond between 
C9 and E10. 
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Figure II-2: HCF-1PRO-repeat cleavage is sensitive to OGT and UDP-GlcNAc concentrations.       
3 µM bacterially purified GST–HCF-1rep1 were incubated in the absence or with increasing 
concentrations of OGT (A) or UDP-GlcNAc (B) in in vitro cleavage assays. The concentrations of the 
remaining components were kept constant (600 nM OGT, 1 mM UDP-GlcNAc, 3 µM GST–HCF-
1rep1). GST–HCF-1rep1 precursor and N-terminal cleavage products were visualized by immunoblot 
using α-GST antibodies. Bands on immunoblots were analyzed using LI-COR Image Quant 
quantification software and cleavage quantified as the percentage of cleaved product to total GST–
HCF-1rep1 protein (full-length uncleaved plus cleaved prouct) in the assay. 
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Figure II-3: Chemical structures of UDP-GlcNAc, UDP-5SGlcNAc and UDP. 
 
 
Table II-1: OGT-binding affinities of OGT cofactors from Schimpl et al. (2012). 
 
 
Kd (dissociation constant) ± standard deviation as determined by Surface Plasmon Resonance. 
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II.2 E10 is crucial for HCF-1PRO-repeat proteolysis 
Previous studies of the HCF-1PRO repeat in a heterologous context in vivo (Wilson et al., 
1995b) and in vitro (Capotosti et al., 2011) have shown that the HCF-1PRO-repeat cleavage 
region and the threonine region display sensitivity to alanine mutations. To validate these 
results using the in vitro cleavage assay with bacterially purified substrates and OGT, I 
analyzed the residues surrounding the cleavage site E10 by an alanine scan (Figure II-4 B): 
Residues lying N-terminal of the cleavage site at E10 displayed decreased cleavage activity 
when mutated to alanine, whereas mutation of the residues T11-E13 C-terminal of E10 had 
less effect on cleavage (compare lanes 3-8 and 11-16 with lanes 1-2). The T14A mutation 
decreased cleavage dramatically (lanes 17 and 18), presumably by perturbing interactions 
with the OGT TPR domain. Consistent with this result, interactions of residue T14 with the 
OGT TPR domain via hydrogen bonds were observed in a crystal structure of human OGT in 
complex with the HCF-1PRO-repeat 2 and UDP-5SGlcNAc (Figure 3 in Lazarus et al., 2013). 
Importantly, E10 was the only residue, when replaced by alanine, for which HCF-1PRO-repeat 
proteolysis could not be detected. This result suggests that E10 is the only residue in the 
HCF-1PRO repeat that is absolutely required for cleavage. 
Because E10, when substituted by alanine, is the only residue in the HCF-1PRO repeat 
that drastically blocks proteolysis, I asked whether substitutions of this glutamate by residues 
with similar side-chain structures, such as glutamine (E10Q) or aspartic acid (E10D; side-
chain structures illustrated in Figure II-4 A) have less drastic effects on proteolysis. To 
determine whether the mechanism of OGT-mediated proteolysis could be similar to the one 
of OGT-mediated O-GlcNAcylation, I also generated an E10S mutant. Serine at the position 
of the cleavage site E10 might potentially provide an O-GlcNAcylation site. I hypothesized 
that this mutated HCF-1PRO repeat could represent an active substrate for O-GlcNAcylation. 
Additionally, I tested the T17-22A mutant, which was described to inhibit HCF-1PRO-repeat 
cleavage (Capotosti et al., 2011), probably by interrupting the interactions with the OGT TPR 
domain. Figure II-4 C shows the results of an in vitro cleavage assay with the E10 and 
Threonine-region mutants. The alanine mutations in the threonine region blocked cleavage 
(lanes 3 and 4), suggesting that binding of the HCF-1PRO-repeat threonine region to the OGT 
TPR domain is important for cleavage. As with the E10A mutation (lanes 5 and 6), the E10 
substitutions by glutamine (E10Q, lanes 7 and 8), aspartic acid (E10D, lanes 9 and 10), or 
serine (E10S, lanes 11 and 12) blocked cleavage, suggesting that even subtle changes in 
the amino acid side-chain structure of glutamate at this position are detrimental for cleavage. 
I thus concluded that the proteolysis mechanism of HCF-1PRO-repeat cleavage requires the 
glutamate side chain at position 10. This result is shown in Figure 1 C in Lazarus et al. 
(2013). The mutation E10S also blocked cleavage. Nevertheless, when O-GlcNAcylation 
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levels of wild-type (WT) and E10S HCF-1rep1, as determined by α-O-GlcNAc immunoblot, 
were compared (Figure II-4 C, lower panel, compare lanes 11 and 12 with lanes 1 and 2), the 
E10S HCF-1rep1 substrate did not display any difference. I thus inferred that either (i): there 
are no changes in the HCF-1rep1 O-GlcNAcylation status upon mutation of E10 to serine or 
(ii): Changes in the HCF-1rep1 O-GlcNAcylation status (i.e., sites of O-GlcNAcylation) cannot 
be identified by immunoblotting using α-O-GlcNAc antibodies. To study changes of O-
GlcNAcylation levels, proteomic approaches are widely used and represent the method of 
choice. These studies are described in section II.3 below and in Chapter IV. 
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Figure II-4: Residue E10 in the HCF-1PRO repeat is crucial for proteolysis.      
(A) Schematic of the HCF-1rep1 precursor construct used to study substrate requirements for HCF-
1PRO-repeat proteolysis at the cleavage site and in the threonine region. Asterisks indicate alanine 
mutations in the threonine region; the side-chain structures of the E10 substituents are illustrated 
below the diagram. (B) In vitro HCF-1rep1 cleavage assay. Alanine scan of the residues surrounding 
the cleavage site at E10. Cleavage efficiencies for each mutant (α-GST blot, upper panel) and OGT 
levels (α-T7 blot, lower panel) in each reaction are shown. (C) In vitro HCF-1rep1 cleavage assay with 
E10 cleavage-site mutants and the Threonine-region mutant T17-22A. HCF-1rep1 cleavage (α-GST 
blot, upper panel) and O-GlcNAcylation (α-O-GlcNAc blot, lower panel) are shown. In (B) and (C), the 
positions of uncleaved precursor proteins (–) and N-terminal cleavage products () are indicated. 
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II.3 Serine at position 10 of the HCF-1PRO repeat activates HCF-1PRO-repeat O-
GlcNAcylation 
Lazarus et al. (2011) determined experimentally the structure of the OGT catalytic domain 
with UDP in complex with an O-GlcNAcylation substrate: A 14-mer peptide 
YPGGSTPVSSANMM derived from Casein Kinase II (CK-II; the S9 GlcNAc acceptor residue 
is underlined). This crystal structure (PDB code 3PE4) was highly valuable for molecular 
modeling studies. Prior to the studies of Lazarus et al. (2013), we performed molecular 
docking simulations in collaboration with Dr. Vincent Zoete to predict how the HCF-1PRO 
repeat would bind inside the OGT catalytic domain in complex with UDP. The peptide 
sequence corresponding to HCF-1PRO repeat 1 was computationally threaded in place of the 
CK-II peptide into the OGT catalytic domain. Interestingly, we observed that the HCF-1PRO 
repeat was predicted to bind to the OGT catalytic domain in a manner similar to the CK-II O-
GlcNAcylation substrate (data not shown). 
In Lazarus et al. (2013), we showed using the experimentally determined OGT–UDP-
5SGlcNAc–HCF-1PRO-repeat 2 E10Q crystal structure (PDB code 4N3B) for an overlay with 
an OGT–UDP-5SGlcNAc–CK-II crystal structure (PDB code 4GYY; Lazarus et al., 2012) that 
the two substrates indeed bind in a similar manner to the OGT catalytic domain. Intriguingly, 
the E10 cleavage-site residue of the HCF-1PRO repeat was superimposed to the CK-II 
GlcNAc acceptor residue (S9) and their respective side-chains displayed an almost perfect 
overlap (Figure II-5). Moreover, the two side-chains were located in close proximity to the 
sugar moiety of UDP-GlcNAc. The HCF-1PRO-repeat cleavage substrate thus binds 
analogous to an O-GlcNAcylation substrate in the OGT active site for O-GlcNAcylation. 
These results suggest that the HCF-1PRO repeat mimics an O-GlcNAcylation substrate in the 
OGT catalytic domain. 
The observations described above led me to test if the E10S mutant, instead of being 
cleaved (Figure II-4 B, lanes 11 and 12), gets O-GlcNAcylated at E10S within the HCF-1PRO 
repeat. The HCF-1rep1 protein is an excellent O-GlcNAcylation substrate because it contains 
several O-GlcNAcylation sites in the sequences upstream of the HCF-1PRO repeat 1 (mapped 
in the Basic region in Capotosti et al., 2011). Identification of potential changes of O-
GlcNAcylation in the HCF-1PRO repeat by immunoblotting is not an adequate method, as the 
α-O-GlcNAc antibody signal gets saturated by the numerous O-GlcNAcylation sites lying 
outside of the HCF-1PRO repeat. To circumvent immunoblot analysis, I subjected GST–HCF-
1rep1 wild-type and E10S protein preparations from transiently transfected HEK 293 cells to 
liquid chromatography tandem mass spectrometry analysis (LC-MS/MS) in collaboration with 
Dr. Patrice Waridel (Protein Analysis Facility, University of Lausanne). This strategy allowed 
the study HCF-1rep1 O-GlcNAcylation by endogenous OGT. Peptides of the HCF-1rep1 
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protein were generated by combining trypsin and Glu-C digestion. The identification of O-
GlcNAcylated peptides surrounding E10S was performed using the MASCOT™ software 
(Perkins et al., 1999). In this analysis, a peptide with the sequence VCSNPPCSTHETGTTN 
(HCF-1PRO repeat 1 sequence, E10S underlined) was identified and contained a potential O-
GlcNAcylation site, whereas the same peptide derived from wild-type HCF-1rep1 did not 
contain O-GlcNAcylated sites (data not shown). The exact location of the O-GlcNAcylated 
residue, however, could not be confirmed in this analysis. To tackle this problem, John 
Janetzko and Dr. Suzanne Walker used a substrate, which does not contain any O-
GlcNAcylated sequences (HCF3R, schematic in Figure 1 A in Lazarus et al., 2013). HCF3R 
contains HCF-1PRO repeats 1, 2 and 3 and the less well-conserved sequences in between the 
repeats. In an in vitro HCF3R–OGT cleavage assay with C14 radiolabeled UDP-GlcNAc, an 
E10S mutation in one of the three HCF-1PRO repeats clearly activated the HCF-1 substrate 
for O-GlcNAcylation (see Figure S10 in Lazarus et al., 2013), consistent with the LC-MS/MS 
results. Thus, a replacement of HCF-1PRO-repeat residue E10 by serine converts the 
cleavage substrate into an O-GlcNAcylation substrate. This result suggests that the 
characteristics of the substrate determine whether to get O-GlcNAcylated or to get cleaved.  
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Figure II-5: The HCF-1PRO repeat binds analogous to an O-GlcNAcylation substrate in the OGT 
catalytic domain.                     
Overlay of two experimentally determined structures of OGT complexes (close-up view of the OGT 
catalytic domain). The HCF-1PRO repeat (carbons are colored in orange) and the CK-II peptide 
(carbons are colored in pink) are shown in ball-and-stick representation, lying over UDP-GlcNAc 
(carbons are colored in gray) in the OGT active site. Atoms are colored as follows: oxygen: red, 
nitrogen: blue, phosphor: green. For this overlay, the experimentally determined crystal structures of 
the OGT–UDP-5SGlcNAc–CK-II complex (PDB code 4GYY; Lazarus et al., 2012) and the OGT–UDP-
5SGlcNAc–HCF-1PRO-repeat 2 E10Q complex (PDB code 4N3B; Lazarus et al., 2013) were used. In 
the HCF-1PRO repeat, E10Q was replaced by glutamate (E10) and in both structures, UDP-5SGlcNAc 
was replaced by UDP-GlcNAc. E10 of the HCF-1PRO repeat and the GlcNAc acceptor residue serine 9 
(S9) of CK-II display an almost perfect overlap. Close-up view created with UCSF Chimera software 
by Dr. Vincent Zoete. 
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II.4 HCF-1PRO-repeat–OGT association is sensitive to UDP-GlcNAc 
In the past, OGT interactions with a single wild-type (WT) HCF-1PRO repeat could not be 
efficiently detected in in vivo co-immunoprecipitation assays. To study the properties of HCF-
1PRO-repeat–OGT association, I established an in vitro HCF-1rep1–OGT “pull-down” binding 
assay that can detect WT HCF-1PRO-repeat–OGT interactions. Before performing the OGT-
directed pull-down, I pre-incubated bacterially synthesized OGT with bacterially synthesized 
HCF-1rep1 substrates for 1 h in the presence of 1 mM UDP-GlcNAc and removed an input 
sample from the mixture. Subsequently, the mixture was incubated with OGT-directed 
antibody conjugates for 1 h (pull-down). Hence, the total incubation time of OGT and HCF-
1rep1 in this assay was only 2 h. The proteins in the immunoprecipitated material and in the 
input were resolved by SDS-PAGE and OGT and HCF-1rep1 were detected by immunoblot 
using the respective antibodies. To establish the appropriate temperature for this assay, I 
tested HCF-1rep1 substrates containing WT or E10A mutated HCF-1PRO repeats for OGT 
binding at different temperatures. The E10A cleavage site mutant inhibits cleavage, and in 
vivo also enhances HCF-1–OGT association (Capotosti et al., 2011). Therefore this mutant 
served as a positive control for HCF-1rep1–OGT binding. The temperatures ranging from 
4°C-42°C for both the pre-incubation and the OGT pull-down influenced HCF-1rep1–OGT 
binding (data not shown): At low temperatures (4°C and 10°C), OGT interactions with HCF-
1rep1 WT and E10A were detectable. However, the E10A mutation did not cause 
enhancement of OGT binding, demonstrating that pull-down assays performed at 4°C and 
10°C do not faithfully reflect in vivo HCF-1–OGT binding. Pull-down assays performed at 
20°C, 30°C or 37°C faithfully reflected in vivo HCF-1–OGT binding and displayed weak WT 
HCF-1rep1–OGT binding and enhanced E10A HCF-1rep1–OGT binding. Pull-down assays 
performed at 42°C caused precipitation of the proteins in the assay. Thus, a temperature of 
20°C was used for all subsequent pull-down assays. At temperatures below 37°C, HCF-1PRO-
repeat cleavage is reduced (Capotosti and Herr, unpublished results) and allows to study 
HCF-1PRO-repeat–OGT binding without the occurrence of prominent cleavage, which would 
reduce the full-length WT binding substrate.  
 As HCF-1PRO-repeat cleavage is sensitive to UDP-GlcNAc concentrations (Figure II-2 
B), I investigated whether HCF-1PRO-repeat–OGT binding displays similar sensitivity to UDP-
GlcNAc. I tested OGT association of HCF-1rep1 WT and E10A at a range of different UDP-
GlcNAc concentrations, using the established pull-down assay described above. I also tested 
the HCF-1rep1 T17-22A mutant in this assay (Figure II-6 A), to investigate whether alanine 
mutations in the threonine region disrupt OGT binding. Figure II-6 B shows the results of this 
HCF-1rep1–OGT binding assay in the absence or presence of increasing concentrations of 
UDP-GlcNAc (0-1.0 mM). In the absence of UDP-GlcNAc, HCF-1rep1 WT and E10A bound 
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indistinguishably well to OGT (lanes 1 and 2, panel a) but the mutant T17-22A bound more 
weakly to OGT (lane 3, panel a). With increasing concentrations of UDP-GlcNAc, both WT– 
and T17-22A–OGT binding decreased, whereas E10A–OGT binding did not decrease 
(compare lanes 2, 5, 8 and 12, panel a). These results suggest that UDP-GlcNAc inhibits 
OGT binding of HCF-1PRO repeats containing the wild-type cleavage site E10 (WT and T17-
22A). In fact, in the presence of 1 mM UDP-GlcNAc, a clear difference between weak WT 
and strong E10A binding was observed (compare lanes 4 and 5, 7 and 8, 11 and 12, panel 
a) and binding of the T17-22A mutant (lane 13, panel a) was almost undetectable. 
I concluded that OGT-bound UDP-GlcNAc inhibits or strains HCF-1PRO-repeat–OGT 
association. The effect of UDP-GlcNAc is even stronger when mutations in the HCF-1PRO-
repeat threonine region are present (T17-22A). Hence, not only HCF-1PRO-repeat cleavage 
but also HCF-1PRO-repeat–OGT association is sensitive to UDP-GlcNAc. Intriguingly, 
maximum inhibition of WT HCF-1PRO-repeat–OGT association coincides with maximum WT 
HCF-1PRO-repeat cleavage in the presence of 1 mM UDP-GlcNAc (compare to cleavage of 
HCF-1rep1 with 1 mM UDP-GlcNAc in Figure II-2 B). I thus hypothesized that the inhibition of 
HCF-1PRO-repeat–OGT association by UDP-GlcNAc might cause cleavage of the HCF-1PRO 
repeat. 
The results obtained with the T17-22A mutant show that the alanine mutations in the 
threonine region indeed impair HCF-1PRO-repeat–OGT association because T17-22A HCF-
1PRO-repeat–OGT binding was consistently less efficient than WT HCF-1PRO-repeat–OGT 
binding (Figure II-6 B). Results obtained in the presence of 1 mM UDP-GlcNAc (lanes 10-13) 
are shown in Figure 3 E in Lazarus et al. (2013). This result is in concordance with an 
examination of the OGT–UDP-5SGlcNAc–HCF-1PRO-repeat crystal structure, which shows 
that the threonines in the HCF-1PRO-repeat threonine region make interactions with the OGT 
TPR domain (Lazarus et al., 2013). I concluded, that the HCF-1PRO-repeat threonine region 
contributes largely to HCF-1PRO-repeat–OGT binding via interactions with the OGT TPR 
domain. 
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Figure II-6: HCF-1PRO-repeat–OGT interactions are sensitive to UDP-GlcNAc.                      
(A) Schematic of the HCF-1rep1 precursor construct used to study HCF-1PRO-repeat–OGT 
association. The positions of alanine-mutated residues at the cleavage site E10 or in the threonine 
region are indicated by asterisks and the red arrowhead marks the cleaved peptide bond. (B) In vitro 
HCF-1rep1–OGT binding assay in the absence or presence of increasing UDP-GlcNAc 
concentrations. Shown are 100 % of the pull-down samples (panels a and b) and 11 % of the input 
samples (panels c and d). Immunoblotting with antibodies directed to GST or to the T7 epitope was 
used to detect GST–HCF-1rep1 and OGT, respectively. IgG heavy chain (*). 
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II.5 Proper HCF-1PRO-repeat–OGT interactions require intact UDP-GlcNAc 
As HCF-1PRO-repeat–OGT association is sensitive to UDP-GlcNAc, I asked next whether this 
association displays similar sensitivity to UDP-5SGlcNAc. As described above, UDP-
5SGlcNAc inhibits HCF-1rep1 cleavage and O-GlcNAcylation and was shown to bind to OGT 
like UDP-GlcNAc would, without altering the conformation of the active site (Lazarus et al., 
2012). To test if UDP-5SGlcNAc changes the HCF-1PRO-repeat–OGT binding mode, I 
performed HCF-1rep1–OGT pull-down assays (described in II.4) in the presence of either 
UDP-GlcNAc, UDP-5SGlcNAc or UDP. Figure II-7 shows an in vitro HCF-1rep1–OGT 
binding assay with HCF-1rep1 constructs containing the wild-type (WT) HCF-1PRO repeat or 
the E10A- or T17-22A-mutated HCF-1PRO repeats. In one instance (Figure II-7, lane 5), I 
included a double mutant containing both, the E10A mutation and the T17-22A mutations 
(E10A/T17-22A) in the assay. This double mutant is not cleaved by OGT (data not shown). 
As expected, in the presence of UDP-GlcNAc, the WT HCF-1PRO repeat displayed weak OGT 
binding (lane 2, panel a), whereas the E10A mutation (lane 3, panel a) enhanced, and the 
T17-22A mutations abrogated binding (lane 4, panel a) with respect to WT. The double 
mutant associated more strongly to OGT than the mutant containing the T17-22A mutations 
alone (compare lanes 4 and 5, panel a), suggesting that the enhancing effect of E10A 
counteracts the binding defect caused by the mutations in the HCF-1PRO-repeat threonine 
region. This result also shows that the HCF-1PRO-repeat threonine region is important for 
HCF-1PRO-repeat–OGT association, even in the presence of the E10A mutation. 
In the presence of UDP-5SGlcNAc, WT HCF-1PRO-repeat–OGT binding increased 
with respect to interactions in the presence of UDP-GlcNAc (compare lane 7 to lane 2). 
Remarkably, also the T17-22A mutant associated more strongly with OGT than in the 
presence of UDP-GlcNAc (compare lane 4 to lane 8). In fact, all three HCF-1rep1 constructs 
bound with the same efficiency to OGT (compare lanes 6-8). These results show that UDP-
5SGlcNAc in the OGT active site alters the HCF-1PRO-repeat–OGT binding mode drastically. 
In the presence of UDP, WT and E10A HCF-1rep1 (lanes 9 and 10) associated strongly and 
indistinguishably to OGT. The association of the T17-22A mutant was slightly weaker than 
WT and E10 OGT association (lane 11), suggesting that, also in the presence of UDP, the 
threonine region is important for OGT association. In the absence of any cofactor, the WT 
HCF-1PRO-repeat as well as the E10A and the T17-22A mutants bound to OGT in a manner 
similar to binding in the presence of UDP (compare lanes 9-11 to 12-14). 
In summary, these results show that not only HCF-1PRO-repeat cleavage (see II.1), 
but also the inhibiting effect of UDP-GlcNAc on HCF-1PRO-repeat–OGT association is 
dependent on the sugar moiety of UDP-GlcNAc because UDP and UDP-5SGlcNAc caused 
changes of the HCF-1PRO-repeat–OGT binding mode. Hence, proper HCF-1PRO-repeat–OGT 
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interactions and HCF-1PRO-repeat cleavage are dependent on the presence of intact UDP-
GlcNAc. The results obtained with UDP-5SGlcNAc, however, were surprising: A sole 
replacement of the oxygen ring atom in the sugar by sulfur inhibits HCF-1PRO-repeat 
cleavage and changes the HCF-1PRO-repeat–OGT binding mode drastically. In the presence 
of UDP-5SGlcNAc, the T17-22A mutant associates more strongly to OGT than in any other 
tested condition (UDP-GlcNAc, UDP, no cofactor), but the reasons for this are currently 
unknown. It is possible that the oxygen atom of the sugar ring plays a role in HCF-1PRO-
repeat–OGT binding and proteolysis. 
 
 
Figure II-7: The sugar moiety of UDP-GlcNAc in the OGT active site is important for proper 
HCF-1PRO-repeat–OGT association.              
In vitro HCF-1rep1–OGT binding assay in the presence of 1 mM UDP-GlcNAc (lanes 1-5), UDP-
5SGlcNAc (lanes 6-8), UDP (lanes 9-11), or in the absence of cofactor (lanes 12-14). Shown are 
panels of the OGT pull-down (panels a and b; 100 % of total pull-down). Immunoblotting with 
antibodies directed to GST or to the T7 epitope was used to detect GST–HCF-1rep1 and OGT, 
respectively. IgG heavy chain (*). 
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II.6 E10 in the HCF-1PRO-repeat cleavage region displays unfavorable 
interactions with the OGT–UDP-GlcNAc complex 
E10 in the HCF-1PRO-repeat cleavage region displays particular OGT-binding properties in 
the presence of UDP-GlcNAc, the reasons for this, however, remained unclear (see II.4 and 
II.5 above). In Lazarus et al. (2013) we reported that the HCF-1PRO-repeat threonine region 
binds stably to the OGT TPR region through a network of hydrogen bonds contacting the 
threonine side-chains and backbones. The binding mode of the HCF-1PRO-repeat cleavage 
region to OGT, however, was less well understood, as binding of the wild-type HCF-1PRO-
repeat to OGT in crystallization conditions ultimately leads to proteolysis. A replacement of 
E10 by E10Q in the HCF-1PRO repeat and substitution of UDP-GlcNAc by UDP-5SGlcNAc 
prevented proteolysis. In the OGT–UDP-5SGlcNAc–HCF-1PRO-repeat E10Q crystal structure 
(PDB code 4N3B), the E10Q side-chain is located in close proximity to the sugar ring of 
UDP-5SGlcNAc (see Figure II-5; Lazarus et al., 2013). To clarify the role of the wild-type 
HCF-1PRO-repeat cleavage region for HCF-1PRO-repeat proteolysis, Dr. Vincent Zoete 
replaced the glutamine side-chain at position 10 by wild-type glutamate and the UDP-
5SGlcNAc cofactor by UDP-GlcNAc. Based on this model, individual side-chain contributions 
to OGT binding for residues P7 to T14 (schematic in Figure II-8 A) were estimated using the 
Molecular Mechanics – Generalized Born Surface Area (MM-GBSA) approach (Figure II-8 
B). The simulations predicted that residues T11-E13 of the HCF-1PRO repeat do not 
contribute, whereas T14 makes a large and favorable contribution to OGT binding. 
Interestingly, these calculations showed that the E10 residue is the only residue in the 
analyzed region that displays highly unfavorable interactions with the OGT–UDP-GlcNAc 
complex. 
 Next, I tested the HCF-1rep1 mutants containing individual HCF-1PRO-repeat alanine 
substitutions from P7A to T14A in an in vitro HCF-1rep1–OGT binding assay in the presence 
of UDP-GlcNAc (Figure II-8 C). Strikingly, only the E10A mutant within the analyzed region 
enhanced HCF-1rep1–OGT association considerably, as shown by immunoblot (Figure II-8 
C, compare lane 6 to adjacent lanes, panel a). The quantification of the bands on this 
immunoblot showed this result even more clearly (Figure II-8 D). I concluded that the E10 
residue is not only unique for its cleavage properties, but also for its OGT-binding properties 
within the analyzed region. This is consistent with the molecular dynamics analysis in Figure 
II-8 B that predicted E10 to be the only residue with largely unfavorable contributions to OGT 
binding. In contrast, the replacement of UDP-GlcNAc by UDP in the in vitro HCF-1rep1–OGT 
binding assay did not promote increased HCF-1rep1 recovery by the E10A mutation (Figure 
II-8 E), suggesting that the unfavorable effect of E10 is dependent on the sugar moiety of 
UDP-GlcNAc. Thus, both molecular dynamics computational analysis and physical 
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interaction assays argue that the E10 residue is the only residue in the HCF-1PRO repeat that 
makes unfavorable interactions with the OGT–UDP-GlcNAc complex. This is in agreement 
with results obtained in sections II.4 and II.5, where a negative effect by UDP-GlcNAc, but 
not by UDP, in HCF-1PRO-repeat–OGT association was observed. 
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Figure II-8: The HCF-1PRO-repeat residue E10 displays unfavorable interactions with the OGT–
UDP-GlcNAc complex.             
(A) The HCF-1PRO-repeat conserved core sequence is shown. The red arrowhead indicates the 
cleaved peptide bond and the analyzed sequence is highlighted. (B) E10 displays an unfavorable 
contribution to OGT binding in a molecular dynamics analysis. Calculated contributions of HCF-1PRO-
repeat residues P7, P8, C9, E10, T11, H12, E13 and T14 to the binding free energy, ∆Gbind, for the 
association between the HCF-1PRO-repeat and OGT. Negative values correspond to favorable 
contributions to binding. (C) In vitro HCF-1rep1–OGT pull-down assay in the presence of UDP-GlcNAc 
with HCF-1rep1 constructs containing individual alanine substitutions in the HCF-1PRO-repeat (P7A-
T14A). Shown are 100 % of OGT pull-down (panels a and b) and 11 % of the input (panels c and d). 
Immunoblotting with antibodies directed to GST or to the T7 epitope was used to detect GST–HCF-
1rep1 and OGT, respectively. IgG heavy chain (*). (D) Quantified HCF-1 recovery from the pull-down 
assay in (C) represented as log2 fold change relative to wild-type. The immunoblot was analyzed 
using LI-COR Image Quant quantification software and HCF-1 recovery was calculated as pull-down 
(values from panel a) over total input (values form panel c extrapolated to 100% input). (E) Quantified 
HCF-1 recovery from an HCF-1rep1–OGT pull-down assay in the presence of UDP (immunoblot not 
shown). Quantification as described in (D). 
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II.7 Strains caused by E10 in the OGT catalytic domain are specific to the 
glutamate side-chain structure 
The observation that E10 is the only residue within the HCF-1PRO repeat displaying particular 
OGT-binding properties in the presence of UDP-GlcNAc, led me to ask if this property is 
dependent on the side-chain structure of the glutamate. I therefore performed in vitro binding 
assays with an enlarged set of E10 mutants described earlier (Figure II-4). Figure II-9 B 
shows HCF-1rep1–OGT binding in the presence (left panels) or absence (right panels) of 
UDP-GlcNAc. As expected, in the presence of the cofactor, the construct containing wild-
type (WT) E10 bound weakly to OGT (lane 2, upper panel), the T17-22A mutant displayed 
even more reduced binding (lane 3, upper panel), and the E10A mutant displayed enhanced 
binding (lane 4, upper panel). The E10 to aspartate (E10D), as well as the E10 to glutamine 
(E10Q) mutants, enhanced OGT binding similarly to E10A, albeit the similarity of the 
aspartate and glutamine side-chains to the WT glutamate side-chain (lanes 5 and 6, upper 
panel). The E10 to serine (E10S) mutant was tested because, unlike the E10D and E10Q 
mutants, the E10S HCF-1PRO repeat represents an active substrate for O-GlcNAcylation 
(Lazarus et al., 2013). In this binding assay, also the E10S mutant enhanced association to 
OGT (lane 7), suggesting that the inhibitory effect of the E10 side-chain on OGT association 
is specific to the glutamate side-chain, which is an active cleavage substrate. When UDP-
GlcNAc was omitted from the assay (right-hand panels), binding of the E10 mutants was not 
noticeably altered (lanes 11-14), whereas OGT binding of the HCF-1PRO repeats containing 
wild-type E10 (WT and T17-22A) increased considerably (compare lanes 9 and 10 to lanes 2 
and 3). These results suggest that the glutamate at position 10 interacts unfavorably with the 
OGT–UDP-GlcNAc complex. This interaction is specific to the glutamate side-chain 
structure, as side-chains with similar charge and structure at the same position alter the 
binding mode.  
 To understand the mechanism through which E10 causes an unfavorable interaction 
with the OGT–UDP-GlcNAc complex, Dr. Vincent Zoete estimated the OGT-binding 
contributions of E10, E10A, E10D and E10Q side-chains in the presence or absence of UDP-
GlcNAc by molecular dynamics (Figure II-9 C). WT E10 was predicted to display the most 
unfavorable OGT interaction among the tested side-chains. E10D displayed more favorable 
interactions than E10, presumably because the similarly negatively charged aspartate side-
chain is one carbon atom shorter than that of glutamate, and thus causes less structural 
impairments in the OGT–UDP-GlcNAc complex. The neutral side-chains of E10A and E10Q 
were both predicted to display favorable interactions with OGT. When UDP-GlcNAc was 
omitted from the OGT active site in the molecular dynamics simulation, the contributions to 
the binding free energy of the unfavorable contacts (E10 and E10D) decreased, suggesting 
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that the strains, occurring in the presence of UDP-GlcNAc, were removed. These results are 
in line with the observations in the pull-down assay in Figure II-9 B. Taking both results 
together, I concluded that the E10 side-chain in the active site of OGT causes specific strains 
in the OGT–UDP-GlcNAc–HCF-1PRO-repeat complex. 
 
 
Figure II-9: The E10 side-chain strains HCF-1PRO-repeat–OGT interactions in the presence of        
UDP-GlcNAc. 
(A) The HCF-1PRO-repeat conserved core sequence is shown. The red arrowhead indicates the 
cleaved peptide bond and the E10 cleavage site residue is highlighted. (B) The side-chain of E10 
interacts with UDP-GlcNAc in the OGT active site. In vitro HCF-1–OGT pull-down assay with an 
enlarged set HCF-1rep1 mutants. Constructs with wild-type (WT, lanes 2 and 9), mutated E10 
residues (lanes 4-7; lanes 11-14) and T17-T22A mutations (lanes 3 and 10) were incubated in the 
presence (left panels) or absence (right panels) of UDP-GlcNAc. Immunoblotting with antibodies 
directed to GST or to the T7 epitope was used to detect GST–HCF-1rep1 and OGT, respectively. IgG 
heavy chain (*). (C) E10 makes unfavorable contributions to OGT binding. Calculated contributions of 
the wild-type (WT, E10), alanine (E10A), aspartate (E10D) or glutamine (E10Q) residue at position 10 
to OGT binding. The binding free energy, ∆Gbind, for the association between the E10 residue and 
OGT is shown. Negative values correspond to favorable contributions to binding. 
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To understand the E10–OGT interactions better, we examined the location of the HCF-1PRO-
repeat E10 side-chain and UDP-GlcNAc in the OGT active site of the crystal structure (PDB 
code 4N3C, Lazarus et al., 2013). Consistent with the above-described results, we noticed 
that the E10 side-chain is located in close proximity (2.8 Å) of the carbonyl oxygen of glycine 
654 in the OGT catalytic domain, potentially causing an unfavorable electrostatic repulsion 
(Figure II-10 A). The E10 carboxylate functional group is maintained in this unfavorable 
position by the glucose moiety of UDP-GlcNAc. When we performed a molecular dynamics 
simulation without UDP-GlcNAc (representative snapshot along the trajectory shown in 
Figure II-10 B), the E10 residue can change its position to prevent the unfavorable interaction 
with glycine 654 and appears to form a favorable interaction with a nitrogen atom in the 
imidazole ring of histidine 498 in the OGT catalytic domain. 
Together, these results suggest that UDP-GlcNAc inhibits HCF-1PRO-repeat–OGT 
association by imposing that the E10 side-chain be in an unfavorable position within the 
complex. This incompatibility may cause strains in the OGT–UDP-GlcNAc–HCF-1PRO-repeat 
complex, which, I hypothesize, initiates or facilitates HCF-1PRO-repeat proteolysis. It is thus 
very likely that the HCF-1PRO-repeat threonine region serves as high-affinity bindings 
interface for the OGT TPR domain and allows for binding of the OGT catalytic domain to the 
HCF-1PRO-repeat cleavage region. Moreover, these results elucidate the reasons for the 
observed enhancement of OGT association by the HCF-1PRO repeat E10A mutation. E10A 
enhances OGT association because the strains between the E10 side-chain and the OGT–
UDP-GlcNAc complex were removed. Other amino acid side-chains such as the ones of 
aspartate, glutamine or serine have similar effects because they display less unfavorable 
interactions in the OGT complex. I thus propose that the mechanism of OGT-mediated HCF-
1 proteolysis involves strains originating from the cleavage substrate. 
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Figure II-10: The E10 side-chain makes unfavorable interactions with the OGT catalytic domain 
in the presence of UDP-GlcNAc. 
(A) Close-up view (4N3C crystal structure; Lazarus et al., 2013) of the OGT active site with the HCF-
1PRO repeat and UDP-GlcNAc. The deprotonated E10 oxygen atom exhibits an unfavorable interaction 
with the backbone carbonyl of OGT glycine 654 and is located in close proximity of the carbon atom 2 
of the sugar moiety of UDP-GlcNAc. (snapshot by Dr. Vincent Zoete). (B) Snapshot from a molecular 
dynamics simulation (based on the 4N3B structure; Lazarus et al., 2013) of the OGT active site in 
complex with the HCF-1PRO repeat without UDP-GlcNAc. The displayed frame is representative of the 
average distances sampled along the simulations. In (A) and (B), the E10 side-chain is shown in ball 
and stick representation (carbons: gray, nitrogen: blue, oxygens: red), and dashed lines indicate 
distances between atoms. 
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II.8 Refinement of the HCF-1PRO-repeat bipartite structure 
The crystal structure of the OGT–UDP-5SGlcNAc–HCF-1PRO-repeat 2 E10Q complex (PDB 
code 4N3B; Lazarus et al., 2013) was invaluable for my follow-up studies. The structure 
allowed the creation of an authentic model of full-length OGT bound to UDP-GlcNAc and the 
HCF-1PRO-repeat wild-type peptide using computational molecular dynamics (Figure II-11 A). 
Capotosti et al. (2011) divided the HCF-1PRO repeat into two regions, termed cleavage 
region and threonine region (Figure I-12). Using bacterially synthesized HCF-1rep1 
substrates for robust in vitro cleavage assays, I confirmed that HCF-1PRO-repeat cleavage 
can be inhibited by substitutions of individual HCF-1PRO-repeat residues by alanine (see 
Figure II-4 B). The residues P7–E10 are important for cleavage because they exhibit reduced 
or no HCF-1PRO-repeat cleavage when replaced by alanine. In contrast, alanine mutations of 
residues T11, H12 and E13 did not display a strong effect on cleavage suggesting that: (i) 
these residues are not important for HCF-1PRO-repeat cleavage or (ii) alanine substitutions of 
these residues do not affect structural properties that are important for cleavage. To test the 
latter hypothesis, we determined the flexibility of the HCF-1PRO-repeat structure bound to 
OGT. A crystal structure represents only one possible conformation that a protein complex 
can adopt, but thermal fluctuations of a given system can provide a more realistic, dynamic 
picture of the complex and can assess flexibility or rigidity of structures. Dr. Ute Roehrig 
performed molecular dynamics simulations of the HCF-1PRO-repeat 2 (residues 5-24) in 
complex with full-length human OGT and UDP-GlcNAc in water at room temperature to 
obtain thermal fluctuations of the system under ambient conditions (based on structure 
4N3B; E10Q replaced by E10, UDP-5SGlcNAc replaced by UDP-GlcNAc using molecular 
dynamics). The Root-Mean-Square Fluctuations (RMSF), i.e., how much each atom 
fluctuates around its average position, were determined and are illustrated in Figure II-11 B 
by a graphical representation of obtained RMSF values and in Figure II-11 C by color and 
size coding of the HCF-1PRO repeat embedded in the OGT structure. Residues T11, H12 and 
E13 of the HCF-1PRO repeat are characterized by higher structural fluctuations than observed 
in the rest of the peptide, suggesting that T11–E13 are not tightly bound to OGT and display 
structural flexibility when in complex with OGT. 
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Figure II-11: The HCF-1PRO repeat contains a flexible region between the E10 cleavage site and 
the threonine region. 
(A) Structure of full-length human OGT in complex with wild-type HCF-1PRO repeat 2 (orange) and 
UDP-GlcNAc (in purple, behind the HCF-1PRO repeat, not entirely visible). The OGT catalytic domain is 
colored in beige, the 13.5 TPR domain is colored in blue. The structure of the OGT TPR region (Jinek 
et al., 2004) has been assembled with the structure of OGT containing 4.5 TPRs in complex with the 
HCF-1PRO-repeat 2 E10Q and UDP-5SGlcNAc (Lazarus et al., 2013) by molecular modeling. UDP-
5SGlcNAc has been replaced by UDP-GlcNAc and the E10Q HCF-1PRO repeat has been replaced by 
the wild-type repeat (Dr. Vincent Zoete). (B) RMSF of the backbone (black open circles) and the full 
peptide (red open squares) of the HCF-1PRO repeat. Residues 11-13 of the HCF-1PRO repeat are 
characterized by higher structural fluctuations. Inset: The structure of the HCF-1PRO repeat, with atom 
size and color given by the respective RMSF (rigid=blue, small; flexible=red, large). (C) Structure of 
the HCF-1PRO repeat, with atom size and color given by the respective RMSF as in (B), embedded in 
the OGT 4.5 TPR structure with UDP-GlcNAc. Simulations in (B) and (C) performed by Dr. Ute 
Roehrig. 
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To examine if the structural flexibility of the residues T11, H12 and E13 is important for HCF-
1PRO-repeat cleavage, I substituted the residues predicted to display the highest flexibility, 
H12 and E13, individually or simultaneously by proline. Proline is known to increase the 
rigidity of peptides due to its cyclic structure. Thus, replacing flexible residues by proline may 
result in a more rigid structure. Figure II-12 A shows the result of an in vitro cleavage assay 
with HCF-1PRO-repeat alanine and proline mutations. I confirmed that individual replacement 
of H12 or E13 by alanine did not affect HCF-1PRO-repeat cleavage (left-hand panels, lanes 3 
and 5, respectively). Individual replacement of H12 and E13 by proline, however, decreased 
HCF-1PRO-repeat cleavage (left-hand panels, lanes 4 and 6, respectively) with respect to 
wild-type HCF-1PRO-repeat cleavage (left-hand panels, lane 1). The double mutant containing 
simultaneous H12P and E13P mutations displayed even less cleavage activity (right-hand 
panels, lane 6) with respect to the mutants containing single proline mutations, suggesting 
that the flexibility of H12 and E13 is important for cleavage. Nevertheless, it cannot be ruled 
out that the effect of proline on the structure of the HCF-1PRO repeat might have an influence 
on HCF-1PRO-repeat cleavage. 
OGT contains a so-called hinge region between the TPRs and the catalytic domain 
(Lazarus et al., 2011), and this OGT hinge region surrounds HCF-1PRO-repeat residues T11–
E13 in the OGT–HCF-1PRO-repeat complex (Lazarus et al., 2013). Analogous to the OGT 
hinge region, we propose that the HCF-1PRO repeat also contains a conserved, flexible hinge 
consisting of residues T11, H12, and E13. Therefore we redefined the HCF-1PRO-repeat 
regions as follows: cleavage region (residues P7–E10), Hinge region (residues T11, H12, 
and E13) and threonine region (T14–T22; see Figure II-12 B). 
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Figure II-12: Refinement of the regions within the HCF-1PRO repeat. 
(A) In vitro cleavage assay of HCF-1rep1 constructs containing the wild-type (WT) HCF-1PRO repeat or 
alanine or proline mutations of selected residues within the HCF-1PRO repeat. The positions of 
uncleaved precursor proteins (–) and N-terminal cleavage products () are indicated. (B) The 
redefined regions of the HCF-1PRO repeat: The cleavage region has been trimmed to residues P7–
E10. The threonine region comprises residues T14–T22. In between the cleavage and the threonine 
regions lies the Hinge region comprising residues T11–E13. The residues in the Hinge region are 
characterized by higher structural flexibility with respect to the adjacent regions when the HCF-1PRO 
repeat is bound to OGT. 
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II.9 Residue T14 in the threonine region is important for interactions with 
residues in the OGT TPR domain 
My studies of HCF-1PRO-repeat–OGT association showed that residue T14 in the HCF-1PRO-
repeat threonine region contributes largely to OGT binding (see Figure II-8 C and D). This 
finding led me to focus on T14 interactions with the OGT TPR domain (Figure II-13 A). Dr. 
Vaibhav Kapuria performed mutational analyses in the human OGT protein to identify 
residues required for HCF-1 proteolysis. Alanine substitutions of TPR residues D431 and 
K396, but not K430, greatly reduced HCF-1rep1 cleavage in an in vitro cleavage assay (Dr. 
Vaibhav Kapuria, data not shown). An examination of the location of these residues in the 
OGT–HCF-1PRO-repeat crystal structure (PDB code 4N3B) revealed that D431 and K396, but 
not K430, are located in close proximity to T14 of the HCF-1PRO repeat (Figure II-13 B, a). 
D431 and K396 are predicted to form hydrogen bonds to the hydroxyl group and to the 
peptide backbone of T14. This examination was in line with the finding that a T14A mutation 
inhibits OGT association, as the alanine side-chain cannot form hydrogen bonds. To 
determine the specificity of the hydrogen bonds formed between D431 and K396 and the 
T14 side-chain and backbone, I replaced T14 by two different amino acids: Serine (S), which 
like threonine contains a hydroxyl group capable of forming hydrogen bonds but lacks a 
methyl group, and asparagine (N), which is known to form strong hydrogen bonds through its 
amide group (see Figure II-13 B, b for side-chain structures). As a replacement of T14 by 
alanine leads to a reduction of cleavage as shown in Figure II-4 B, replacement of T14 by 
serine or asparagine could reactivate cleavage. Figure II-13 C shows the result of an in vitro 
cleavage assay with the described mutants. As expected, the T14A mutation inhibited HCF-
1PRO-repeat cleavage strongly (Figure II-13 C, lane 2, lower panel). Substitution by serine 
(lane 3) or asparagine (lane 4) did not reactivate T14A cleavage, suggesting that the side-
chain structure of T14 i.e., its additional methyl group compared to serine is crucial for the 
contacts to residues in the OGT TPR domain. I concluded that the hydrogen bonds formed 
between T14 and residues in the OGT TPR domain (D431 and K396) are highly specific. As 
other threonines in the HCF-1PRO-repeat threonine region are also predicted to contribute to 
OGT TPR domain binding through a network of hydrogen bonds (Lazarus et al., 2013), it is 
conceivable that also these interactions are highly specific.  
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Figure II-13: Residue T14 in the threonine region is important for interactions with residues in 
the OGT TPR domain.             
(A) The HCF-1PRO repeat with its redefined regions is shown. The red arrowhead indicates the cleaved 
peptide bond. In this experiment, focus is given on residue T14 in the threonine region. (B) a, 
Structural snapshot of the HCF-1PRO-repeat–OGT crystal structure 4N3B (Lazarus et al., 2013) around 
T14 of the HCF-1PRO repeat (orange). Helices of the OGT TPR region are colored in blue. Hydrogen 
bonds are illustrated as light blue lines. b, Side-chain structures of the amino acids threonine, alanine, 
serine and asparagine to study the role of T14 in OGT TPR binding. (C) In vitro cleavage assay with 
HCF-1rep1 constructs containing wild-type (WT, lane 1), alanine (lane 2), serine (lane 3) or 
asparagine (lane 4) substitutions at position T14 in the HCF-1PRO repeat. The positions of uncleaved 
precursor proteins (–) and N-terminal cleavage products () are indicated.   
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Discussion 
The HCF-1PRO repeat contains a flexible region (Hinge region) 
OGT-mediated HCF-1PRO-repeat cleavage requires a large recognition sequence of 21 amino 
acids within the HCF-1PRO repeat (Capotosti et al., 2011). Molecular dynamics analyses of 
eight residues within this sequence in the OGT–UDP-GlcNAc–HCF-1PRO-repeat complex 
predicted higher structural flexibility of HCF-1PRO repeat residues T11, H12 and E13 with 
respect to adjacent residues (Figure II-11). It has been proposed that OGT opens its 
substrate-binding cleft by a hinge-like motion around a pivot point, called hinge region, 
between the TPR domain and the catalytic domain (Lazarus et al., 2011). Residues T11, H12 
and E13, when bound to OGT, are surrounded by this OGT hinge region, thus their flexibility 
is likely to be caused by the flexible OGT hinge. This hypothesis is in agreement with both 
molecular dynamics analyses and in vitro HCF-1–OGT pull-down assays showing that T11, 
H12 and E13 do not contribute to OGT binding (Figure II-8 B and D). The flexibility of T11, 
H12 and E13 (together called HCF-1PRO-repeat Hinge region) appears to be important for 
HCF-1PRO-repeat cleavage (Figure II-12 A). The HCF-1PRO-repeat Hinge region might be 
important to accommodate the HCF-1PRO repeat inside the OGT enzyme by providing 
flexibility in the area formed between the OGT hinge and the HCF-1PRO repeat. Indeed, it has 
been suggested that the movement of the OGT hinge region might be required to 
accommodate large substrates (Lazarus et al., 2011), such as is HCF-1. Nevertheless, 
residues T11, H12 and E13 are highly conserved (like their adjacent residues) arguing for a 
function of these residues beyond simply contributing to flexibility. 
HCF-1PRO-repeat proteolysis requires intact UDP-GlcNAc 
UDP-GlcNAc is the donor substrate for OGT’s glycosyltransferase activity, but it is also 
required for HCF-1PRO-repeat proteolysis. Indeed, the efficiency of HCF-1PRO-repeat cleavage 
increases with increasing concentrations of UDP-GlcNAc (Figure II-2 B). Two reasons for this 
requirement could be: (i) UDP-GlcNAc allosterically activates the OGT active site for 
proteolysis. Allosteric modulators (proteins or small molecules) can bind to a region of the 
enzyme that does not participate directly in substrate recognition and processing (allosteric 
site). The allosteric site can enhance substrate to product transition through conformational 
changes in the enzyme (Drag and Salvesen, 2010). Evidence for allosteric activation by 
UDP-GlcNAc could not be found, given that UDP-5SGlcNAc does not allow for cleavage 
despite its similar OGT-binding properties (Lazarus et al., 2012). Another possibility is that (ii) 
UDP-GlcNAc could actively participate in the reaction mechanism occurring during 
proteolysis and would thus not be only a cofactor, but also a cosubstrate for the reaction 
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(UDP-GlcNAc is also a cosubstrate for the O-GlcNAcylation reaction, see section I.6.3). A 
cosubstrate is a cofactor that is utilized or transformed during the enzymatic reaction, and is 
therefore a substrate. The second, preferred hypothesis is consistent with the fact that UDP 
and UDP-5SGlcNAc inhibit proteolysis.  
The HCF-1PRO-repeat residue E10 is the only residue in the HCF-1PRO-repeat 
cleavage region, which exhibits inhibitory properties for OGT association (Figure II-8). The 
presence of UDP-GlcNAc in the OGT–UDP-GlcNAc–HCF-1rep1 complex interfered with 
binding of the E10 side-chain to OGT (Figures II-6 and II-7). Subsequent experiments 
showed that the E10 side-chain forms unfavorable contacts with residues in the OGT 
catalytic domain. The unfavorable position of E10 in the OGT active site is stabilized by 
UDP-GlcNAc, and becomes less unfavorable in the absence of UDP-GlcNAc (Figures II-9 
and II-10). UDP in the OGT active site does not cause unfavorable interactions of the E10 
side-chain, suggesting that the sugar moiety of UDP-GlcNAc is crucial for this effect (Figure 
II-8 E). Why could a strained interaction between a cleavage substrate and its enzyme be 
important for proteolysis? In fact, a release from the substrate strains in the OGT–UDP-
GlcNAc-HCF-1PRO-repeat complex would be energetically favored. Thus, I propose that the 
energy required for E10 binding is used to favor HCF-1PRO-repeat proteolysis, which causes 
the release from the strains. 
It has been proposed that E10 lies in the catalytic center for cleavage (Capotosti et 
al., 2011), and on the basis of the present data, this hypothesis is likely true. It is also evident 
now why the E10A mutation enhances HCF-1–OGT association. Physical interaction assays 
and molecular dynamics simulations with E10A, E10Q and E10D substitutions (Figure II-9) 
clearly showed that alanine — but also residues with slightly different side-chain structures 
with respect to glutamate — “enhance” HCF-1PRO-repeat–OGT association because they 
display less unfavorable interactions within the OGT–UDP-GlcNAc–HCF-1PRO-repeat 
complex. In other words, they simply “fit better” inside the OGT catalytic domain. 
Proposed initial step for HCF-1PRO-repeat proteolysis 
The HCF-1PRO-repeat E10 residue is unique within the HCF-1PRO-repeat cleavage region for 
its cleavage and binding properties, and its side-chain structure is crucial for HCF-1PRO-
repeat proteolysis (Figure II-4 C). Lazarus et al. (2013) showed that after proteolysis, the 
glutamate side-chain E10 forms an amino-terminal pyroglutamate on the cleaved HCF-1PRO-
repeat polypeptide, supporting a model in which the E10 side-chain participates in the 
proteolysis mechanism. The pyroglutamate is likely the endproduct of the in vitro cleavage 
reaction, however, the reactions occurring during cleavage before pyroglutamate formation 
are unknown.  
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The HCF-1PRO repeat adopts the conformation of an O-GlcNAcylation substrate in the 
OGT active site and the E10 side-chain is located in close proximity to the UDP-GlcNAc 
sugar moiety. Moreover, replacement of E10 by serine activated the HCF-1PRO repeat for O-
GlcNAcylation but blocked proteolysis (Lazarus et al., 2013). Based on these data, in 
Lazarus et al. (2013) we proposed a model for the initial step of the cleavage reaction (Figure 
II-14): The anomeric carbon atom of UDP-GlcNAc could undergo a nucleophilic attack by the 
E10 side-chain. Consequently, the bond between the anomeric carbon atom and the oxygen 
of the β-phosphate would break, leading to hydrolysis of UDP-GlcNAc and, perhaps, to a 
transient glutamylester (O-GlcNAcylated E10 side-chain). This proposed initial mechanism is 
also in agreement with the observation that UDP-5SGlcNAc inhibits cleavage: sulfur is less 
electronegative than oxygen and would activate the anomeric carbon atom less efficiently for 
a nucleophilic attack (Dr. Vincent Zoete and Dr. Ute Roehrig, personal communications). To 
support this model, Dr. Vincent Zoete has performed molecular dynamics simulations of the 
cleavage mechanism. The simulation along the trajectory can be seen in a short movie 
(please follow the link http://www.molecular-modelling.ch/SN2-like.mov). The simulation 
shows that the proposed initial step for the cleavage reaction (Figure II-14) is 
thermodynamically possible: Dr. Vincent Zoete engineered movements of the E10 side-chain 
equivalent to an activation of the cleavage reaction. Following this activation, indeed, an 
elongation of the bond between the anomeric carbon atom and the oxygen of the β-
phosphate of UDP-GlcNAc can be observed. Consequently, the anomeric carbon atom 
moves closer towards E10. The resulting elongated bond is too long to be considered a 
covalent bond and this indicates hydrolysis of UDP-GlcNAc and possible O-GlcNAcylation of 
E10. As discussed above, this initial step for the cleavage reaction could be triggered by the 
substrate strains originating from E10 in the OGT catalytic domain. 
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Figure II-14: Proposed initial step for the HCF-1PRO-repeat cleavage mechanism.     
Arrow 1: The anomeric carbon atom of UDP-GlcNAc undergoes a nucleophilic attack by the 
deprotonated glutamate side-chain at position 10 of the HCF-1PRO repeat (E10). Arrow 2: 
Consequently, the bond between the anomeric carbon atom and the oxygen of the β-phosphate 
elongates and breaks, leading to UDP-GlcNAc hydrolysis and, perhaps, to transiently O-GlcNAcylated 
glutamate. The α- and β-phosphates of UDP-GlcNAc are indicated. Figure adapted from Lazarus et al. 
(2013). 
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The analog UDP-5SGlcNAc changes the HCF-1PRO-repeat–OGT binding mode 
drastically 
When I probed HCF-1PRO-repeat–OGT association with UDP-5SGlcNAc instead of UDP-
GlcNAc, I obtained startling results (Figure II-7). Whereas strong OGT association of wild-
type or E10A HCF-1PRO repeats was observed, I also observed strong OGT association of an 
HCF-1PRO repeat containing the T17-22A mutations. As these mutations normally disrupt 
OGT–HCF-1PRO-repeat association in the presence of UDP, UDP-GlcNAc or in the absence 
of cofactor, this result was unexpected. The reasons for this effect are unclear, but given that 
UDP-5SGlcNAc inhibits HCF-1 O-GlcNAcylation and proteolysis, the following scenario could 
be possible: The E10 side-chain could have been “locked” in the OGT catalytic domain by 
the events that would normally lead to proteolysis. On the basis of our proposed model (see 
above), the E10 side-chain could attack the anomeric carbon atom of UDP-5SGlcNAc. 
Contrary to promoting hydrolysis of the bond between the anomeric carbon atom and the 
phosphate, UDP-5SGlcNAc cannot be (or can merely be) hydrolyzed (Gloster et al., 2011). 
This could lead to a covalent intermediate of E10 bound to UDP-5SGlcNAc in the OGT 
catalytic domain. The covalent intermediate could promote strong interactions between the 
HCF-1PRO repeat and OGT, even in the presence of the T17-22A mutations. 
The HCF-1PRO-repeat threonine region is important for HCF-1PRO-repeat–OGT 
association 
In Lazarus et al. (2013) we showed that the HCF-1PRO-repeat threonine region stably 
interacts with the OGT TPR region. This observation was consistent with the negative effects 
of the HCF-1rep1 threonine region mutant T17-22A on OGT binding and HCF-1PRO-repeat 
cleavage (Figure II-4 B). Thus, the threonine region represents the main OGT-binding 
sequence within the HCF-1PRO repeat. The cleavage region, instead, forms a binding 
interface with UDP-GlcNAc in the OGT catalytic domain (Lazarus et al., 2013). These results 
were in agreement with the prediction of a bipartite OGT–HCF-1PRO-repeat interaction mode 
(Capotosti et al., 2011 and section I.7.3). It is very likely that the stable interactions between 
the HCF-1PRO-repeat threonine region and the OGT TPR region are required to 
accommodate the HCF-1PRO-repeat cleavage region correctly inside the OGT catalytic 
domain. Perhaps, without these strong interactions, the HCF-1PRO-repeat cleavage region 
would not bind to OGT because of the unfavorable interactions between the E10 side-chain 
and residues in the OGT catalytic domain (discussed above). 
 Residue T14 within the threonine region is a representative for the threonines within 
the threonine region because it displays large and favorable interactions with residues in the 
OGT TPR domain via hydrogen bonds (Figures II-8 B and D and Figure II-13). The T14–TPR 
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domain interactions are specific because T14 cannot be replaced by a residue with related 
side-chain structure (serine) or by a residue, which can form strong hydrogen bonds 
(asparagine, Figure II-13). It is not yet understood how OGT recognizes and binds to its 
multitude of O-GlcNAcylation substrates (see section I.6.2), but it has been debated that O-
GlcNAcylation substrates might bind to the OGT TPR domain analogous to how the HCF-
1PRO-repeat threonine region binds to the TPR domain (Lazarus et al., 2013). A search in the 
Swissprot protein data bank, using the Basic Local Alignment Search Tool (BLAST; Johnson 
et al., 2008), did not reveal sequence motifs similar to the HCF-1PRO-repeat threonine region 
in any characterized protein other than in HCF-1 proteins. I therefore propose that the 
interactions between the HCF-1PRO-repeat threonine region and the OGT TPR domain are of 
highly specific nature, to allow for cleavage in the HCF-1PRO-repeat cleavage region. 
Conventional O-GlcNAcylation substrates might therefore interact differently with the OGT 
TPR domain. 
A glycosyltransferase coopted as protease? 
The glycosyltransferase OGT is an unusual protease. The substrate requirements for 
proteolysis within the HCF-1PRO repeat include multiple elements: (i) The HCF-1PRO-repeat 
cleavage region with the essential residue E10, (ii) the HCF-1PRO-repeat flexible Hinge 
region, and (iii) the HCF-1PRO-repeat threonine region for OGT binding. The HCF-1PRO repeat 
binds in the OGT active site analogous to a CK-II O-GlcNAcylation substrate. Interestingly, 
both the HCF-1PRO-repeat and the CK-II substrate, contain a proline residue two positions N-
terminal of the E10 cleavage site or of the GlcNAc acceptor site (S9), respectively. This 
suggests that both substrates could have similar motifs for the association with the OGT 
catalytic domain. In fact, it seems that the HCF-1PRO repeat mimics an O-GlcNAcylation 
substrate and that it uses OGT and UDP-GlcNAc to induce its cleavage. I propose that OGT 
is a bona fide glycosyltransferase that has been coopted by HCF-1 for cleavage of the HCF-
1PRO repeats. The substrate itself determines the type of post-translational modification 
catalyzed in the OGT active site: A single amino acid side-chain at position 10 of the HCF-
1PRO repeat can either promote proteolysis (glutamate) or O-GlcNAcylation (serine). 
 UDP-GlcNAc and particularly the GlcNAc moiety are essential for HCF-1PRO-repeat 
proteolysis. As introduced in section I.5.3, intracellular UDP-GlcNAc levels are proposed to 
reflect the cellular nutrient status via the hexosamine biosynthetic pathway. It is thus possible 
that HCF-1 coopted OGT as its protease to couple cellular nutrient levels to one of HCF-1’s 
major functions — the regulation of cell-cycle progression. 
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Chapter III :  
Requirements for HCF-1 proteolysis outside of the 
HCF-1
PRO
 repeat 
Introduction 
HCF-1PRO-repeat cleavage has been probed in the past using small HCF-1 precursor 
constructs containing one to three HCF-1PRO repeats. The HCF-1PRO repeat was either in its 
natural HCF-1 context (e.g., HCF-1rep1, HCF3R, HCF-1rep123 in Capotosti et al., 2011 and 
Lazarus et al., 2013) or in a heterologous context within the C-terminal region of the Oct-1 
POU transcription factor (Wilson et al., 1995b). In all these cases, HCF-1PRO-repeat cleavage 
could be observed using SDS-PAGE followed by immunoblot analysis or Coomassie 
staining. To create a heterologous HCF-1PRO-repeat construct that can be synthesized and 
purified from E. coli, Capotosti and Herr (unpublished results) designed a smaller construct 
called POUrep2, which contains the HCF-1PRO repeat 2 embedded between the two 
structured domains of the Oct-1 POU DNA-binding domain (POU-homeo domain and POU-
specific domain; Herr et al., 1988). Surprisingly, in contrast to the other heterologous HCF-
1rep constructs, the POUrep2 construct was inactive for cleavage in vitro using in vitro 
substrates synthesized in rabbit reticulocyte translation extracts (Capotosti and Herr, 
unpublished results).  
 Having identified requirements within the HCF-1PRO repeat for cleavage (see Chapter 
II), I investigated here what HCF-1 sequences lying outside of the HCF-1PRO repeat might be 
required for cleavage. 
Results 
III.1 Sequences lying outside of the HCF-1PRO repeat promote cleavage 
The POUrep2 construct (Figure III-1 A) did not display cleavage activity in previous 
experiments with in vitro translated proteins (Capotosti and Herr, unpublished results). I 
confirmed this result in an in vitro cleavage assay using bacterially synthesized precursors 
and in an in vivo cleavage assay. The bacterial assay was performed as described in 
Chapter II. For the in vivo cleavage assay, vectors encoding the HCF-1rep1 or POUrep2 
constructs were transiently expressed in HEK 293 cells and resulting uncleaved precursor 
and N-terminal cleavage products were purified via an N-terminal HA-epitope tag. Cleavage 
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was then assayed by immunoblot using α-HA or α-GST antibodies. Whereas the HCF-1rep1 
wild-type construct was cleaved by OGT in vitro (Figure III-1 B a, lanes 1 and 2, upper panel) 
and in vivo (Figure III-1 B b, lane 1, upper panel), the POUrep2 construct displayed only 
poor, if any, cleavage activity in these two assay systems (a, lanes 3 and 4; b, lane 2, upper 
panel). When O-GlcNAcylation of the protein precursors and cleaved products was probed 
by α-O-GlcNAc immunoblot, contrary to HCF-1rep1, which displayed strong O-GlcNAcylation 
(a, lanes 1 and 2; b, lane 1, lower panel), the POUrep2 precursor protein did not display O-
GlcNAcylation (a, lanes 3 and 4; b, lane 2, lower panel). These results suggest that HCF-
1PRO-repeat proteolysis is context dependent. In the heterologous context of the POU 
domain, the HCF-1PRO repeat is not efficiently cleaved, indicating that there might be 
additional HCF-1 sequences lying outside of the HCF-1PRO repeat that are important for 
cleavage. Moreover, the lack of O-GlcNAcylation of the POUrep2 construct might be related 
to the poor cleavage efficiency of this construct. 
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Figure III-1: HCF-1PRO-repeat cleavage is context dependent.                     
(A) Schematic representation of the HCF-1 full-length protein and the GST-fusion constructs used in 
this experiment. The HCF-1rep1 construct is described in Chapter II. POUrep2 contains GST fused to 
HCF-1PRO repeat 2 embedded in the variable linker between the Oct-1-derived POU-specific (POUS) 
and POU-homeo (POUH) domains. The sequence alignment of the HCF-1PRO repeats 1 and 2 below 
shows that their 20 amino acid HCF-1PRO-repeat core sequences (Kristie et al., 1995) are identical. 
The black arrowhead indicates the cleaved peptide bond. (B) HCF-1PRO-repeat cleavage is context 
dependent. (a) HCF-1PRO-repeat cleavage in an in vitro assay with bacterially synthesized substrates 
and OGT and (b) in an in vivo assay with proteins from transiently transfected HEK 293 cells followed 
by immunoprecipitation via an N-terminal HA-tag. Cleavage and O-GlcNAcylation were visualized by 
immunoblot using, respectively, α-GST (a, lanes 1–4, top panel) and α-HA (b, lanes 1 and 2 top panel) 
antibodies for cleavage, and α-O-GlcNAc antibodies (a and b, bottom panels) for O-GlcNAcylation. 
The positions of uncleaved precursor proteins (–), prominent () or faint (¢) cleavage products and 
background C-terminal precursor truncations (*) are indicated. 
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III.1.1 Subdivision of HCF-1rep1 sequences for deletion analysis 
To identify HCF-1rep1 sequences outside of the HCF-1PRO repeat that might affect cleavage, 
I divided the residues upstream of the HCF-1PRO repeat 1 into three regions: Region I (867-
891), comprising identified O-GlcNAcylation sites in Capotosti et al. (2011) and Region II 
(892-949) and Region III (950-1009), which contain about the same number of residues 
between Region I and the HCF-1PRO repeat, 58 and 60, respectively. Remarkably, these 
three regions are conserved in vertebrate species, in which HCF-1 cleavage is mediated by 
OGT, but not in invertebrate species, in which HCF cleavage is mediated by Taspase1 
(Figure III-2). Figure III-2 also shows the high degree of conservation of the HCF-1PRO 
repeats 1 (rep1) and 2 (rep2) among vertebrate species, and the less well-conserved stretch 
in between them, which I called Region IV. Region IV displays a lower degree of 
conservation, mainly because this sequence is absent in fish HCF-1 proteins. I thus 
generated deletion constructs containing only one of the three Regions I-III (+I, +II, +III) or 
constructs lacking only one of the three regions (∆I, ∆II, ∆III). Additionally, I deleted Region I, 
II, and III all together (∆I.II.III). The HCF-1PRO repeat and the non-conserved Region IV (36 
residues) were retained in all constructs (a schematic illustration of all deletion constructs is 
shown in Figure III-3 A). I analyzed these deletion constructs in three different cleavage 
assay systems, in order to accurately determine the effect of Regions I, II, III, and later also 
IV on HCF-1PRO-repeat cleavage. The HCF-1PRO-repeat mutations E10A and T17-22A, 
described in Chapter II, were used as negative controls for cleavage. 
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Figure III-2: Sequence conservation of HCF-1 sequence 867-1098.         
Sequence conservation among vertebrate and invertebrate species of the HCF-1 sequences 867-
1098. Six different vertebrate species where HCF-1 is cleaved by OGT: Human, Mouse, Xenopus 
tropicalis, Xenopus leavis, Fugu rubripes and Danio rerio were aligned with two invertebrate species 
where HCF is cleaved by Taspase1: Apis mellifera and Drosophila melanogaster, using the Jalview 
bioinformatics tool (Waterhouse et al., 2009). Residues are colored in blue according to conservation 
following the Blosum62 score. Regions I, II, III, IV, and the HCF-1PRO repeats 1 (rep1) and 2 (rep2) are 
indicated, and the residues were numbered according to the human HCF-1 sequence. The black 
arrowheads indicate exon boundaries in the human gene HCFC1 encoding HCF-1. 
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III.1.2 In vitro HCF-1 cleavage assay with in vitro transcribed and translated 
substrates 
To test whether the deletions described above (Figure III-3 A) have an effect on HCF-1PRO-
repeat cleavage, I synthesized the substrates by in vitro transcription and translation and 
subjected them to an in vitro cleavage assay (Figure III-3 B), as described previously 
(Capotosti et al., 2011). To distinguish cleavage products from background bands resulting 
from in vitro synthesis of the polypeptides, I developed a PCR-strategy that allowed the 
synthesis of markers corresponding to the same molecules as the N-terminal cleavage 
products for each deletion construct (lanes 1, 4, 7, 10, 13, 16, 19, 22 and 25, respectively). In 
summary, the cleavage assay of HCF-1rep1 full-length (FL) resulted in a slightly slower 
migrating, uncleaved precursor (lane 3, indicated by –), indicative of O-GlcNAcylation, and in 
a cleaved N-terminal product (lane 3, indicated by ). The analysis of the negative control for 
cleavage, the HCF-1rep1 E10A mutant, revealed no cleavage product at the indicated size 
(lanes 4-6). The ∆I.II.III construct displayed little, if any, cleavage (lanes 7-9), suggesting that 
the HCF-1PRO repeat is not efficiently cleaved in the absence of sequences lying N-terminal 
of the repeat. The loss-of-function analysis of constructs lacking only one of the three regions 
(∆I, ∆II, ∆III, lanes 19-27), as well as the gain-of-function analysis of constructs containing 
only one of the three regions (+I, +II, +III, lanes 10-18) suggested that, among all three 
regions, Region II is the most active region in promoting HCF-1PRO-repeat cleavage.  
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Figure III-3: Deletion analysis with substrates synthesized in a wheat-germ extract in vitro 
transcription and translation system.            
(A) Schematic of the HCF-1rep1 deletion constructs used in this study. Constructs ∆I, ∆II, and ∆III lack 
Regions I, II or III, respectively. ∆I.II.III is a deletion of Regions I, II, and III together and was also 
generated with the E10A or T17-22A mutations that inhibit cleavage. Constructs +I, +II, and +III 
contain Regions I, II or III, respectively. The non-conserved Region IV (36 residues) was retained in all 
constructs. (B) Region II promotes HCF-1PRO-repeat cleavage in vitro: Cleavage assay of in vitro 
synthesized deletion constructs (illustrated in A) in wheat-germ extract in the presence (+) or absence 
(-) of human OGT, produced and purified from insect cells (Capotosti et al., 2011). Proteins were 
resolved by SDS-PAGE and visualized by autoradiography. The markers indicate the size of the N-
terminal cleavage products. The positions of uncleaved precursor proteins (–), and prominent () or 
faint (¢) cleavage products are indicated.  
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III.1.3 In vivo HCF-1 cleavage assay in HEK 293 cells 
To extend the aforementioned in vitro studies, I analyzed cleavage in vivo using the cleavage 
assay described in section III.1. Figure III-4 A shows an in vivo cleavage assay with the full-
length and the HCF-1rep1-deletion constructs. As the amount of protein synthesis cannot be 
controlled in vivo, cleavage activities of these constructs can only be assessed when the 
ratios of precursor versus cleavage product for each sample are compared. Consistent with 
the results obtained in vitro, the presence or absence of the three regions together affected 
cleavage efficiency (FL vs. ∆I.II.III constructs, lanes 1-3, upper panel). The loss-of-function 
analysis revealed that, among the three regions, the lack of Region II had the strongest 
negative effect on cleavage (lanes 4-6, upper panel). The addition of each of the three 
regions individually enhanced HCF-1PRO-repeat cleavage (lanes 7-9, upper panel) with 
respect to the ∆I.II.III construct (lane 2, upper panel), with Region II, offering the greatest 
enhancement. Probing the immunoblot with α-O-GlcNAc antibodies (lower panel) revealed 
that HCF-1rep1 constructs containing Region I or Region II were O-GlcNAcylated. The 
presence of Region II generated the strongest O-GlcNAcylation signal (constructs FL, ∆I, ∆III 
and +II), suggesting that Region II activates the HCF-1 precursor for O-GlcNAcylation, 
perhaps by containing O-GlcNAcylation sites. These results indicate a correlation between 
the cleavage activity of HCF-1rep1 deletion constructs and their O-GlcNAcylation status.   
The results of the in vivo HCF-1rep1 cleavage assay displayed variability among 
independent experiments, particularly in reference to the ∆I.II.III and ∆III constructs (Figure 
III-4 B), due to constant protein synthesis and processing in cells. Nevertheless, these results 
led me to conclude that, although all three regions display cleavage-enhancement activity, 
Region II has the most pronounced activity on HCF-1PRO-repeat proteolysis. 
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Figure III-4: HCF-1PRO-repeat cleavage analysis with HCF-1rep1 wild-type and deletion 
substrates synthesized in HEK 293 cells in vivo.  
(A) Region II promotes cleavage in vivo. HEK 293 cells were transfected with expression vectors 
encoding HCF-1rep1 FL (full-length) or deletion constructs (see Figure III-3 A). Proteins were 
immunoprecipitated by an N-terminal HA-epitope tag and assayed for cleavage by visualization via α-
HA-epitope-tag immunoblot. The positions of cleavage products () and non-specific background 
bands (*) are indicated. (B) In vivo cleavage activities of HCF-1rep1-deletion constructs from three 
independent experiments (exp.1, exp. 2, exp. 3). Cleavage activities of HCF-1rep1 constructs were 
assayed as in (A). Bands on immunoblots were analyzed using LI-COR Image Quant quantification 
software and the cleavage efficiencies quantified as ratio of cleaved product to total GST–HCF-1rep1 
protein (full-length plus cleaved fragment) in the assay. 
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III.1.4 In vitro HCF-1 cleavage assay with bacterially synthesized substrates and OGT 
To complement the studies with wheat-germ extract in vitro translated precursors and the in 
vivo studies, I performed in vitro cleavage assays with bacterially synthesized precursors and 
OGT. Figure III-5 A shows the results of such an in vitro cleavage incubated with bacterially 
purified OGT in cleavage buffer for 16 h as described in Capotosti et al. (2011). Surprisingly, 
unlike in the experiment with in vitro translated substrates and in the in vivo experiment 
described above, in this assay, only a minor difference in cleavage activity between the HCF-
1rep1 FL construct (lanes 1 and 2, upper panel) and the construct lacking all three regions 
together (∆I.II.III, lanes 3 and 4, upper panel) could be observed. And yet, the negative 
control for cleavage, construct ∆I.II.III containing the T17-22A mutations within the HCF-1PRO-
repeat (∆I.II.III/T17-22A), was not cleaved (lanes 5 and 6, upper panel), suggesting that the 
conditions of the in vitro cleavage assay were appropriate to identify cleavage activities. The 
gain-of-function analysis (lanes 7-12, upper panel), as well as the loss-of-function analysis 
(lanes 13-18, upper panel) did not reveal any particular effect of Region II on HCF-1PRO-
repeat cleavage in comparison with the effects of Regions I or III. In contrast, probing the 
immunoblot with α-O-GlcNAc antibodies (lower panel), revealed the same pattern as in the in 
vivo O-GlcNAcylation analysis above (Figure III-4 A, lower panel) with Region II promoting 
the most prominent O-GlcNAcylation of HCF-1rep1 proteins (Figure III-5, lower panel, lanes 
1 and 2, 9 and 10, 13 and 14, 17 and 18). 
 The aforementioned studies represent a single endpoint analysis, in which initial rates 
of cleavage were not determined. Such an analysis can obscure differences between 
enzymatic or substrate activities if the rates reach a plateau over time. Thus, to test if any 
difference in HCF-1PRO-repeat cleavage activation promoted by Region I, II or III can be 
observed after shorter incubation periods with OGT, I examined the cleavage efficiencies of 
a subset of constructs in an 8 h in vitro cleavage assay time course (Figure III-5 B). The rate 
of cleavage for the ∆I.II.III HCF-1rep1 construct was substantially lower than for the FL 
construct. The +II construct displayed slightly more activity than FL, whereas +III displayed 
activity similar to ∆I.II.III. The difference was particularly evident at the earlier time points i.e., 
after 1 and 2 hours. These results indicate a robust role for Region II in HCF-1PRO-repeat 
cleavage enhancement. I concluded that HCF-1rep1 cleavage enhancement by regions N-
terminal of the first HCF-1PRO repeat occurs in a time-dependent manner. Thus, I analyzed 
cleavage activities of HCF-1rep1 constructs after 4 or 8 hours of incubation with OGT in all 
subsequent in vitro cleavage assays, unless stated otherwise. 
 To conclude, the analysis of HCF-1rep1 cleavage in three different cleavage-assay 
systems (in vitro transcription and translation, in vivo and in vitro with bacterially synthesized 
substrates) showed that results obtained in these three systems are consistent with each 
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other. The in vitro cleavage assay with synthesized substrates in wheat-germ extract proved 
to be useful to assay cleavage activities of a large set of substrates in a short time and 
suggested that Region II has enhancing effects on HCF-1PRO-repeat cleavage. The in vivo 
cleavage assay was crucial to understand if similar activities can be observed in vivo, 
mediated by endogenous OGT. The in vitro cleavage assay with bacterially synthesized 
substrates and OGT was essential to assay activities of the different regions on HCF-1PRO-
repeat cleavage at the early time points of the cleavage reaction. Strikingly, this assay 
revealed that the initial rates of cleavage are affected, suggesting that the cleavage-
enhancing regions affect HCF-1PRO-repeat cleavage before reaching a plateau. Based on 
these data, I conclude that Region II enhances HCF-1PRO-repeat cleavage. 
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Figure III-5: In vitro HCF-1PRO-repeat cleavage analysis with substrates and OGT synthesized 
and purified from E. coli.             
(A) Bacterially synthesized substrates and OGT were incubated for 16 h and products resolved by 
SDS-PAGE. HCF-1 or O-GlcNAcylated proteins were visualized by immunoblot using α-GST- (top 
panel) or α-O-GlcNAc-directed (bottom panel) antibodies, respectively. The positions of prominent () 
or faint (¢) cleavage products are indicated. (B) Region II augments the rate of HCF-1PRO-repeat 
cleavage in vitro. Cleavage efficiency over time during a bacterial in vitro cleavage assay of selected 
HCF-1rep1 constructs. HCF-1rep1 constructs were incubated with OGT for 0 to 8 h and precursor and 
resulting N-terminal cleavage products were resolved by SDS-PAGE and analyzed for cleavage by α-
GST-immunoblot. Cleavage efficiencies were quantified as the percentage of cleaved product to 
uncleaved and cleaved HCF-1rep1 protein for each sample, using LI-COR Image Quant software. 
Shown are the means and standard deviations of three independent experiments. 
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III.2 Region II can activate a heterologous HCF-1PRO-repeat substrate for 
cleavage and O-GlcNAcylation 
To test whether Region II can activate the HCF-1pRO repeat in the POUrep2 construct (see 
Figure III-1), I inserted Region II or Region III upstream of the HCF-1PRO repeat 2 in POUrep2 
(Figure III-6 A). As shown in an in vivo cleavage assay (Figure III-6 B), POUrep2 displayed 
weak, if any, cleavage activity (lane 2, upper panel, open circle). Inserting Region III 
upstream of the HCF-1PRO repeat in POUrep2 (+III-POUrep2) weakly enhanced cleavage 
(lane 3, upper panel, open circle), whereas inserting Region II (+II-POUrep2) activated 
strong HCF-1PRO-repeat cleavage (lane 4, upper panel, filled circle). O-GlcNAcylation of the 
uncleaved and cleaved POUrep2 constructs was assayed using α-O-GlcNAc antibodies 
(lower panel). Whereas POUrep2 and +III-POUrep2 displayed weak, if any, apparent O-
GlcNAcylation, +II-POUrep2 displayed prominent O-GlcNAcylation, demonstrating that 
Region II can activate the POUrep2 construct not only for proteolysis, but also for O-
GlcNAcylation. These results suggest that Region II can enhance HCF-1PRO-repeat cleavage 
in an HCF-1 context, as well as in a heterologous context. As Region II and Region III are 
essentially of the same size, the activation by Region II is unlikely to be simply a spacing 
effect between the HCF-1PRO repeat and the POUS domain. To investigate the role of Region 
II in HCF-1PRO-repeat proteolysis, I performed genetic analyses of Region II, presented in the 
following sections. The link between Region II cleavage-enhancement activity and O-
GlcNAcylation activity is addressed in Chapter IV. 
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Figure III-6: Region II can activate HCF-1PRO-repeat cleavage in a heterologous context.             
(A) Schematic of the GST-fusion construct POUrep2 containing HCF-1PRO repeat 2 (rep2), embedded 
in the linker between the POUS and POUH domains. Region II or Region III were inserted N-terminal of 
rep2. (B) In vivo cleavage activities in HEK 293 cells transiently transfected with transfection medium 
(mock) or POUrep2-encoding vectors. Precursors and N-terminal cleavage products were purified via 
immunoprecipitation of an N-terminal HA-epitope tag. Cleavage (upper panel) and O-GlcNAcylation 
(lower panel) were detected using α-HA- and α-O-GlcNAc antibodies, respectively. The positions of 
prominent () and faint (¢) cleavage products are indicated. 
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III.3 Region II activity on HCF-1PRO-repeat cleavage is sequence specific 
Region II represents an HCF-1PRO-repeat cleavage enhancer sequence. To test the 
sequence specificity of Region II’s cleavage-enhancing activity, I replaced the wild-type 
Region II sequence in the HCF-1rep1 +II construct by a scrambled Region II sequence (see 
schematics in Figure III-7 A). As shown in Figure III-7 B, in a bacterial in vitro HCF-1 
cleavage assay, Region II_scrambled (lanes 5 and 6) showed little cleavage activation 
potential when compared to wild-type Region II (lanes 3 and 4), suggesting that the effect of 
Region II is sequence specific and neither caused only by its size nor by its amino acid 
composition. To test whether Region II, in isolation from Region I and III, could enhance 
proteolysis of an HCF-1PRO-repeat threonine region mutant, I introduced the four HCF-1PRO-
repeat threonine mutations (T17-22A, see Chapter II) in construct +II (+II_T17-22A, lanes 7 
and 8). This mutant disrupts HCF-1PRO-repeat–OGT TPR interactions and, consistent with 
this property, cleavage of this mutant was inhibited, showing that defective HCF-1PRO-repeat–
OGT TPR interactions cannot be rescued by Region II activity.  
 The Region III sequence displays little cleavage activation potential (section III.1). To 
test if genetic manipulations of Region III elicit similar effects on cleavage, as observed for 
Region II manipulations, I tested a scrambled Region III sequence and an unrelated 
heterologous sequence of the same size (derived from the replication protein HdaA of the 
bacterium Caulobacter crescentus) in an in vitro cleavage assay (Figure III-7 C). Neither the 
scrambled Region III sequence (lanes 3 and 4) nor the heterologous sequence (lanes 5 and 
6) altered cleavage efficiency as compared to +III (lanes 1 and 2). Indeed, they all displayed 
∆I.II.III activity (lanes 7 and 8). Thus, Region III, unlike Region II, possesses little, if any, 
HCF-1PRO-repeat cleavage enhancement activity. Together, these results show that efficient 
HCF-1PRO-repeat cleavage, in the context of HCF-1rep1, depends on the Region II sequence 
and proper HCF-1PRO-repeat–OGT interactions.  
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Figure III-7: The effect of Region II on HCF-1PRO-repeat cleavage is sequence specific.               
(A) Schematic representation of the different HCF-1rep1 recombinants used in this experiment. 
Bacterial in vitro cleavage assay (incubation for 4 h at 37°C) of different Region II (B) or (C) Region III 
HCF-1rep1 constructs. HCF-1 precursor proteins and N-terminal cleavage products were visualized by 
immunoblot using α-GST-directed antibodies. In (B) and (C), the positions of prominent () and faint 
(¢) cleavage products are indicated.  
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III.4 Region II activity displays positional specificity 
The aforementioned studies established that HCF-1PRO-repeat the cleavage-enhancement 
activity of Region II is sequence specific. To further characterize the activity of Region II, I 
generated a set of mutants containing Region II placed C-terminal of the HCF-1PRO repeat 
(Figure III-8 A). Figure III-8 B shows an in vivo cleavage assay. Whereas HCF-1rep1 FL and 
+II displayed prominent cleavage (lanes 1 and 2, respectively), the HCF-1rep1 +II_C mutant 
(lane 3) displayed only little, if any, cleavage activity, suggesting that the position of Region II 
is important for its activity on cleavage. Because Region II is inactive at the C-terminus of the 
HCF-1PRO repeat, I tested whether reinserting Region II at the N-terminus of the HCF-1PRO 
repeat would rescue cleavage activity (construct +II_N/C). I also inserted Region III N-
terminal of the HCF-1PRO-repeat (construct +III_N_II_C) to control for a potential size effect of 
the N-terminal Region II sequence. Figure III-8 C shows a bacterial in vitro cleavage assay 
with the constructs described above. As expected, and in concordance with the in vivo 
cleavage experiments (Figure III-8 B), +II displayed prominent cleavage (lanes 1 and 2), 
whereas +II_C displayed only little, if any, cleavage activity (lanes 3 and 4). Placing Region II 
N-terminal of the HCF-1PRO repeat in construct +II_C did not rescue cleavage (lanes 5 and 
6), suggesting that Region II at the C-terminus actively inhibits HCF-1PRO-repeat cleavage. 
Replacing the N-terminal Region II by Region III (+III_N_II_C), surprisingly, reactivated 
cleavage to some extent (lanes 7 and 8) when compared to the activities of +II_C or +II_N/C. 
This result was unexpected, as isolated Region III had lower activity on HCF-1PRO-repeat 
cleavage than Region II. These results highlight that HCF-1PRO-repeat cleavage is context-
dependent and that Region II’s activity on cleavage is complicated being sensitive to its 
position relative to the HCF-1PRO repeat. 
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Figure III-8: Region II C-terminal of the HCF-1PRO repeat inhibits HCF-1PRO-repeat cleavage.      
(A) Schematic representation of the HCF-1 full-length protein and the HCF-1rep1 recombinants used 
in this experiment. (B) In vivo cleavage assay. HEK 293 cells were transfected with the indicated 
constructs and subjected to N-terminal α-HA-epitope tag immunoprecipitation. The uncleaved 
precursor protein and N-terminal cleavage products were visualized by α-GST immunoblot. (C) In vitro 
cleavage assay with 4 h incubation time. Resulting uncleaved precursor and N-terminal cleavage 
products were analyzed for cleavage by α-GST immunoblot. In (B) and (C), the positions of prominent 
() and faint (¢) cleavage products are indicated.  
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III.5 Region II activity is dependent on Region IV 
Region II displays not only sequence, but also positional specificity for HCF-1PRO-repeat 
cleavage enhancement. As the latter indicates a context-specific activity of Region II, I tested 
whether the less well-conserved Region IV, consisting of 36 amino acids C-terminal of the 
HCF-1PRO repeat 1, is required for Region II activity. I therefore deleted Region IV in the 
HCF-1rep1 FL or in the +II construct, resulting in constructs ∆IV and +II_∆IV (Figure III-9 A). 
In an in vivo cleavage assay (Figure III-9 B), the FL construct (lane 1) displayed evident 
cleavage activity, whereas the ∆IV construct (lane 2) displayed less activity. This result 
suggests that Region IV might play a role for HCF-1PRO-repeat cleavage. Consistent with this 
observation, +II_∆IV (lane 4) also displayed reduced cleavage with respect to +II (lane 3). 
These results were more evident in an in vitro cleavage assay (Figure III-9 C). These findings 
indicate that the sequence C-terminal of the first HCF-1PRO repeat, Region IV, is important for 
Region II’s cleavage-enhancement activity. 
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Figure III-9: The effect of Region II on HCF-1PRO-repeat cleavage is dependent on Region IV. 
(A) Schematic representation of the HCF-1 full-length protein and the HCF-1rep1 recombinants used 
in this experiment. (B) In vivo cleavage assay. HEK 293 cells were transfected with transfection 
medium (mock) or with the indicated constructs and subjected to N-terminal α-HA-epitope tag 
immunoprecipitation. The uncleaved and cleaved products were visualized by α-HA immunoblot. (C) 
In vitro cleavage assay with 4 h incubation time. Resulting precursor and N-terminal cleavage 
products were analyzed for cleavage by α-GST immunoblot. In (B) and (C), the positions of prominent 
() and faint cleavage products (¢) are indicated. 
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III.6 Regions I, II, and III together potentially affect cleavage of                    
HCF-1PRO repeats 1, 2, and 3 
I have identified activities of conserved sequences lying N-terminal of the first HCF-1PRO 
repeat, in particular Region II, on cleavage of the HCF-1PRO repeat 1. As each of the six 
HCF-1PRO repeats represents a functional cleavage site for OGT and preference for cleavage 
of a particular repeat could not be determined (Wilson et al., 1995b), I tested whether the 
sequences comprising Regions I, II, and III could also affect cleavage of the HCF-1PRO 
repeats 2 and 3. To this end, I used an HCF-1 substrate called HCF-1rep123, which contains 
half of the HCF-1 Basic Region, Regions I–IV, and the first three HCF-1PRO repeats 
(Capotosti et al., 2011; Capotosti et al., 2007; Figure III-10 A). I created deletion constructs 
HCF-1rep123 ∆II and ∆I.II.III. Because the HCF-1rep123 protein is insoluble during bacterial 
synthesis and purification, I subjected HCF-1rep123 and its deletion constructs to an in vivo 
cleavage assay. Figure III-10 B shows an OGT co-immunoprecipitation assay with wild-type 
or mutant HCF-1rep123 constructs transiently expressed in HEK 293 cells. HCF-1rep123 is 
cleaved at all three HCF-1PRO repeats (lane 1, panel a) and associates with OGT (lane 1, 
panel c). The same construct containing E10A mutations within all three repeats (HCF-
1repXXX) did not display cleavage (lane 2, panel a), but enhanced OGT association (lane 2, 
panel c), as expected (see Chapter II and Capotosti et al., 2011). Deletion of Region II (HCF-
1rep123 ∆II) did not cause any detectable decrease of cleavage activity of HCF-1PRO repeats 
1, 2 and 3 (lane 3, panel a), but decreased OGT association when compared to wild-type 
HCF-1rep123 (compare lane 3 to lane 1, panel c). Deletion of Regions I, II, and III together, 
slightly decreased HCF-1PRO-repeat cleavage. The strongest decrease of cleavage was 
observed for HCF-1PRO repeat 3 (lane 4, panel a, open circle). Interestingly, this construct 
also displayed decreased OGT association (lane 4, panel c). 
 I concluded that deletion of Region II alone, in the more natural context of the HCF-
1rep123 precursor construct, does neither affect cleavage of HCF-1PRO repeat 1, nor of HCF-
1PRO repeats 2 and 3 in a transient in vivo assay. Deleting Regions I, II, and III together, 
however, slightly affects the cleavage efficiency of the three HCF-1PRO repeats. In transient in 
vivo cleavage assays, the simultaneous synthesis and processing of HCF-1 precursor 
proteins impedes the determination of differences between the activities of different regions 
on cleavage (III.1.3). It is thus possible that Regions I, II, and III also play a role for the 
enhancement of HCF-1PRO-repeat cleavage in the HCF-1rep123 context or in the HCF-1 full-
length context. OGT co-immunoprecipitation revealed that deletion of Region II decreases 
OGT association with the HCF-1 precursor HCF-1rep123, suggesting that Region II can 
associate with OGT. This result was surprising, as in previous studies (Capotosti et al., 2011; 
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Daou et al., 2011) the main OGT-interaction domain was attributed to the HCF-1PRO repeats. 
The role of Region II in OGT association is addressed in Chapter IV. 
 
 
 
Figure III-10: Regions I, II, and III together affect cleavage of a substrate containing 
HCF-1PRO repeats 1, 2, and 3.            
(A) Schematic representation of full-length HCF-1 and the precursor protein HCF-1rep123 (amino 
acids 686-1166) containing Regions I, II, III, and IV as illustrated. (B) In vivo cleavage assay and OGT 
co-immunoprecipitation. HEK 293 cells were transfected with the wild-type HCF-1rep123 construct 
(lane 1), and HCF-1rep123 constructs containing mutated, non-cleavable HCF-1PRO repeats (HCF-
1repXXX; X=E10A, lane 2), or lacking either Region II (HCF-1rep123 ∆II, lane 3) or Regions I, II, and 
III together (HCF-1rep123 ∆I.II.III, lane 4). Transiently synthesized proteins were subjected to native 
N-terminal α-HA-epitope tag immunoprecipitation (HA-IP, panel a). Co-immunoprecipitated material 
was probed for OGT association via α-OGT immunoblot (HA-IP, c). The uncleaved and N-terminal 
cleavage products were visualized by α-HA immunoblot. The positions of N-terminal cleaved products 
at the three repeats (rep1, rep2, rep3) and prominent () and faint (¢) cleavage products are indicated. 
(*) Non-specific bands.  
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Discussion 
HCF-1PRO-repeat cleavage can get enhanced by flanking HCF-1 sequences  
HCF-1PRO-repeat proteolysis is a slow reaction compared to other proteolytic reactions. For 
instance, complete casein digestion by trypsin occurs in the range of minutes (Fraser and 
Powell, 1950). In contrast, maximum HCF-1PRO-repeat cleavage (approximately 50 %) is 
reached only after 8 h of incubation with OGT. HCF-1PRO-repeat cleavage is even less 
efficient in the absence of sequences flanking the first HCF-1PRO repeat (Regions I, II, and 
III), as an HCF-1rep1 construct lacking these regions (construct ∆I.II.III) was cleaved only at 
an efficiency of approximately 20 % after 8 h (Figure III-5 B). Of all regions, Region II, a 58 
amino acid sequence rich in serines and threonines, displayed most prominent cleavage-
enhancement activity. As cleavage enhancement occurs prominently at the early time points 
of the reaction, I propose that Region II promotes cleavage in a time-dependent manner.  
Region II cleavage enhancement shows similarities with the activity of transcriptional 
enhancers. Transcriptional enhancers are cis-acting DNA regulatory elements that can up-
regulate (i.e. enhance) the transcription of target genes. In many cases, they can be found at 
a large distance to their target genes. Moreover, they are proposed to form loops, a property 
that might enable them to interact with their targets (reviewed in Plank and Dean, 2014). 
Region II at the protein level, lies at a distance of 70 amino acids from the HCF-1PRO repeat 1 
cleavage site and enhances HCF-1PRO-repeat cleavage — a parallel to enhancement of 
transcription by transcriptional enhancers at the DNA level. Nevertheless, it is not known if 
Region II can form loops to interact with the HCF-1PRO-repeat cleavage site from this 
distance. Transcriptional enhancers can recruit transcription factors. Interestingly, in one 
experiment, OGT recruitment by Region II was indicated by an in vivo co-
immunoprecipitation assay (Figure III-10). Region II–OGT association is addressed in 
Chapter IV. 
 Regions I, II, and III are required for efficient HCF-1PRO-repeat proteolysis. This raises 
the question, why an HCF-1 substrate lacking Regions I–III, the HCF3R construct (schematic 
in Figure 1 A in Lazarus et al., 2013), is effectively cleaved? HCF3R contains the first HCF-
1PRO repeat and a stretch of C-terminal sequences covering Region IV and HCF-1PRO repeats 
2 and 3 and does not undergo substantial O-GlcNAcylation (Lazarus et al., 2013). HCF3R 
was incubated with OGT and UDP-GlcNAc for 5 h, and resulting reaction products were 
resolved by SDS-PAGE (Lazarus et al., 2013). In this experiment, cleavage of HCF-1PRO 
repeat 3 was less efficient than cleavage of the other two HCF-1PRO repeats. This is 
consistent with results from an in vivo cleavage assay with HCF-1rep123 constructs, in which 
the absence of Regions I–III decreased cleavage of the third HCF-1PRO repeat (Figure III-10). 
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Nevertheless, to compare cleavage activities between the HCF3R and HCF-1rep1 
constructs, they have to be examined in parallel in the same experiment, but this has not 
been done yet. In summary, efficient HCF-1PRO-repeat cleavage is promoted by sequences 
flanking the first HCF-1PRO repeat. 
Region II activity on HCF-1PRO-repeat cleavage is complex  
To determine the properties of Region II’s cleavage-enhancement activity, I performed 
genetic analyses of the Region II sequence. Placing Region II C-terminal of the HCF-1PRO 
repeat inhibited cleavage (Figure III-8) and removal of the non-conserved Region IV also 
impaired Region II activity (Figure III-9). I conclude that Region II activity is complex and 
dependent on its HCF-1 context. One explanation for this context dependence could be that 
the sequences surrounding Region II contribute to Region II activity via their structural 
properties. The HCF-1rep1 sequences comprising residues 867-1071 are, however, 
predicted to be unstructured. In fact, the online bioinformatics tool PSIPRED (Jones, 1999), 
predicted very little secondary structure and thus the potential to form loops in Region II (Dr. 
Ute Roehrig, unpublished results). Thus, structural impairments caused by the HCF-1rep1 
secondary structure are unlikely. Moreover, placing Region II in between two structured 
domains, the POU-specific and the POU-homeo domain, does not impair Region II activity 
(Figure III-6). Nevertheless, it remains to be determined whether HCF-1–OGT complexes 
possess structural properties that can influence Region II activity and HCF-1PRO-repeat 
proteolysis. 
Interestingly, a scrambled Region II sequence did not activate HCF-1PRO-repeat 
cleavage (Figure III-7), indicating sequence specificity for Region II activity. It is therefore 
possible that Region II allosterically activates HCF-1PRO-repeat cleavage by binding to the 
enzyme, OGT. As described in the discussion of Chapter II, allosteric effectors can bind to a 
region of the enzyme that does not participate directly in substrate recognition and 
processing (allosteric site). The allosteric site can enhance substrate to product transition 
through conformational changes in the enzyme. Indeed, allosteric activation by proteins 
derived from nucleosomes has been described for polycomb repressive complex 2 (PRC2) 
activity (Yuan et al., 2012). In this case, an amino acid stretch derived from histone H3 
enhances PRC2 activity through binding to one of the PRC2 subunits. A scrambled histone 
H3 peptide, however, does not display this activity, similarly to what I observed using the 
Region II scrambled sequence. PRC2 is a large protein complex quite distinct from OGT as it 
is composed of four different proteins that interact with each other (oligomeric complex). In 
fact, most allosteric enzymes are oligomeric. In contrast, OGT consists of only one 
polypeptide chain that folds into two structurally distinct domains, the catalytic domain and 
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the TPR domain (see Figure I-8). It thus remains to be solved if OGT is an allosteric enzyme 
and if Region II can act as an allosteric effector. 
HCF-1 cleavage activity correlates with HCF-1 O-GlcNAcylation efficiency 
Immunoblot of HCF-1 proteins using α-O-GlcNAc antibodies after in vitro or in vivo cleavage 
assays suggested that Region II contains or activates a number of residues for O-
GlcNAcylation (Figures III-4–III-6). These results suggest that Region II activity might be 
linked to O-GlcNAcylation activity. Nevertheless, it is important to keep in mind that, in the 
context of the HCF3R construct, O-GlcNAcylation does not appear to be required for 
proteolysis (Lazarus et al., 2013). I thus conclude that HCF-1 O-GlcNAcylation correlates 
with HCF-1PRO-repeat cleavage efficiency, but that this correlation does probably not reflect 
causality. 
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Chapter IV :  
HCF-1–OGT-association and O-GlcNAcylation 
activities and linkage to HCF-1
PRO
-repeat cleavage 
Introduction 
I identified a complex activity of an HCF-1 sequence called Region II, which lies N-terminal of 
the first HCF-1PRO repeat. This region enhances HCF-1PRO-repeat cleavage when placed N-
terminal of the HCF-1PRO repeat. Since, in the aforementioned studies, Region II cleavage 
activity correlates with O-GlcNAcylation and OGT association, I dissected these three 
activities further to understand the mechanism of Region II cleavage enhancement. In this 
chapter, I present mutational, protein–protein association, and proteomic analyses of Region 
II. Eventually, I propose a hypothetical model that aims to explain Region II activity. This part 
of the project was developed in collaboration with Dr. Patrice Waridel (Protein Analysis 
Facility, University of Lausanne). 
Results 
IV.1 Region II enhances HCF-1–OGT association 
In vivo co-immunoprecipitation studies with HCF-1 constructs lacking the cleavage-enhancer 
sequence Region II indicated that the latter is involved in HCF-1–OGT association (Figure 
III-10). As Region II influenced HCF-1PRO-repeat cleavage neither by its size nor by its amino 
acid composition (Figure III-7), I investigated whether Region II represents a sequence-
specific OGT-binding site. I assayed HCF-1–OGT association in an in vitro HCF-1rep1–OGT 
binding assay, as described in Chapter II. Figure IV-1 B, panel a, shows HCF-1 recovery 
from this OGT-directed pull-down assay with a set of HCF-1rep1-deletion substrates 
(illustrated in Figure IV-1 A). As expected, full-length wild-type HCF-1rep1 (FL, lane 2) bound 
more weakly to OGT than the E10A mutant (FL_E10A, lane 3). The ∆I.II.III deletion construct 
displayed weak OGT association (lane 4), correlating with its low cleavage efficiency (see 
Chapter III). The +II construct bound strongly to OGT in comparison with +I or +III (compare 
lane 6 to lanes 5 and 7), correlating with strong HCF-1PRO-repeat cleavage enhancement by 
Region II (Chapter III). Surprisingly, Region II without Regions I and III (lane 6) displayed 
higher OGT affinity than in the context of its surrounding regions in FL (lane 2), indicating 
inhibitory effects of Region I and/or III on OGT binding. When assaying constructs containing 
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individual deletions of Region I (∆I, lane 8), Region II (∆II, lane 9) or Region III (∆III, lane 10), 
only weak OGT association, if any, could be detected in the absence of Region I (lane 8) or 
Region II (lane 9). The absence of Region III, however, promoted moderate OGT binding 
(lane 10), suggesting that Region III has inhibitory effects on Region II–OGT association. 
These highly reproducible results show that Region II enhances HCF-1–OGT association. 
Region II might therefore contain an OGT-binding site. 
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Figure IV-1: Region II enhances HCF-1rep1–OGT association.        
(A) Schematic of the full-length (FL) HCF-1rep1 precursor construct and the HCF-1rep1-deletion 
constructs used in this experiment. (B) In vitro HCF-1–OGT binding assay with HCF-1rep1 constructs 
containing WT, or E10A HCF-1PRO-repeats (lanes 1-3) or with deletion constructs either containing 
(lanes 4-7) or lacking Regions I, II or III (lanes 8-10), respectively, in the presence of UDP-GlcNAc. 
Shown are 100 % of OGT pull-down (panels a and b) and 11 % of the input (panels c and d). 
Immunoblotting with antibodies directed to GST or to the T7 epitope was used to detect GST–HCF-
1rep1 and OGT, respectively. The positions of HCF-1 proteins displaying strong () or weak (¢) OGT 
binding are indicated. IgG heavy chain (*). 
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IV.2 Region II represents an independent OGT-binding sequence 
As the HCF-1PRO repeat is an OGT-binding site (Chapter II and Lazarus et al., 2013), I 
investigated whether Region II can bind OGT independently of the HCF-1PRO repeat and 
whether the binding mode is similar to the HCF-1PRO-repeat–OGT interaction. To test this in 
an in vitro HCF-1–OGT binding assay, I used two main mutational strategies: First, I mutated 
the HCF-1rep1 substrate to obtain a set of constructs either containing an OGT-binding-
defective HCF-1PRO repeat (+II_T17-22A) or the Region II or Region III sequences alone 
(II_alone or III_alone). Additionally, I engineered a scrambled Region II sequence in the 
absence of additional HCF-1 sequences (II_scramb_alone) to assess if Region II displays 
sequence-specific binding to OGT (Figure IV-2 A). The second strategy allowed me to 
understand if the OGT TPR domain is involved in Region II binding. For this purpose, I used 
the HCF-1 cleavage and O-GlcNAcylation compromised 5N-5A OGT mutant (kindly provided 
by Dr. Vaibhav Kapuria), containing alanine mutations of five conserved asparagines, which 
mediate interactions with the HCF-1PRO repeat (Lazarus et al., 2013). Figure IV-2 B shows an 
HCF-1–OGT binding assay with the described constructs in an assay with wild-type OGT 
(WT) or 5N-5A OGT. The constructs containing the Region II sequence associated strongly 
with WT OGT (lanes 2 and 3, panel a). Although a scrambled Region II sequence did not 
enhance HCF-1PRO-repeat proteolysis (see Chapter III), this scrambled sequence bound to 
OGT (lane 4), suggesting that, contrary to Region II’s cleavage-enhancement activity, Region 
II–OGT binding is not dependent on the Region II sequence, but on its amino acid 
composition. The Region III sequence did not bind to OGT (lane 5), correlating with its weak 
cleavage-activation potential, and further showing that Region III–OGT association is 
specific. When the same assay was performed with 5N-5A OGT (right panel a), OGT binding 
of the Region II sequences was dramatically reduced (lanes 7-9), suggesting a role of the 
OGT TPR domain in Region II recognition and binding. 
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Figure IV-2: Region II is an independent OGT-binding sequence.        
(A) Schematic representation of the HCF-1rep1 recombinants used in this experiment. (B) In vitro 
HCF-1–OGT binding assay in the presence of UDP-GlcNAc. HCF-1rep1 constructs containing Region 
II N-terminal of a binding defective HCF-1PRO repeat (+II_T17-22A, lanes 2 and 7), or GST-fusion 
constructs containing Region II alone (lanes 3 and 8) or a scrambled Region II sequence alone (lanes 
4 and 9) were tested for binding with wild-type (WT) OGT (left panel) or with the OGT TPR mutant 5N-
5A (right panel). The construct III_alone (lanes 5 and 10) was used as a negative control for OGT 
binding. Shown are 100 % of OGT pull-down (panels a and b) and 11 % of the input (panels c and d). 
Immunoblotting with antibodies directed to GST or to the T7 epitope was used to detect GST–HCF-
1rep1 and OGT, respectively. The positions of HCF-1 proteins displaying weak (¢) OGT binding are 
indicated. 
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Because Region IV interferes with Region II activity for cleavage (Figure III-9), I asked next, 
whether the non-conserved Region IV also interferes with Region II–OGT binding and in this 
case, if Region IV represents an independent OGT–binding site. To test this, I engineered an 
HCF-1 construct containing only Region IV (IV), and I used the deletion constructs containing 
or lacking Region IV that were tested for cleavage activity in Chapter III (schematics in Figure 
IV-3 A). Region IV itself does not associate efficiently with OGT (Figure IV-3 B, lane 2, panel 
a). Deleting Region IV from the HCF-1rep1 FL construct (∆IV) decreased OGT association 
(lane 4) with respect to FL–OGT association (lane 3). Consistent with this result, deleting 
Region IV from the +II construct (+II_∆IV) reduced Region II–OGT binding efficiency (lane 6) 
when compared to +II (lane 5). These results suggest that Region IV does not represent an 
efficient OGT-binding sequence on its own, but it rather cooperates with the Region II 
sequence to promote HCF-1–OGT association. 
 Summing up these results, I conclude that the Region II cleavage-enhancer 
sequence binds autonomously to OGT, representing an independent OGT-binding 
sequence. As I was not able to detect efficient OGT binding to a single wild-type HCF-1PRO 
repeat in the absence of Region II (Figure IV-1 B, ∆I.II.III, lane 4), I conclude that Region II, 
next to the six HCF-1PRO repeats, is one major OGT-binding site of the HCF-1 protein. 
Furthermore, Region II–OGT interactions are mediated by OGT’s TPR domain, suggesting 
that the TPRs can recognize not only the HCF-1PRO-repeat threonine region, but also other 
HCF-1 sequences lying outside of the HCF-1PRO repeat. 
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Figure IV-3: Region IV supports Region II–OGT association.         
(A) Schematics of the full-length (FL) HCF-1rep1 precursor recombinants used in this experiment. (B) 
In vitro HCF-1–OGT binding assay in the presence of UDP-GlcNAc. Shown are 100 % of OGT pull-
down (panels a and b) and 11 % of the input (panels c and d). Immunoblotting with antibodies directed 
to GST or to the T7 epitope was used to detect GST–HCF-1rep1 and OGT, respectively. The positions 
of HCF-1 proteins displaying strong () or weak (¢) OGT binding are indicated. IgG heavy chain (*). 
The protein band corresponding to HCF-1rep1_∆IV (lane 4) co-migrates with the IgG heavy chain. 
  
GSTHCF-1rep1 FL 1
II IIII IV
+II 1I
1∆ IV
+II_∆ IV 1I
(II.rep1.IV)
(I.II.III.rep1)
(I.II.III.rep1.IV)
(II.rep1)
(IV.)IV
 IV
+
∆ 
IVFL + I
I
+ + +
GS
T
+
HCF-1rep1
ncOGT
+ 
II_
∆ 
IV
+
36
130
95
OGT
Pull-
down
kDa
Input
130
95
36
HCF-1
(α-GST)
OGT
(α-T7)
OGT
(α-T7)
HCF-1
(α-GST)
A
B
1 2 3 4 5 6
*
a
b
c
d
CHAPTER IV 
 100 
IV.3 Efficient Region II–OGT binding requires the OGT TPR domain 
The results from the binding experiments above indicated that the OGT TPRs are involved in 
Region II recognition and binding (Figure IV-2). Furthermore, Region II–OGT binding 
appears to be supported by Region IV. Therefore I tested which OGT TPRs are required to 
bind to Region II, and if Region IV is involved in TPR binding. For this binding experiment, I 
used three OGT TPR mutants (kindly provided by Dr. Vaibhav Kapuria), containing N-
terminal deletions of TPRs 1–6, 1–8 or 1–9 (schematically illustrated in Figure IV-4 A; a). I 
used HCF-1 constructs either containing only Region II (II_alone) or Region II and Region IV 
(II.IV; Figure IV-4 A; b). In general, in in vitro HCF-1–OGT binding assays, the bands 
resulting from GST-directed antibodies (to detect HCF-1 binding) on immunoblots need to be 
analyzed. This signal, however, is often obscured by the presence of HCF-1 O-
GlcNAcylation sites, making the detection of HCF-1 proteins difficult. To assay OGT–HCF-1 
binding without the interference of O-GlcNAcylation, I omitted UDP-GlcNAc from the in vitro 
binding assay shown in Figure IV-4 B. Whereas the construct II.IV bound strongly to full-
length ncOGT (FL; lane 2, panel a), OGT binding efficiency decreased when either OGT 
TPRs 1–6 (∆1–6, lane 5) or 1–8 (∆1–8, lane 8) were removed. OGT binding was not 
detectable in an assay with OGT containing a deletion of TPRs 1–9 (∆1–9, lane 11, panel a). 
In contrast, II_alone–OGT binding was only detected when assayed with FL ncOGT (lane 3, 
panel a) and could not be detected with any of the TPR deletion mutants (lanes 6, 9 and 12). 
I conclude that efficient Region II association with OGT requires a large proportion of the 
OGT TPR domain. Region IV can provide stability to Region II–OGT association, consistent 
with results described in section IV.2 above. 
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Figure IV-4: Efficient Region II–OGT binding requires the OGT TPR domain.      
(A) Schematic representation of the OGT (a) and HCF-1 (b) constructs used in this experiment (not to 
scale). (a) Human full-length OGT (ncOGT) and the OGT recombinants with TPR deletions 1–6 (∆1–
6), 1–8 (∆1–8), or 1–9 (∆1–9). (b) HCF-1 constructs II.V and II_alone were derived from the HCF-
1rep1 precursor construct. (B) In vitro HCF-1–OGT binding assay in the absence of UDP-GlcNAc. 
Shown are 100 % of OGT pull-down (panels a and b) and 11 % of the input (panels c and d). 
Immunoblotting with antibodies directed to GST or to the T7 epitope was used to detect GST–HCF-
1rep1 and OGT, respectively. The positions of HCF-1 proteins displaying detectable () and 
undetectable (¢) OGT binding in this assay are indicated. This experiment was performed twice and 
obtained data was reproduced . 
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IV.4 Region II contains a cluster of O-GlcNAcylation sites 
HCF-1 is known to be a highly O-GlcNAcylated protein, and O-GlcNAcylation sites, 
predominantly in the N-terminal subunit, have been identified in several studies (Capotosti et 
al., 2011; Myers et al., 2013; Wang et al., 2010a; Daou et al., 2011). Analysis for O-
GlcNAcylation by immunoblot of the HCF-1rep1 precursor protein revealed that Region II 
promotes HCF-1 O-GlcNAcylation (Chapter III). As an analysis via immunoblot using α-O-
GlcNAc antibodies does not reveal the exact positions of the modifications, I subjected the 
HCF-1rep1 protein to liquid chromatography tandem mass spectrometry (LC-MS/MS) 
followed by O-GlcNAcylation analysis in collaboration with Dr. Patrice Waridel. O-
GlcNAcylation sites in an HCF-1 precursor construct comprising HCF-1 residues 686 to 1166 
(HCF-1rep123) have previously been reported (Capotosti et al., 2011). The HCF-1 sequence 
immediately upstream of the first HCF-1PRO repeat, spanning Region II, was not covered by 
the peptides generated by combined trypsin and Glu-C digestion in this analysis. Thus, O-
GlcNAcylation sites could be identified in Region I, but not in Region II and parts of Region 
III. Since the lack of trypsin and Glu-C sites was the major hurdle to achieve full peptide 
coverage, I engineered trypsin cleavage sites (lysines) by mutagenesis at two different 
positions within the HCF-1 sequence (A933K and M951K). The mutations had no effect on 
HCF-1rep1 cleavage and O-GlcNAcylation levels, as determined by immunoblot (data not 
shown). 
I purified transiently synthesized HCF-1rep1 full-length (FL) with the engineered 
trypsin cleavage sites from HEK 293 cells and analyzed the precursor uncleaved band 
(Figure IV-5, band a), as well as the N-terminal cleavage product (band b) for O-
GlcNAcylation. The identified O-GlcNAcylation sites of the HCF-1rep1 uncleaved precursor 
and the N-terminal cleavage product were nearly identical (Table IV-1), suggesting that HCF-
1PRO-repeat proteolysis has minor effects on the HCF-1rep1 O-GlcNAcylation pattern. Figure 
IV-5 illustrates schematically the results of the O-GlcNAcylation analysis of the HCF-1rep1 
uncleaved precursor protein. Because of the new trypsin cleavage sites, full peptide 
coverage of the HCF-1 sequence was achieved, and the previously identified confident O-
GlcNAcylation sites (red squares; Capotosti et al., 2011) in Region I were confirmed. 
Additionally, a cluster of four confident (red squares) and two potential (blue squares) O-
GlcNAcylation sites in Region II and only one confident and two potential O-GlcNAcylation 
sites in Region III were identified. The HCF-1PRO repeat contained two O-GlcNAcylated sites 
in the threonine region. These results confirm the O-GlcNAcylation pattern observed by 
immunoblot of the HCF-1rep1 deletion constructs: Region I contains some, Region III only a 
few, and Region II contains several (six) O-GlcNAcylation sites. The O-GlcNAcylated 
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residues in Region II are concentrated in the C-terminal half of Region II and form a cluster, 
typical for highly O-GlcNAcylated proteins (Trinidad et al., 2012). 
 Since HCF-1 is phosphorylated (Wysocka et al., 2001a; Dephoure et al., 2008; Olsen 
et al., 2010) and cross-talk between O-GlcNAcylation and phosphorylation has been 
observed in previous studies (reviewed in Hart et al., 2011), we also searched for 
phosphorylation sites in the LC-MS/MS analysis (Figure IV-5, yellow circles). We confirmed a 
phosphorylation site in Region III at S984 (a potential glycogen synthase kinase-3 (GSK-3) 
phosphorylation site; Myers et al., 2013) and identified a novel phosphorylation site at S1070 
within Region IV. In an in vivo cleavage assay, both an alanine substitution of S984 to inhibit 
phosphorylation and an aspartate substitution of S984 to constitutively mimic 
phosphorylation did not alter O-GlcNAcylation levels or cleavage efficiencies of the HCF-
1rep1 substrates, as detected by immunoblot (data not shown). These results indicate that 
phosphorylation of S984 in Region III interferes neither with HCF-1PRO-repeat cleavage nor 
HCF-1rep1 O-GlcNAcylation. Curiously, however, whereas we detected phosphorylation of 
S984 in the HCF-1rep1 precursor and cleaved products, we only detected S984 O-
GlcNAcylation in the cleaved product (Table IV-1). 
 
 
 
Figure IV-5: Identification of O-GlcNAcylation and phosphorylation sites in the uncleaved   
HCF-1rep1 precursor (see also Table IV-1).                    
(Left) The full-length (FL) HCF-1rep1 precursor and the N-terminal cleavage product were purified 
from HEK 293 lysates via α-HA-epitope immunoprecipitation and visualized by Coomassie staining. 
The uncleaved precursor (a) and the N-terminal cleavage band (b) were analyzed for O-GlcNAcylation 
and phosphorylation by LC-MS/MS. (Right) Schematic representation of identified HCF-1rep1 O-
GlcNAcylation and phosphorylation sites in the uncleaved HCF-1rep1 precursor. The entire HCF-1 
sequences covered by the LC-MS/MS analysis (867-1071) and the engineered trypsin cleavage sites 
A933K and M951K are indicated below the diagram. Red and blue squares indicate confident or 
potential O-GlcNAcylated residues, respectively. Squares surrounded in black indicate identified sites 
in Capotosti et al. (2011). Yellow circles indicate confident phosphorylation sites.  
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Table IV-1: Identification of O-GlcNAcylation and phosphorylation sites of the in vivo 
synthesized uncleaved HCF-1rep1 protein and the N-terminal HCF-1rep1 cleavage product. 
Modification HCF-1rep1 uncleaved HCF-1rep1 cleaved Reference 
O-GlcNAcylation T877 T877 Capotosti et al., 2011 
O-GlcNAcylation T878 T878 Capotosti et al., 2011 
O-GlcNAcylation T881 T881 Capotosti et al., 2011 
O-GlcNAcylation N/D 
S901, T902, S903, T905 
(ambiguous localization) 
novel 
O-GlcNAcylation N/D T918 novel 
O-GlcNAcylation N/D S920 novel 
O-GlcNAcylation S921 S921 novel 
O-GlcNAcylation T927 N/D novel 
O-GlcNAcylation S932 S932 novel 
O-GlcNAcylation T936 T936 novel 
O-GlcNAcylation T937 T937 novel 
O-GlcNAcylation T939 T939 novel 
O-GlcNAcylation T950 T950 novel 
O-GlcNAcylation S955 S955 novel 
O-GlcNAcylation N/D S980 novel 
Phosphorylation S984 S984 Myers et al., 2013 
O-GlcNAcylation N/D S984 novel 
Phosphorylation 
T986/T987 
(ambiguous localization) 
T986/T987 
(ambiguous localization) 
novel 
O-GlcNAcylation T995 T995 novel 
O-GlcNAcylation T1020 N/A novel 
O-GlcNAcylation T1025 N/A novel 
Phosphorylation S1070 N/A novel 
Residues in red and black are confident O-GlcNAcylation and phosphorylation sites (Mascot score > 
23 & probability of localization > 70 %) respectively, and residues in blue are potential                       
O-GlcNAcylation sites (Mascot score 14-22 or probability of localization 50-70%). 
N/A, not applicable; N/D, not detected 
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IV.5 Region II placed C-terminal of the HCF-1PRO repeat is differentially          
O-GlcNAcylated  
Since the insertion of Region II C-terminal of the HCF-1PRO repeat (construct HCF-1rep1 
+II_C) inhibited HCF-1PRO-repeat cleavage (Figure III-8), I investigated whether the C-
terminal Region II would still be O-GlcNAcylated and in this case, if the O-GlcNAcylated 
residues would be identical to Region II located N-terminal of the HCF-1PRO repeat 
(schematics of the constructs in Figure IV-6 A). To ensure full HCF-1 sequence coverage for 
mass spectrometry analyses of construct HCF-1rep1 +II_C, I engineered two new trypsin 
cleavage sites (lysines, one of which lies in the HCF-1 sequence, see Figure IV-6 B) and 
retained the A933K mutation (described in IV.4 above). The HCF-1 precursor protein was 
synthesized in HEK 293 cells, purified (Figure IV-6 B, uncleaved band) and analyzed by LC-
MS/MS. We obtained full peptide coverage of the HCF-1 sequence, and O-GlcNAcylation 
sites were identified, as schematically illustrated in Figure IV-6 B. Region II C-terminal of the 
HCF-1PRO repeat contained a total of 10 confident and potential O-GlcNAcylation sites. 
These are four more sites with respect to the number of sites mapped in the N-terminal 
Region II in the HCF-1rep1 FL context (Figure IV-5). Moreover, only two of these 10 O-
GlcNAcylated residues (S921 and T927) are in common with sites in the N-terminal Region II 
sequence. In summary, the number of O-GlcNAcylation sites of C-terminal Region II 
increased, and the O-GlcNAcylation pattern changed, with respect to N-terminal Region II. 
One additional O-GlcNAcylation site was found in Region IV (S1058). 
 I conclude that the HCF-1PRO-repeat cleavage-enhancer Region II not only loses its 
activity when placed C-terminal of the HCF-1PRO repeat, but also displays an altered O-
GlcNAcylation pattern, suggesting that aberrant O-GlcNAcylation might cause loss of Region 
II activity. Moreover, these results show that HCF-1 O-GlcNAcylation is context sensitive and 
does not require strong sequence signals.  
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Figure IV-6: Region II placed C-terminal of the HCF-1PRO repeat displays an altered                     
O-GlcNAcylation pattern.             
(A) Schematics of HCF-1rep1 recombinants analyzed for their cleavage activities (evaluated in Figure 
III-8). (B) Left-hand-side: HCF-1rep1 +II_C uncleaved precursor (arrowhead) was purified from HEK 
293 lysates via α-HA-epitope immunoprecipitation, visualized by Coomassie staining and analyzed for 
O-GlcNAcylation by LC-MS/MS. (*) Non-specific background bands. Right-hand-side: Schematic 
representation of identified O-GlcNAcylation sites in +II_C. HCF-1 sequences covered by the LC-
MS/MS analysis and the engineered trypsin cleavage sites (G to K mutation in the GST sequence, 
and HCF-1 A933K and G1038K) are indicated below the diagram. Red and blue squares indicate 
confident or potential O-GlcNAcylated residues, respectively. Filled squares indicate sites that were 
also identified in the N-terminal Region II sequence (HCF-1rep1 FL analysis Figure IV-5); open 
squares indicate novel O-GlcNAcylation sites that are unique to the +II_C construct. 
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IV.6 Subdivision of Region II leads to reduced cleavage activities of the     
sub-regions in vivo 
As the Region II cleavage-enhancer sequence consists of 58 amino acids, I investigated 
whether its activity could be attributed to a smaller sub-region. Mass spectrometry analysis of 
the HCF-1rep1 precursor protein revealed that Region II contains concentrated O-
GlcNAcylation sites at the C-terminus of its sequence (Figure IV-5). I thus divided Region II 
into a 23 amino acid N-terminal half, called Region II-a, and a 25 amino acid C-terminal half, 
called Region II-b, covering the concentrated O-GlcNAcylation sites. I created HCF-1rep1 
deletion constructs containing either Region II-a or Region II-b (constructs +II-a or +II-b, 
Figure IV-7 A) and I tested them for cleavage and O-GlcNAcylation activities in a 16 hours in 
vitro cleavage assay (Figure IV-7 B). The +II-a construct displayed prominent cleavage 
activity (lanes 5 and 6) in comparison with ∆I.II.III (lanes 3 and 4) and with +II (lanes 1 and 
2), which displayed weak and prominent cleavage activities, respectively. The +II-b construct 
displayed weak cleavage activity (lanes 7 and 8) similarly to ∆I.II.III. It is important to point 
out that cleavage activities in 16 h in vitro cleavage assays are elevated (see Figure III-5). In 
vitro cleavage assays for 4 h showed that cleavage and O-GlcNAcylation activities of 
constructs +II-a and +II-b were generally weaker (data not shown). Nevertheless, data 
obtained after 4 h or 16 h incubation gave similar results. Unexpectedly, construct +II-a 
displayed strong (lanes 5 and 6, lower panel), whereas +II-b displayed little O-GlcNAcylation 
activity (lanes 7 and 8, lower panel), suggesting that the II-a sequence is hyper- and the II-b 
sequence is hypo-O-GlcNAcylated when these sequences are isolated from one another. 
This result was surprising, since I expected the II-b sequence to retain its O-GlcNAcylation 
sites as in the FL context after the deletion of the surrounding sequences.  
 I investigated further whether the above-described constructs display similar activities 
in an in vivo cleavage assay (Figure IV-7 C). Contrary to results obtained in vitro, in the in 
vivo assay, construct +II-a (lane 2, upper panel) displayed weak cleavage activity when 
compared to FL HCF-1rep1 (lane 1). Moreover, the +II-b construct (lane 4) displayed slightly 
more cleavage activity than +II-a, once the ratios between uncleaved and cleaved products 
were compared (lanes 2 and 4). However, +II-b displayed less cleavage activity than the FL 
construct (lanes 1 and 4), suggesting that subdivision of Region II results in a loss of 
cleavage-enhancement activity (note that the in vivo activities of FL and +II are similar, see 
Figure III-4). In contrast to the in vitro results, O-GlcNAcylation levels of constructs +II-a and 
+II-b were similar (compare lanes 2 and 4, lower panel). Duplicating the II-a and II-b 
sequences (constructs +II-a_dupl. and +II-b_dupl.) resulted in similar cleavage and O-
GlcNAcylation activities in comparison to constructs containing only a single II-a or II-b 
sequence. This result suggests that duplications of Region II-a and Region II-b, respectively, 
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do not display full Region II (not shown in this experiment) or FL activity (compare lanes 3 
and 5 and lanes 2 and 4 with lane 1). 
 The in vivo results are in stark contrast with the results obtained in vitro. In fact, this 
was the only analysis, in which I observed great differences between in vitro and in vivo 
activities of tested HCF-1 constructs (see Table Appendix-1). I concluded that, in this case, 
the results obtained in vivo reflect the properties of Region II sub-regions more accurately 
than the in vitro data. When I isolated the HCF-1rep1 +II-b protein after bacterial in vitro 
synthesis, I noticed that the yield, compared to the HCF-1rep1 +II-a protein, was much lower. 
This is indicative of defective protein folding and/or precipitation. Moreover, custom-
synthesized Region II-b peptide was insoluble in a range of different solvents (data not 
shown), supporting the hypothesis that Region II-b solubility is limited. These observations 
suggest that the in vitro cleavage and O-GlcNAcylation activities of the +II-b construct 
(Figure IV-7 B) have to be interpreted carefully. 
 The in vivo results indicate that splitting the Region II sequence into two sub-regions 
results in sequences displaying lower cleavage and O-GlcNAcylation activities than the entire 
Region II sequence. If the individual activities of Region II-a and Region II-b sum up to 
Region II activity remains unclear because in vivo cleavage assays are not suitable to assess 
cleavage efficiencies from a single experiment in a quantitative manner (described in section 
III.1). Nevertheless, these results indicate that Region II does not contain a sub-region 
displaying full Region II activity. Because of potential misfolding of the +II-b construct during 
bacterial in vitro synthesis, I did not assay OGT-binding activities of Regions II-a and II-b in 
an in vitro HCF-1–OGT binding assay, leaving unresolved whether the Region II sub-regions 
display differential OGT-binding activities. 
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Figure IV-7: Region II dissection: analysis of Region II sub-regions for cleavage                      
and O-GlcNAcylation activities.               
(A) Schematics of HCF-1rep1 recombinants. In vivo O-GlcNAcylation sites are schematized as blue 
squares. (B) In vitro cleavage assay with 16 h incubation time. Resulting precursor and N-terminal 
cleavage products were analyzed for cleavage and O-GlcNAcylation by α-GST and α-O-GlcNAc 
immunoblot, respectively. (C) In vivo cleavage assay with proteins from transiently transfected HEK 
293 cells, followed by immunoprecipitation via an N-terminal HA-epitope tag. Cleavage and O-
GlcNAcylation were detected by immunoblot using the indicated antibodies. (*) Background product. In 
(B) and (C), the positions of prominent () and faint (¢) cleavage products are indicated. 
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IV.7 HCF-1PRO-repeat proteolysis does not interfere with Region II                  
O-GlcNAcylation 
It has been suggested that inhibition of HCF-1PRO-repeat proteolysis by E10A mutations in 
the HCF-1PRO repeat decreases general HCF-1 O-GlcNAcylation levels (Capotosti et al., 
2011). To understand if there is a link between Region II O-GlcNAcylation and HCF-1PRO-
repeat proteolysis, I tested whether O-GlcNAcylation levels in Region II are affected by the 
absence of HCF-1PRO-repeat proteolysis. For this purpose, I assessed the in vivo O-
GlcNAcylation levels of a representative Region II peptide (peptide sequence underlined in 
Figure IV-8 A, HCF-1 sequence 901-933) by LC-MS/MS. The LC-MS/MS analysis of HCF-
1rep1 proteins revealed that this Region II peptide can either contain 0, 1, 2 or 3 O-
GlcNAcylation sites, showing that HCF-1 is modified sub-stoichiometrically. This pool of 
Region II peptides was either derived from wild-type (WT), or from cleavage inactive HCF-
1rep1, and the proportions of their different O-GlcNAcylated forms was assessed. Cleavage 
inactive mutants containing the E10 mutations (E10A, E10D, E10Q and E10S), displayed 
decreased Region II O-GlcNAcylation levels when compared to peptides derived from WT 
uncleaved and cleaved proteins (Figure IV-8 B). These mass spectrometry results were 
confirmed in a second independent experiment and suggest that the inactivation of HCF-
1PRO-repeat cleavage by an E10 mutation leads to decreased O-GlcNAcylation of Region II. 
Additionally, I analyzed Region II peptides derived from the T17-22A mutant that 
inhibits cleavage through a defective HCF-1PRO-repeat–OGT TPR domain interaction (see 
Chapter II). Interestingly, Region II peptides derived from this mutant displayed nearly 
identical O-GlcNAcylation levels in comparison with peptides derived from WT HCF-1rep1. 
This suggests that OGT binding to the HCF-1PRO repeat is not required for O-GlcNAcylation 
of HCF-1 sequences. Furthermore, these results show that the decreased O-GlcNAcylation 
levels observed in the HCF-1rep1 E10 mutants are specific to mutations at the E10 cleavage 
site and not to the inhibition of cleavage per se. To support these results, I deleted the entire 
HCF-1PRO repeat in construct HCF-1rep1 to obtain a mutant called HCF-1rep1 ∆PRO and 
found nearly identical O-GlcNAcylation levels when compared to WT and T17-22A HCF-
1rep1 (Figure IV-8 B). 
I drew two conclusions from these results: First, the HCF-1PRO repeat is not 
necessary for O-GlcNAcylation of sequences lying outside of the HCF-1PRO repeat (LC-
MS/MS analysis of other peptides derived from Region I gives similar results, data not 
shown). Second, mutations at the E10 cleavage enhance OGT–HCF-1PRO-repeat association 
(see Chapter II) and thereby prevent O-GlcNAcylation of flanking HCF-1 sequences. Thus, 
HCF-1PRO-repeat proteolysis per se does not interfere with O-GlcNAcylation of Region II and 
other flanking HCF-1 sequences.    
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Figure IV-8: The Region II O-GlcNAcylation status is influenced by HCF-1PRO-repeat E10 
mutations but not by the absence of HCF-1PRO-repeat cleavage per se.      
(A) Top: Schematic representation of the full-length (FL) HCF-1rep1 precursor protein. In vivo O-
GlcNAcylation sites are schematized as blue squares. Bottom: The Region II sequence (confident O-
GlcNAcylation sites are colored in red, potential sites are colored in blue) and a representative peptide 
with an engineered trypsin cleavage site (901-933K) analyzed by LC-MS/MS for O-GlcNAcylation 
levels in (B). (B) Proportions of Region II peptides corresponding to HCF-1 residues 901-933K (see A) 
with 0, 1, 2, or 3 attached O-GlcNAc moieties. The samples were derived from HCF-1rep1 constructs 
synthesized in HEK 293 cells. HCF-1rep1 either contains wild-type (WT) or mutated (E10A, E10D, 
E10Q, E10S, T17-22A) HCF-1PRO repeats or a deletion of the entire HCF-1PRO repeat 1 (∆PRO). 
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IV.8 Region II enhances HCF-1PRO-repeat proteolysis independently of its  
 O-GlcNAcylation status 
As the Region II O-GlcNAcylation status is not influenced by HCF-1PRO-repeat proteolysis per 
se, I asked whether HCF-1PRO-repeat cleavage could be influenced by Region II O-
GlcNAcylation. To address this question, I tested HCF-1PRO-repeat proteolysis by an OGT 
swap mutant that retains wild-type cleavage activity, but is compromised for its O-
GlcNAcylation activity (D554H H558D, kindly provided by Dr. Vaibhav Kapuria). The D554H 
H558D mutant displayed no difference in binding of Regions I, II or III as compared to wild-
type (WT) OGT in an in vitro HCF-1–OGT binding assay (data not shown). I then compared 
cleavage and O-GlcNAcylation activities of WT and D554H H558D OGT on HCF-1rep1 FL or 
+II and +III substrates. Cleavage efficiencies of substrates cleaved by WT OGT or by D554H 
H558D OGT were nearly identical (Figure IV-9 B, upper panel, lanes 2, 3, 5, 6, 8 and 9). 
Importantly, whereas O-GlcNAcylation was detected in the HCF-1rep1 FL and +II construct 
when cleaved by WT OGT (lanes 2 and 5, middle panel), highly reduced O-GlcNAcylation 
was observed when cleaved with the D554H H558D mutant (lanes 3 and 6, middle panel), 
showing that HCF-1PRO-repeat cleavage can be observed although O-GlcNAcylation of HCF-
1 sequences is compromised. (The lack of D554H H558D O-GlcNAcylation activity explains 
the difference in mobility of WT and D554H H558D OGT cleavage products during 
electrophoresis.) These results suggest that Region II enhances HCF-1PRO-repeat cleavage 
independently of its O-GlcNAcylation status. I thus conclude that HCF-1 O-GlcNAcylation 
and HCF-1PRO-repeat proteolysis do not influence each other. 
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Figure IV-9: Region II O-GlcNAcylation is not fundamental for Region II activity on                
HCF-1PRO-repeat proteolysis.             
(A) Schematic representation of the HCF-1rep1 full-length (FL) construct. In vivo O-GlcNAcylation 
sites are schematized as blue squares. (B) In vitro cleavage and O-GlcNAcylation activities (1 h 
incubation time) of wild-type (WT) OGT and an O-GlcNAcylation compromised OGT mutant (D554H 
H558D) on selected HCF-1rep1 substrates. Cleavage and O-GlcNAcylation were analyzed by 
immunoblot using the indicated antibodies. The positions of prominent () and faint (¢) cleavage 
products are indicated. 
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IV.9 HCF-1 O-GlcNAcylation levels are independent of OGT-mediated       
HCF-1PRO-repeat processing 
Capotosti et al. (2011) showed that OGT-mediated proteolysis is important for proper cell-
cycle progression through the activation of the HCF-1C subunit. A full-length HCF-1 construct, 
in which the entire HCF-1PRO-repeat domain had been replaced by two Taspase1 cleavage 
sites, CS1 and CS2 of the MLL protein (see Figure I-4), was not able to rescue cell-division 
defects caused by HCF-1 knockdown in HeLa cells. As the HCF-1 construct containing the 
Taspase1 cleavage sites was efficiently cleaved, the authors concluded that OGT-mediated 
HCF-1 proteolysis, but not proteolysis per se, is important to activate HCF-1C functions. This 
led to the hypothesis that proper HCF-1N O-GlcNAcylation might be involved in the promotion 
of HCF-1 functionality. But the O-GlcNAcylation status of the Taspase1 cleaved HCF-1N and 
HCF-1C subunits was not assessed.  
 To determine whether the HCF-1 subunits produced by Taspase1 are still efficiently 
O-GlcNAcylated, I tested the O-GlcNAcylation status of the HCF-1 constructs full-length wild-
type (WT), and HCF-1 full-length ∆PRO with functional (MLL) or mutated (MLL Mut) MLL 
Taspase1 cleavage sites (Figure IV-10 A). I transiently transfected these HCF-1 
recombinants in HEK 293 cells and subjected them to N-terminal immunoprecipitation (IP), 
followed by SDS-PAGE and immunoblot with α-HA or α-O-GlcNAc antibodies. Native IP of 
the ectopic HCF-1 full-length wild-type (WT) protein and subsequent immunoblotting using 
antibodies directed towards the N-terminus (α-HA) revealed an uncleaved precursor band 
and N-terminal cleavage products (Figure IV-10 B, lane 2, upper panel). ∆PRO MLL 
displayed an uncleaved precursor band and two N-terminal cleavage products (lane 3, upper 
panel), whereas the construct containing the mutated Taspase1 cleavage sites (∆PRO MLL 
Mut) displayed an uncleaved band and no cleavage products (lane 4, upper panel). HCF-1 
WT, ∆PRO MLL and ∆PRO MLL Mut displayed prominent O-GlcNAcylation signals (lanes 2-
4, middle panel). Comparing the HCF-1 WT with the HCF-1 ∆PRO MLL construct revealed 
no apparent difference in O-GlcNAcylation levels (compare lanes 2 and 3, middle panel). 
Interestingly, both constructs displayed a C-terminal O-GlcNAcylated cleavage product 
(lanes 2 and 3, middle and bottom panels), which disappeared upon boiling of the protein 
complexes before IP (denaturing IP, lanes 6 and 7, middle and bottom panels). 
 These results suggest that the HCF-1 construct containing Taspase1 cleavage sites 
(∆PRO MLL) is efficiently O-GlcNAcylated, despite the lack of OGT-mediated proteolysis and 
the lack OGT–HCF-1PRO-repeat association. It is important to point out that O-GlcNAcylation 
analysis by immunoblot cannot reveal subtle changes in O-GlcNAcylation levels or aberrant 
O-GlcNAcylation patterns, and my studies have shown that these can easily vary in 
unexpected ways (Figures IV-6 and IV-7). Nevertheless, these results are in concordance 
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with the O-GlcNAcylation analysis of a smaller HCF-1 fragment, the HCF-1rep1 ∆PRO 
mutant, which did not display different O-GlcNAcylation levels and patterns when compared 
to HCF-1rep1 WT (see Figure IV-8). This analysis also shows that the HCF-1C subunit is 
significantly O-GlcNAcylated and that it therefore also possesses sites for OGT recognition 
and O-GlcNAcylation. HCF-1 O-GlcNAcylation is therefore not restricted to just one of its 
subunits. 
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Figure IV-10: HCF-1 O-GlcNAcylation levels are independent of OGT-mediated HCF-1PRO-repeat 
processing. 
(A) Schematic representation of different HCF-1 constructs. CS1 and CS2 indicate the two Taspase1 
cleavage sites of the MLL protein in their wild-type (WT) or non-cleavable (Mut) form (Hsieh et al., 
2003; constructs engineered by Sophie Guernier, former Herr laboratory member). (B) Native and 
denaturing N-terminal immunoprecipitation (IP): HEK 293 cells were transfected with transfection 
medium (mock) or with the indicated HCF-1 constructs and subjected to α-HA IP using the HA-epitope 
tag. Precursor and N-terminal cleavage products were visualized by α-HA and protein O-
GlcNAcylation by α-O-GlcNAc immunoblot. Precursor proteins (–), and the positions of N-terminal () 
and C-terminal O-GlcNAcylated (¢) cleavage products are indicated. 
  
 HCF-1∆PRO
 HCF-1∆PROMLL
CS1CS2
Kelch Basic HCF-1PRO Acidic Fn3
1 2 3 4 5 6 2035
   NLS
D/GADD
D/GVDD
AAADD
AAADD
 HCF-1WT
CS1:
CS2:
MutWT
1 2 3
H
C
F
-1
 (
α
-H
A)
4
α
-O
-G
lcN
Ac
Denaturing 
HA-IP
α
-O
-G
lcN
Ac
 (r
ed
)
α
-H
A 
(H
CF
-1
) (
gr
ee
n)
HA-tag
5 6 7 8
130
95
kDa
250
72
130
95
250
72
 W
T
∆P
RO
 M
LL
∆P
RO
 M
LL
 M
ut
M
oc
k
Native
HA-IP
M
oc
k
A
B
 W
T
∆P
RO
 M
LL
∆P
RO
 M
LL
 M
ut
CHAPTER IV 
 117 
Discussion 
Region II represents a novel OGT-binding sequence 
The Region II sequence, identified as a sequence-specific HCF-1PRO-repeat-cleavage 
enhancer in Chapter III, represents a novel OGT-binding sequence. Although a multitude of 
O-GlcNAcylated and OGT-interacting proteins have been identified in the past (see I.5 
above), only few OGT-binding sequences and their interactions with OGT have been 
characterized in detail: (i) A 14 amino acid sequence of casein kinase 2 (Lazarus et al., 2011; 
Lazarus et al., 2012), (ii) a 13 amino acid sequence derived from the innate immunity 
signaling protein TAB1 (Schimpl et al., 2012), and (iii) a 17 amino acid sequence derived 
from the HCF-1PRO repeat 2 (Lazarus et al., 2013). Region II represents another 58 amino 
acid OGT-binding sequence (Figure IV-2). 
Region II, in addition to its potent OGT-association activity, also possesses strong 
cleavage-enhancement activity. Thus, I hypothesize that Region II recruits OGT close to the 
cleavage site at the first HCF-1PRO repeat to induce proteolysis. Consistent with this 
hypothesis, Region II cleavage-enhancement activity is particularly evident at the earliest 
time points of the cleavage reaction before reaching a plateau (Figure III-5). This indicates 
that OGT could first get recruited to Region II, and then promotes cleavage enhancement. 
The sequences covering Regions I, II, and III as well as the HCF-1PRO repeats are predicted 
to be highly unstructured and could form extensive loops, such that Region II could, via a 
loop, approach the first HCF-1PRO repeat (see model below). Region II might thus cause 
enrichment of OGT at the HCF-1PRO repeat 1 and thereby promote cleavage, perhaps 
because individual HCF-1PRO repeats do not represent effective OGT-binding sequences 
(see Chapter II and Figure IV-1). 
Interestingly, OGT can bind to a scrambled Region II sequence (Figure IV-2), which 
does not enhance HCF-1PRO-repeat cleavage (Figure III-7). It is thus clear that OGT binding 
to Region II is not sufficient to promote cleavage. This could be explained by the following 
scenario: Although the scrambled Region II sequence is bound by OGT, the structural 
consequences (e.g. looping) can perhaps not be achieved, and thus the enhancement of 
cleavage would be impaired. In support of this hypothesis, the C-terminal Region II construct 
(+II_C) is not cleaved (Figure III-8), but displays prominent OGT-binding activity (data not 
shown). 
The mechanism by which OGT recognizes Region II is unknown. OGT does not 
display sequence specificity for Region II recognition, but the amino acid composition, and 
perhaps the enrichment in serines and threonines could play a role in Region II recognition (a 
serine and threonine density map of the HCF-1rep1 protein is shown in Figure Appendix-1). 
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Moreover, the OGT TPR domain might be involved in Region II recognition as N-terminal 
TPR deletions of OGT decreased Region II–OGT association (Figure IV-4) and the 5N-5A 
OGT mutant did not bind to Region II (Figure IV-2). Region II–OGT association is context 
dependent and can be enhanced or impaired by sequences adjacent to Region II and to the 
HCF-1PRO repeat 1. Region IV C-terminal of Region II enhances (Figures IV-3 and IV-4), 
whereas Region III impairs Region II–OGT association (Figure IV-1), correlating with the 
roles of these regions in HCF-1PRO-repeat cleavage enhancement (Chapter III). I therefore 
suspect, as already mentioned in Chapter III, that when OGT is bound to the HCF-1 protein, 
the regions surrounding Region II and the HCF-1PRO repeat might display structural 
properties supporting or impairing Region II–OGT association. 
Region II is rich in O-GlcNAcylated serines and threonines 
Proteomic analysis of O-GlcNAcylation sites in the HCF-1rep1 precursor protein revealed 
that the respective activities of Regions I, II, and III on HCF-1PRO-repeat cleavage correlate 
with the number of O-GlcNAcylation sites identified in these regions (Figure IV-5), consistent 
with immunoblot results in Chapter III. Whereas identification of O-GlcNAcylated proteins by 
immunoblot revealed the big differences in O-GlcNAcylation levels, LC-MS/MS analysis 
revealed both O-GlcNAcylation patterns (the positions of O-GlcNAcylated residues) and 
levels (the proportions of O-GlcNAcylated residues in a sub-stoichiometrically O-
GlcNAcylated peptide mixture). Region II contained the largest number of O-GlcNAcylated 
residues, correlating with Region II–OGT binding efficiency and HCF-1PRO-repeat cleavage-
enhancement activity. It is therefore likely that strong O-GlcNAcylation in Region II is a result 
of strong OGT association to this sequence. Manipulation of Region II, for example by 
placing it C-terminal of the HCF-1PRO repeat or by splitting it into sub-regions, alters its O-
GlcNAcylation pattern dramatically (Figures IV-6 and IV-7). Thus, O-GlcNAcylation of HCF-1 
sequences appears to be highly variable because O-GlcNAcylation patterns vary with the 
sequence context. 
 Subdivision of Region II into two sub-regions and the subsequent isolation of these 
sub-regions from their surrounding sequences suggested, using an in vivo assay, that both of 
these sub-regions display weaker cleavage and O-GlcNAcylation activities with respect to 
the activity of the entire Region II sequence (Figure IV-7 C). Perhaps Regions II-a and II-b 
act together for HCF-1PRO-repeat cleavage enhancement and isolation of these two sub-
regions from one another disrupts this cumulative or synergistic effect. Intriguingly, the HCF-
1rep1 +II-b protein was unstable or insoluble during bacterial synthesis and purification. 
Region II-a could be required for stabilization or for correct folding of Region II-b. 
Nevertheless, the Region II-b construct was synthesized in vivo as well as the Region II-a 
construct, suggesting that other cellular proteins could interact with and stabilize the Region 
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II sequence. Interestingly, OGA, the enzyme that removes O-GlcNAc moieties from proteins, 
is a possible binding partner of HCF-1, and might therefore affect HCF-1 O-GlcNAcylation 
and maybe also cleavage in vivo. 
Region II O-GlcNAcylation and HCF-1PRO-repeat proteolysis are independent 
It has been proposed that O-GlcNAcylation and proteolysis influence each other during HCF-
1 protein maturation (Daou et al., 2011). According to the definition of cross-talk between 
post-translational modifications (see I.2.2), a change in HCF-1PRO-repeat proteolysis 
efficiency should cause changes in HCF-1 O-GlcNAcylation patterns or levels and vice-
versa. Unexpectedly, using proteomic and mutational analyses (Figures IV-8 and IV-9), HCF-
1 O-GlcNAcylation and HCF-1PRO-repeat proteolysis appear to be two independent OGT 
activities. Upon replacement of the cleavage site E10 by alanine, glutamine, aspartate or 
serine in HCF-1rep1 precursor constructs, O-GlcNAcylation levels of the HCF-1 proteins 
decreased, consistent with results obtained with HCF-1 E10A mutants (Capotosti et al., 
2011). As I have discussed in Chapter II, amino acids different from glutamate at position 10 
of the HCF-1PRO repeat promote OGT association to the HCF-1PRO repeat. Alanine, 
glutamine, aspartate or serine accommodate their side-chains more favorably in the OGT–
UDP-GlcNAc–HCF-1PRO-repeat complex and they therefore bind better to OGT. Thus, it is 
very likely that the E10 mutations, which enhance HCF-1PRO-repeat–OGT binding, sequester 
available OGT and consequently reduce OGT binding to HCF-1 sequences outside of the 
HCF-1PRO repeat, resulting in reduced overall HCF-1 O-GlcNAcylation. I conclude that 
Region II O-GlcNAcylation is not influenced by HCF-1PRO-repeat proteolysis per se because 
HCF-1rep1 mutants inactivated for cleavage using different mutational strategies (T17-22A 
and ∆PRO mutations) did not decrease Region II O-GlcNAcylation levels (Figure IV-8). The 
O-GlcNAcylation compromised OGT mutant (D554H H558D) cleaved HCF-1 substrates 
containing Region II as efficiently as wild-type OGT, suggesting that prominent O-
GlcNAcylation of Region II is not fundamental for Region II activity on cleavage. I therefore 
propose that the cross-talk observed between HCF-1 O-GlcNAcylation and HCF-1PRO-repeat 
proteolysis (Daou et al., 2011) may have simply resulted from the fact that the same enzyme 
is responsible for both activities. 
 Why is Region II and, more generally, the HCF-1 N-terminal subunit highly O-
GlcNAcylated? An HCF-1 construct cleaved via Taspase1-mediated proteolysis is defective 
for M-phase functions during the cell cycle (Capotosti et al., 2011), but displayed prominent 
O-GlcNAcylation in an in vivo assay (Figure IV-10), suggesting that HCF-1 O-GlcNAcylation 
levels are independent from OGT-mediated proteolysis. Yet, this experiment cannot rule out 
that the lack of OGT-mediated proteolysis changed the O-GlcNAcylation patterns (and not 
the levels) of the HCF-1 recombinant protein, as proteomic studies have not been performed. 
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I have not identified any role of Region II O-GlcNAcylation for HCF-1 proteolysis. I 
rather propose that Region II O-GlcNAcylation is a result of enhanced OGT association to 
this sequence. Recently, two interesting studies shed light on more general roles of protein 
O-GlcNAcylation: The laboratory of Juerg Mueller showed that O-GlcNAcylation prevents 
aggregation of the polycomb protein Polyhomeotic in Drosophila, and interestingly, a similar 
role for Drosophila HCF has also been implicated in this study (Gambetta and Muller, 2014). 
Another study by the David Vocadlo laboratory proposed that O-GlcNAcylation promotes 
protein stability during and after protein translation of the transcription factor Sp1 (Zhu et al., 
2015). It is thus possible that O-GlcNAcylation of HCF-1 promotes its stability and/or 
prevents its aggregation. These scenarios appear reasonable, given that HCF-1 is 
synthesized as a particularly large precursor protein of 2035 amino acids, which may require 
additional support for protein stability and integrity before stable HCF-1N and HCF-1C subunit 
association. 
Proposed model for Region II activity on HCF-1PRO-repeat cleavage 
Summing up the results from Chapters III and IV, I propose three hypothetical steps for HCF-
1PRO-repeat cleavage enhancement (Figure IV-11). 
1. It has been shown that about 50% of OGT associates with HCF-1 in the nucleus 
(Daou et al., 2011). This is a large proportion of available nuclear OGT. I therefore 
suggest that several OGT molecules can associate with one HCF-1 molecule at 
distinct OGT-binding sequences (OBS), for example, the HCF-1PRO repeat and 
Region II. A single HCF-1PRO repeat represents an OGT-binding sequence with rather 
low affinity compared to the Region II–OGT-type association. Therefore, competition 
of these binding sequences for OGT recruitment might take place (Figure IV-11, step 
1). 
2. Region II represents a strong OGT-binding sequence and this sequence thus 
associates efficiently with OGT, which results in Region II O-GlcNAcylation. At the 
same time, HCF-1PRO-repeat proteolysis might be induced at slow rates (Figure IV-11, 
step 2). 
3. Region II and its adjacent sequences might have structural properties, allowing to 
approach HCF-1PRO repeat 1. This results in more OGT molecules in proximity of the 
cleavage site. These processes may enhance HCF-1PRO-repeat proteolysis (Figure 
IV-11, step 3). 
It is still unknown if Region II affects proteolysis of all six HCF-1PRO repeats in the HCF-1 full-
length context. However, I suspect that HCF-1 contains more sequences, which may serve 
as binding sites for OGT..  
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Figure IV-11: Proposed model for Region II cleavage enhancement of the first HCF-1PRO repeat. 
OGT and the HCF-1 protein are schematically illustrated (not to scale). HCF-1 Regions II, III, and IV 
and the HCF-1PRO repeats 1 (rep1) and 2 (rep2) are illustrated. The cleavage sites within rep1 and 
rep2 are indicated by the red arrowhead; OBS, OGT-binding sequence. Prominent O-GlcNAcylation is 
indicated by blue squares. Step 1: HCF-1 and OGT are abundant in the nucleus. Region II (strong 
OBS) and rep1 (weak OBS) compete for OGT binding. Step2: Region II associates efficiently to OGT, 
whereas rep1 associates to OGT and gets cleaved at slow rates. Step 3: Region II (including bound 
OGT) bends towards rep1 and enhances rep1 cleavage. 
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Chapter V :  
Conclusions and Perspectives 
Two post-translational modifications (PTMs), reversible O-GlcNAcylation and irreversible 
site-specific proteolysis, catalyzed by a single enzyme — OGT — are the major focus in this 
thesis. OGT represents without doubt an unusual enzyme that executes the catalysis of two 
very different PTMs within a single active site (Lazarus et al., 2013). In this thesis, I 
characterized substrate requirements for O-GlcNAcylation and site-specific proteolysis of the 
transcriptional co-regulator HCF-1. In this chapter, I present the main conclusions elaborated 
here and I place them into a larger context. I also present ideas that could stimulate future 
studies on this topic. 
V.1 The HCF-1PRO repeats are highly specific protease recognition sites 
containing three different elements important for cleavage 
Proteases must faithfully and specifically recognize their target substrates. This recognition 
depends largely on the complementarity between the protease active site and the sequence 
surrounding the scissile bond of the substrate. Whereas the five families of mammalian 
aspartyl, cysteine, metallo-, serine or threonine proteases display, on average, specificities 
between 4 and 6 amino acids surrounding the scissile bond, OGT displays a specificity of 21 
residues within the HCF-1PRO repeat. The interactions between the HCF-1PRO repeat and 
OGT are highly specific being most prominent at the E10 cleavage site residue (P1’ position) 
and within the threonine region (see II.2 and II.9; Lazarus et al., 2013). So far, homologous 
HCF-1PRO-repeat sequences in proteins other than HCF-1 proteins, have not been identified, 
it thus seems very unlikely that OGT could cleave substrates other than HCF-1 proteins. 
The HCF-1PRO-repeat threonine region 
The HCF-1PRO-repeat threonine region binds to the OGT TPR region through a large network 
of hydrogen bonds (Lazarus et al., 2013), and I showed using the example of a 
representative residue within the threonine region, T14, that this interaction is very important 
for binding and cleavage. Additionally, OGT–HCF-1rep1 cleavage assays using N-terminal 
and internal TPR deletion mutants engineered by Dr. Vaibhav Kapuria, revealed that the 
TPRs most C-terminal to the OGT catalytic domain are required for cleavage (Kapuria and 
Herr, unpublished results). The HCF-1PRO-repeat threonine region is not directly involved in 
the cleavage chemistry for HCF-1PRO-repeat proteolysis, as it lies far away from the OGT 
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catalytic domain. Nevertheless, it is fundamental for cleavage because its specific 
interactions with the OGT TPR domain probably allow for the correct accommodation of the 
HCF-1PRO-repeat cleavage region inside the OGT catalytic domain. The OGT TPRs were 
proposed to interact with other OGT O-GlcNAcylation substrates in a manner similar to how 
they bind to the threonine region (Lazarus et al., 2013). This hypothesis is questionable, 
given that the HCF-1PRO-repeat threonine region–TPR domain interactions display such high 
specificity. As the TPRs clearly support cleavage of the HCF-1PRO repeat, one might ask 
conversely: What is their role for O-GlcNAcylation or for substrate recognition of O-
GlcNAcylation substrates? I have two hypotheses: (i) the OGT TPR domain could display no 
particular specificity for any substrate other than HCF-1PRO repeats. Perhaps the interactions 
between the HCF-1PRO-repeat cleavage region and the OGT catalytic domain require such 
specificity between the OGT TPRs and the threonine region. Other O-GlcNAcylation 
substrates probably do not contain a region similar to the HCF-1PRO-repeat cleavage region 
with its particular OGT-binding properties (see below). Thus, the OGT TPR domain might 
simply form favorable contacts with a variety of different substrates via a combination of 
factors, such as electrostatic interactions or hydrophobic pockets (as described in I.6.2). This 
suggests that OGT could bind to a multitude of O-GlcNAcylation substrates without great 
specificity. (ii) OGT could use HCF-1 as an adaptor protein that recruits OGT to HCF-1 
binding partners that can then be O-GlcNAcylated. OGT could dissociate from cleaved HCF-
1, implying that premature HCF-1 would be more effective to recruit OGT to its O-
GlcNAcylation substrates. But OGT could also remain associated with Region II and 
therefore HCF-1 could bring OGT to its O-GlcNAcylation substrates, even after cleavage. 
The latter possibility could explain why OGT and HCF-1 are often found to co-occupy 
genomic regions (especially active promoters), as described in I.7.4. Further studies will be 
needed to clarify these scenarios. 
The HCF-1PRO-repeat cleavage region 
The HCF-1PRO-repeat cleavage region binds in the OGT catalytic domain and forms a binding 
interface with the nucleotide sugar UDP-GlcNAc (Lazarus et al., 2013). I showed that the 
amino acid side-chain of glutamate at position 10 of the HCF-1PRO repeat (E10) surprisingly 
displays highly unfavorable interactions with the OGT-UDP-GlcNAc complex and is in fact 
the only residue in the cleavage region to display this unusual activity. The energy involved in 
binding E10 might be used to favor HCF-1PRO-repeat cleavage (see II.6 and II.7). Thus, the 
threonine region clamps the HCF-1PRO-repeat to OGT, whereas the cleavage region causes 
strains in the OGT-UDP-GlcNAc-HCF-1PRO-repeat complex. Enzymatic mechanisms 
involving substrate strains in catalysis have been previously described for bacterial carbon-
carbon lyases (Phillips et al., 2014). These enzymes catalyze the hydrolytic cleavage of 
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either one of the amino acids tryptophan and tyrosine, using substrate strains to increase 
substrate specificity and catalytic efficiency. Interestingly, the substrate strains originating 
from the E10 residue in the HCF-1PRO-repeat cleavage region are dependent on the sugar 
moiety of UDP-GlcNAc, indicating that HCF-1 proteolysis is coupled to UDP-GlcNAc 
availability and maybe indirectly to the cellular nutrient status. The mechanisms by which 
substrate strains contribute to catalysis are not completely understood and could be a 
subject for future studies. 
The HCF-1PRO-repeat Hinge region 
Although interactions between the OGT TPRs and the threonine region are quite rigid and 
favor binding of the cleavage region to the OGT catalytic domain, there is structural flexibility 
of residues between these two critical regions for proteolysis. These residues — the Hinge 
region — consist of three amino acid residues displaying flexibility in the OGT-UDP-GlcNAc-
HCF-1PRO-repeat complex (see II.8). One of the major questions about OGT–HCF-1PRO-
repeat binding is how OGT can fit a long polypeptide chain of 2035 amino acids inside its 
catalytic domain and inside the tunnel formed by the TPRs. One possibility is that OGT 
makes hinge-like motions between the TPRs and the catalytic domain (this region is called 
the OGT hinge; Lazarus et al., 2011). This movement could allow for the HCF-1 polypeptide 
to be accommodated inside OGT, potentially aided by unfolding and refolding of the TPR 
superhelical structure. Flexibility in the HCF-1PRO-repeat Hinge region, which is surrounded 
by the OGT hinge in the complex, could therefore be important for this process. Interestingly, 
the three residues in the Hinge region are highly conserved, arguing for an additional role 
beyond simply contributing to flexibility and this would still need to be explored. 
V.2 A single invariant amino acid side-chain is essential for proteolysis 
The E10 side-chain displays particular properties within the HCF-1PRO repeat. Based on 
OGT–HCF-1PRO-repeat binding data and molecular dynamics analyses, I propose that E10 
initiates the cleavage reaction by causing strains in the OGT-UDP-GlcNAc-HCF-1PRO-repeat 
complex. The products of cleavage of a single HCF-1PRO repeat are two HCF-1 polypeptide 
chains, one of which bears an N-terminal pyroglutamate formed by cyclization of E10. 
Pyroglutamate is a post-translational modification that can be found in humans (e.g., 
immunoglobulins are modified by pyroglutamate; Liu et al., 2011). The physiological roles of 
pyroglutamate are not completely understood. The modification has been proposed to 
contribute to protein stabilization in vivo but it can also be removed by pyroglutamate 
aminopeptidase (Kumar and Bachhawat, 2012). It is not known if the presence or absence of 
pyroglutamate at the HCF-1 cleaved polypeptide plays a role for HCF-1’s cellular functions. 
The development of antibodies directed to N-terminal pyroglutamate of the HCF-1PRO repeat 
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would be a step forward toward understanding if and in which cellular compartment 
pyroglutamate modified HCF-1 occurs in vivo. 
 In Lazarus et al. (2013), we proposed a model for the initial step of the cleavage 
reaction, in which a deprotonated E10 side-chain leads a nucleophilic attack on the anomeric 
carbon atom of UDP-GlcNAc, which would result in transient O-GlcNAcylation of E10 (Figure 
II-14). This model was based on the observation that UDP-GlcNAc is required for cleavage 
and that a replacement of E10 by serine activates HCF-1PRO-repeat O-GlcNAcylation but 
blocks cleavage (Lazarus et al., 2013). Furthermore, I showed that the sugar moiety of UDP-
GlcNAc is crucial for proper OGT–HCF-1PRO-repeat association (see II.5 and II.6). 
Nevertheless, the reactions following this initial step still remain to be elucidated. The 
cofactor analog UDP-5SGlcNAc could be an excellent tool to study the cleavage chemistry. I 
showed that this cofactor alters the OGT–HCF-1PRO-repeat binding mode dramatically 
(Figure II-7). UDP-5SGlcNAc might react with the HCF-1PRO repeat and an analysis of this 
reaction involving organic chemistry methods could lead to a better understanding of the 
cleavage reaction. Furthermore, to understand if UDP-GlcNAc indeed reacts during the 
cleavage reaction (if it is a cosubstrate), I propose to determine if there is free UDP after the 
in vitro HCF-1–OGT cleavage reaction. For this purpose, an HCF-1 substrate devoid of O-
GlcNAcylation sites should be used, for example the HCF3R substrate. UDP in UDP-GlcNAc 
could be labeled with a fluorescent marker and an assay would need to be developed that 
can detect free fluorescent UDP. 
A recent study proposed involvement of the α-phosphate of UDP-GlcNAc in the O-
GlcNAcylation mechanism (Schimpl et al., 2012). In fact, substitution of the α-phosphate of 
UDP-GlcNAc by sulfur blocks O-GlcNAcylation of TAB1, a normally O-GlcNAcylated innate 
immunity signaling protein. It is not known if the proteolysis and the O-GlcNAcylation 
mechanisms are similar, thus studies addressing HCF-1PRO-repeat cleavage with UDP-
GlcNAc α-phosphate analogs would be highly valuable to extend studies of the HCF-1PRO-
repeat cleavage mechanism. In summary, although 21 amino acids within the HCF-1PRO 
repeat are required for full cleavage activity, only a single amino acid side-chain within the 
repeat — E10 — is essential for HCF-1PRO-repeat proteolysis and thus for HCF-1C functions 
during the cell-division cycle. 
V.3 How did OGT-induced cleavage of the HCF-1PRO repeats arise? 
OGT possesses dual enzymatic activity that, to my knowledge, is unique within the families 
of glycosyltransferases and proteases. The HCF-1PRO repeat adopts the conformation of an 
O-GlcNAcylation substrate in the OGT active site and replacement of E10 by serine 
transforms the cleavage substrate into an O-GlcNAcylation substrate. Interestingly, OGT has 
a preference for O-GlcNAcylation of substrates containing a proline residue close to the site 
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of O-GlcNAcylation, which enforces an extended structure of the substrate. The HCF-1PRO 
repeat also contains a highly conserved proline at the P2 position. Could it be that HCF-1 
mimics an O-GlcNAcylation substrate to use OGT as its protease? 
OGT-mediated HCF-1 cleavage can only be found in vertebrates. In insects, HCF 
proteins are cleaved by Taspase1 — the same protease that cleaves the MLL protein both in 
humans and flies. Why is the HCF-1 cleavage mechanism in vertebrates different from 
Taspase1-mediated HCF cleavage in insects? To answer this question, it might be useful to 
know the origin of the HCF-1PRO repeats. The hypothesis has been put forward that the HCF-
1PRO repeats were inserted into the HCF-1 gene of an early vertebrate millions of years ago 
by a viral transposition event. Indeed, sequences homologous to the repeats are nowhere to 
be found other than being very highly conserved in HCF-1 proteins. Human HCF-1 contains 
eight repeats, two of which are inactive because they have diverged in sequence. These 
eight repeated sequences — and a large part of the Region III sequence — are encoded by 
a single extraordinarily large exon of 1476 base pairs, which supports the hypothesis of a 
viral transposition event. Sequence comparison of the HCF-1PRO repeats in vertebrates 
suggests that the HCF-1PRO repeats arose through serial duplication of progressively larger 
sets of repeats (Wilson et al., 1995a). Selective pressure might have removed the 
intervening sequences generating variable numbers of repeats in different vertebrate 
species. 
Viruses utilize their host’s replication, transcription and translation machineries to 
coordinate their infection cycle with the life cycle of the host. Moreover, viruses are known to 
often process generated polyproteins by proteases encoded by the viral genome. Perhaps, 
however, a virus, which infected a common ancestor of today’s vertebrates, used a host 
protease to cleave its polyproteins. OGT could have been coopted as a protease for 
cleavage of a viral polyprotein containing the sequence of the HCF-1PRO repeat. The virus 
would thus have succeeded to couple the metabolic status of the host cell with the 
production and activation of its own proteins. Subsequent transposition of viral genomic 
sequences into the host HCF-1 gene locus might have led to an HCF-1 protein containing 
both Taspase1 and HCF-1PRO-repeat cleavage sites. HCF-1PRO-repeat cleavage by OGT has 
been apparently selected during evolution. This is not unreasonable given that this 
mechanism might allow the linkage of the cellular metabolic state to the control of cell-cycle 
progression. Intriguingly, human and other vertebrate HCF-1s indeed contain vestigial 
Taspase1 cleavage sites (see I.7.5) indicating that vertebrates did not just “lose” their 
Taspase1 cleavage sites, but that they were simply not retained intact when HCF-1PRO-
repeat cleavage arose as the main proteolytic mechanism. 
Bioinformatic evolutionary studies could help to shed light on the origins of the HCF-
1PRO repeats by comparison of the genes encoding HCF-1 in different vertebrate species. 
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Analyses like these would lead to a better understanding of the evolutionary background of 
OGT-mediated proteolysis. 
V.4 Efficient HCF-1PRO-repeat cleavage requires HCF-1 sequences flanking 
the HCF-1PRO repeat  
HCF-1PRO-repeat cleavage is a slow and inefficient reaction compared to other proteolytic 
reactions (see Chapter III). A single HCF-1PRO repeat in isolation from its surrounding 
sequences represents a cleavage substrate with low activity (POUrep2 substrate, see III.1). 
As the HCF-1PRO repeat consists of 26 amino acids, additional requirements for efficient 
proteolysis were unexpected. My studies showed that HCF-1 sequences flanking the first 
HCF-1PRO repeat can enhance its cleavage efficiency. One of these flanking sequences, 
Region II, displays particularly strong, sequence-specific cleavage-enhancement activity 
correlating with strong O-GlcNAcylation and OGT-binding activities. In fact, I identified six 
clustered O-GlcNAcylation sites in the C-terminal half of Region II, but I could not find 
evidence for a role of Region II O-GlcNAcylation in HCF-1PRO-repeat proteolysis. Region II–
OGT association can vary depending on the context of the surrounding HCF-1 sequences. It 
thus appears that the surrounding regions have properties that can interfere with Region II–
OGT binding. Currently, there is no evidence for structured protein domains in the HCF-1 
Basic region, in Regions I, II, and III or in the HCF-1PRO repeats. In fact, Regions I, II, and III 
are predicted to be unstructured. These properties have led me to propose a model in which 
Region II recruits OGT close to the cleavage site at the first HCF-1PRO repeat, followed by 
loop formation of Region II with the support of the other flanking regions (see discussion of 
Chapter IV). This might be a possible scenario to explain how HCF-1 sequences outside of 
the HCF-1PRO repeat can influence cleavage. Region II might cause enrichment of OGT 
molecules at the first HCF-1PRO repeat, perhaps because the HCF-1PRO repeat itself does not 
represent a strong OGT-binding sequence. For future studies, it would be useful to compare 
OGT-binding affinities to Region II and to the HCF-1PRO repeat to determine whether Region 
II is indeed a stronger OGT-binding site than the HCF-1PRO repeat. Affinity studies using 
Surface Plasmon Resonance techniques, for instance, could complement my in vitro HCF-1–
OGT binding studies. 
 Interestingly, within the HCFC1 gene, Regions I and II lie on exons and the HCF-1PRO 
repeats lie on a separate exon. This suggests that the sequences encoding Regions I and II 
were probably not inserted together with the HCF-1PRO repeats by the proposed viral 
transposition event described above. The high degree of conservation of these regions in 
vertebrates suggests, however, that these sequences have a conserved function (see III.1.1). 
In fact, co-evolution of OGT-mediated proteolysis and the cleavage-enhancing activities of 
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the flanking sequences might have led to conservation of both the flanking sequences and 
the HCF-1PRO repeats. 
Because Region II is predicted to be highly unstructured and homologous structures 
of Region II could not be found in the PDB (Dr. Ute Roehrig, personal communication), it is 
unfeasible to predict how Region II could interact with OGT using molecular dynamics 
approaches. It would therefore be interesting to perform crystallization studies of Region II in 
complex with OGT to understand how Region II binds to OGT and if this binding mode 
resembles the one of the HCF-1PRO repeat. My studies using TPR deletion mutants indicate 
that the TPRs are involved in Region II recognition (see IV.3). A Region II–OGT crystal 
structure would not only shed light on the mechanisms of HCF-1PRO-repeat cleavage 
enhancement but it would also be a major advancement in the OGT field, which lacks an 
understanding of how OGT recognizes its O-GlcNAcylation substrates. 
V.5 The two faces of OGT 
Site-specific proteolysis of HCF-1 is irreversible and promotes cell-cycle progression (Julien 
and Herr, 2003). O-GlcNAcylation, in contrast, is known to be a highly dynamic PTM that can 
respond to changes in the environment. It is not known if O-GlcNAcylation of HCF-1 is 
reversible. I identified extensive O-GlcNAcylation of the HCF-1N subunit, but I also detected 
O-GlcNAcylation of HCF-1C, consistent with available mass spectrometry data (Myers et al., 
2013) (see IV.9). O-GlcNAcylation of HCF-1 does not appear to be regulated in a cell-cycle 
dependent manner (Capotosti, Michaud, Herr, unpublished results) and it is unknown if OGA 
associates with HCF-1. Studies aimed at identifying HCF-1-OGA complexes by 
immunoprecipitation and mass spectrometry, for example, could contribute to uncover if 
HCF-1 O-GlcNAcylation is reversible. 
 The role of O-GlcNAcylation for HCF-1 function remains enigmatic. Using a genetic 
approach to dissect O-GlcNAcylation from proteolysis, I did not find evidence for a role of 
HCF-1 O-GlcNAcylation in proteolysis (see IV.8). Furthermore, proteolysis at the HCF-1PRO 
repeats does not influence O-GlcNAcylation of sequences N-terminal (Regions I, II, and III) 
of the first HCF-1PRO repeat (see IV.7). Therefore, there is no evidence for cross-talk between 
O-GlcNAcylation and site-specific proteolysis of the HCF-1 protein. Nevertheless, I showed 
that an E10 mutation in the HCF-1PRO repeat decreases HCF-1 O-GlcNAcylation levels, 
consistent with data showing that E10 mutations cause an enhancement of OGT–HCF-1PRO-
repeat association (see II.7). Because a mutated HCF-1PRO repeat traps OGT to this binding 
site, it is possible that there is competition for OGT binding between different OGT-binding 
sites including Region II and the HCF-1PRO repeat (see IV.7).  
The proposed mechanism for cleavage in Chapter II (Figure II-14) included transient 
O-GlcNAcylation of the E10 residue. This seems contradictory with my proposal that O-
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GlcNAcylation is not fundamental for HCF-1PRO-repeat proteolysis. I suggest that the 
potential O-GlcNAcylation of the E10 residue could be a non-conventional type of O-
GlcNAcylation in a specific context —t he HCF-1PRO repeat — that cannot be compared to 
classical O-GlcNAcylation of other substrates or of sequences lying outside of the HCF-1PRO 
repeat. Hence, even though transient O-GlcNAcylation of E10 might be required for 
proteolysis, O-GlcNAcylation outside of the HCF-1PRO repeat might not be fundamental for 
proteolysis. 
Whereas site-specific proteolysis of HCF-1 is highly specific, I showed that O-
GlcNAcylation of HCF-1 is highly variable and dependent on the sequence context (see IV.5 
and IV.6). At least in HCF-1, there are no strong sequence motifs that promote HCF-1 O-
GlcNAcylation. Interestingly, HCF-1 O-GlcNAcylation occurs mainly in regions that are 
predicted to be highly unstructured such as the Basic region and Region II. This is in 
concordance with other studies predicting that O-GlcNAcylated residues cluster in highly 
unstructured regions (Hunter, 2007). It was recently shown that O-GlcNAcylation can occur 
co-translationally and that the modification can stabilize highly unstructured protein domains 
during and/or after translation (Zhu et al., 2015). Moreover, O-GlcNAcylation was implicated 
in the prevention of protein aggregation (Gambetta and Muller, 2014). Intriguingly, HCF-1 is 
synthesized as a long precursor protein that might require stabilization of its unstructured 
regions. It would be interesting to conduct studies, addressing the role of O-GlcNAcylation for 
HCF-1 protein stability and integrity. 
Importantly, such studies cannot be carried out using OGT inhibitors such as 5S-
GlcNAc or RNA interference (RNAi) against OGT mRNA. These approaches would lead to a 
defect in HCF-1 proteolysis, and any effects on HCF-1 O-GlcNAcylation and functions would 
have also to be attributed to HCF-1C defects during cell-cycle progression and to other 
pleiotropic effects resulting from OGT inactivation. It is thus advisable to dissect O-
GlcNAcylation from proteolysis carefully, for example by a genetic approach. OGT mutants 
that are defective for one PTM, but fully active for the other PTM are very useful for this 
purpose. The D554H H558D OGT mutant (Dr. Vaibhav Kapuria), for instance, is 
compromised for its O-GlcNAcylation activities but highly active for proteolysis (see IV.8). In 
the case of HCF-1, I would not recommend a mutational strategy to replace single O-
GlcNAcylated serines or threonines by alanines for the following reasons: (i) there are too 
many O-GlcNAcylated serines and threonines in HCF-1N. Alanine mutations could also affect 
the functions of these HCF-1 sequences. (ii) My studies showed that HCF-1 O-GlcNAcylation 
is highly variable and dependent on the HCF-1 sequence context. Thus, an alanine 
substitution could prevent O-GlcNAcylation at one site but induce O-GlcNAcylation at 
another site that would normally not get O-GlcNAcylated. 
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In summary, OGT has two faces: One that O-GlcNAcylates HCF-1 heavily in regions 
predicted to be highly unstructured. This modification does not appear to be highly specific. 
OGT has another face that cleaves HCF-1, with high specificity, within the HCF-1PRO repeats. 
The cleavage efficiency at least at the first HCF-1PRO repeat can be enhanced by neighboring 
HCF-1 sequences that display strong OGT-association and O-GlcNAcylation activities. 
V.6 Final remarks 
In the introduction to this thesis, I mentioned four methods that can contribute to the 
investigation of protein post-translational modifications: Mutational analyses, proteomics, 
structural biology, and molecular dynamics. In the present work, these approaches were 
combined to study the mechanisms of OGT-mediated HCF-1 maturation. Despite continuous 
improvement of the technologies for these approaches, the study of protein post-translational 
modifications (and their reciprocal influence) still represents a challenging endeavor. 
Ancient types of post-translational modifications, such as acetylation and 
phosphorylation, were involved in energy sensing but have since then been coopted to other 
functions. The glycosyltransferase OGT is an example of an evolutionary old protein that has 
been coopted to perform a different function. Likely, OGT has been “hijacked” by HCF-1 as 
its protease, and therefore the mechanism by which OGT mediates HCF-1PRO-repeat 
cleavage is unusual. It seems that it is the HCF-1PRO-repeat substrate that dictates the type 
of the post-translational modification: OGT can either perform its normal function (O-
GlcNAcylation) or it can engage in HCF-1PRO-repeat proteolysis. Within the HCF-1PRO repeat, 
despite multiple elements being important for cleavage, there is only a single amino acid 
side-chain that is decisive for the outcome of the OGT–HCF-1 interaction. A curiosity of 
nature! Additional mechanisms could have co-evolved to ensure efficient HCF-1PRO-repeat 
cleavage, for example through the HCF-1 sequences flanking the HCF-1PRO repeats. 
In the light of how deeply fundamental cellular processes (e.g., circadian rhythm, 
metabolism and the cell division cycle) are interwoven with each other, it appears less 
unexpected that an important regulator of metabolism (OGT) and of cell-cycle progression 
(HCF-1) are connected with each other via this unusual maturation process. 
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Materials and Methods 
Plasmid constructs and DNA template preparation 
The bacterial expression plasmid pGEX-HCF-1rep1 (encoding HCF-1 amino acids 867-1071) 
containing the wild-type or E10A HCF-1PRO repeat 1 was described in Capotosti et al. (2011). 
Deletions of Region I (867-891), Region II (892-949), Region III (850-1009), and Region IV 
(1037-1071) were obtained by QuickChange site-directed mutagenesis (Agilent 
Technologies). The scrambled sequences of Regions II and III were generated by random 
permutation of the amino acids in Region II or Region III and the resulting oligonucleotide 
sequence with additional BamHI restriction sites at the 5’ and 3’ ends custom synthesized. 
The fragments were PCR amplified and inserted into the pGEX-HCF-1rep1 vector using the 
BamHI restriction sites. For the heterologous HdaA construct, a sequence encoding for 
amino acids 151-210 of the HdaA protein of Caulobacter crescentus was custom synthesized 
and inserted into the pGEX-HCF-1rep1 vector using the strategy specified above. The 
mutations E10D, E10Q, E10S, T17-22A (Thr 17, Thr 19, Thr 21, and Thr 22; see Capotosti et 
al., 2011), and ∆PRO (deletion of HCF-1 residues 1010-1035) in the HCF-1PRO repeat were 
engineered by QuickChange site-directed mutagenesis. The HCF-1rep1 trypsin cleavage 
sites A933K and M951K for peptide generation in LC-MS/MS analysis were engineered by 
site-directed mutagenesis. The insertion of Region II C-terminal of the HCF-1PRO repeat 
(construct HCF-1rep1 +II_C) was obtained by overlap extension PCR (Lee et al., 2004). The 
pCGNHCF-1rep123 construct was described in Capotosti et al. (2007 and 2011). Deletions 
of Region II and Regions I, II and III were obtained by QuickChange site-directed 
mutagenesis. 
For in vitro transcription/translation, DNA templates encoding GST–HCF-1-fusion 
proteins were prepared by PCR amplification from the different pGEX-HCF-1rep1 plasmid 
constructs. PCR reactions were performed using a forward primer including the phage T7 
promoter and human β-globin translation initiation codon and this template was directly used 
for in vitro transcription/translation using the wheat-germ extract based TNT T7 
transcription/translation system as recommended (Promega). 
For transient expression of the HCF-1rep1 deletion constructs in HEK 293 cells, a 
PCR fragment encoding the GST–HCF-1rep1 sequence was amplified and inserted into a 
pCGN vector, using XbaI and KpnI restriction sites. The sequence encoding the POUrep2 
protein (Oct-1 sequence 280-439, in which the HCF-1PRO repeat 2 was embedded) was 
amplified from the pET11c vector and inserted as a GST-fusion protein into the pCGN vector, 
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using KpnI and BamHI restriction sites. Constructs containing Regions II or III upstream of 
the HCF-1PRO repeat were obtained by overlap extension PCR [42]. 
 The bacterial expression plasmid pET24 containing N-terminal T7 and 8-His tags was 
described in Lazarus et al. (2013). Site-directed mutagenesis was used as described above 
to generate the catalytic domain D554H_H558D OGT mutant, as well as the TPR domain 
mutants 5N-5A, ∆ 1-6, ∆ 1-8, and ∆ 1-9. 
Cell culture and plasmid transfections 
HEK 293 cells were grown on plates at 37°C in DMEM with 10% FBS. For plasmid 
transfection, 105 cells were seeded onto a 10 cm plate in 12 ml of DMEM with 10% FBS, and 
transfected one and a half days after seeding with 4.8 µg of plasmid and 60 µl of 
Lipofectamin in Opti-MEM medium as described (Invitrogen). 
Bacterial protein expression 
GST–HCF-1rep1 constructs 
The recombinant HCF-1rep1 protein encoding HCF-1 amino acids 867-1071 and its mutants 
were verified by sequencing. Proteins were synthesized in E. coli BL21 (DE3) as a fusion 
with N-terminal GST and C-terminal 6-Hist tag and purified using Nickel affinity 
chromatography according to the QIAexpressionist™ protocol (Qiagen) for native protein 
purification. Briefly, a starter culture of BL21 (DE3) was grown for 6 h at 37°C. 100 ml Luria 
Bertani (LB) medium containing 100 µg/ml carbenicillin was inoculated with 1 ml of starter 
culture and grown over night at 22°C. Protein synthesis was induced the next morning with 
0.4  mM IPTG at 16°C for 6  h to reduce the synthesis of C-terminal truncation products of the 
GST–fusion protein. The bacterial pellet was resuspended in lysis buffer supplemented with 
Complete protease inhibitor cocktail (Roche) and 0.1  mg/ml lysozyme and incubated for 20 
min on ice. The lysate was sonicated 12 times for 10 seconds, cleared at maximum speed 
for 30 min at 4°C, and incubated for 90 min at 4°C with Ni-NTA agarose superflow resin 
(Qiagen). The resin was washed three times with wash buffer and eluted in 4 ml elution 
buffer. The proteins were concentrated in Amicon concentration tubes (Milipore) and dialyzed 
against PBS supplemented with 1 mM DTT overnight at 4°C. The concentrated dialyzed 
protein was frozen in liquid nitrogen and stored at -70 °C. 
 
Human OGT 
Recombinant human OGT was synthesized as a His-tag fusion protein in E. coli BL21 (DE3) 
cells as described in Lazarus et al. (2013) with minor modifications: Bacterial cultures were 
grown in 200 ml volumes at 27°C after diluting an overnight culture 1 to 200 in fresh 
kanamycin supplemented LB media. Cells were grown to an OD600 of 1.1 and the 
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temperature was lowered to 16°C for 30  min. Protein expression was induced with 0.4  mM 
IPTG at 16°C for 16  h. The bacterial pellet was resuspended in 20 ml lysis buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 0.1 % Triton X-100, 10 % glycerol) supplemented with Complete 
protease inhibitor cocktail (Roche) and 0.1  mg/ml lysozyme final concentration and incubated 
for 30 min on ice. The lysate was then sonicated 12 times for 10 sec to remove viscosity and 
ensure further lysis. The lysate was cleared by high-speed centrifugation for 45 min at 4°C 
and incubated for 90 min at 4°C with Ni-NTA agarose superflow resin (Qiagen). The flow-
through was removed and the resin washed with 3 column volumes PBS supplemented with 
40  mM imidazole. The protein was then eluted in PBS supplemented with 250  mM imidazole 
and the elute concentrated in Amicon concentration tubes (Milipore). The elute was dialyzed 
against PBS supplemented with 1 mM DTT overnight at 4°C. The concentrated dialyzed 
protein was supplemented with 1 mM DTT and stored at -70°C. 
In vitro HCF-1–OGT binding assay 
GST–HCF-1rep1–OGT pull-down assays were performed as in Lazarus et al. (2013) with 
few modifications: Prior to the OGT pull-down, 20 µl of a slurry of α-T7 antibody-conjugated 
beads (polyclonal from goat, Abcam) were incubated with PBS containing 5% (w/v) bovine 
serum albumin (BSA) for 1 h at 4°C to decrease non-specific binding of GST–HCF-1rep1 to 
the agarose beads. Subsequently, the beads were washed extensively in PBS. For the 
OGTpull-down, 2.5 µg GST–HCF-1rep1 and 5 µg of OGT were pre-incubated in 0.5% NP40, 
10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 5 mM MgCl2 (NP40 buffer; (Misaghi et al., 2009)) 
supplemented with 5 mM DTT, in the presence or absence of 1 mM UDP-GlcNAc, in a 
rotating incubator for 1 h at 20°C. After incubation, 9 % of the reaction was removed as an 
input control for the OGT pull-down. The washed α-T7 agarose beads were added to the 
reaction, the volume increased to 500 µl using NP40 buffer and the suspension incubated for 
1 h at 20°C. The beads were washed in NP40 buffer at least three times for 5 min at room 
temperature and the OGT–GST–HCF-1rep1 complexes eluted by boiling for 5 min in 20 µl of 
2-fold SDS sample buffer. HCF-1rep1–OGT binding was subsequently analyzed by SDS-
PAGE followed by immunoblot. 
HCF-1 cleavage and O-GlcNAcylation assays 
In vitro cleavage assay with wheat-germ extract synthesized substrates 
DNA templates encoding GST–HCF-1rep1 or deletion constructs were prepared as specified 
above according to the manufacturer’s protocol (Promega). For the in vitro cleavage assay, 1 
µl of wheat-germ extract was incubated in 100 mM HEPES (pH 7.9), 5 mM MgCl2, 20 mM 
KCl, 5 mM DTT, and 10 % sucrose (cleavage buffer), 5 mM UDP-GlcNAc, and insect cell 
synthesized human OGT (Capotosti et al., 2011) at a final volume of 15 µl for 16 h at 37°C. 
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Resulting reaction products were resolved by SDS-PAGE and detected using 
autoradiography. 
 
In vitro cleavage assay with bacterially synthesized substrates and OGT 
In vitro HCF-1PRO-repeat cleavage and HCF-1 O-GlcNAcylation assays with bacterially 
synthesized substrates and OGT were performed in 100 mM HEPES (pH 7.9), 5 mM MgCl2, 
20 mM KCl, 5 mM DTT, and 10 % sucrose at a final volume of 15 µl at 37 °C for the 
indicated time. For a typical assay, bacterially purified GST–HCF-1rep1 (3 µM; concentration 
measured by comparative analysis with a protein loading control on Coomassie gel) was 
incubated with bacterially purified OGT (0.6 µM, concentration measured as described 
above) in the presence or absence of 1 mM UDP-GlcNAc and the reaction stopped by 
transfer of the tube to -20°C and boiling in SDS-sample buffer. HCF-1 cleavage and O-
GlcNAcylation were examined by immunoblot. 
 
In vivo cleavage assay 
In vivo HCF-1 cleavage assays were performed as follows: HEK 293 cells were transfected 
in 10 cm dishes with pCGN vectors encoding the HCF-1rep1 or POUrep2 precursor proteins 
as described above. 48 hours after transfection, cells were washed in PBS and lysed in 0.5% 
NP40, 10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 5 mM MgCl2 (NP40 buffer; Misaghi et al., 
2009) supplemented with Roche Complete protease inhibitors and 10 µg/ml Pefabloc SC 
(AEBSF from Roche Life Science) final concentration for 20 min on ice. The lysate was 
cleared in a table centrifuge at maximum speed at 4°C for 20 min and incubated with 30 µl 
mouse α-HA-conjugated agarose beads (Sigma) overnight at 4°C. Beads were washed four 
times in 0.5% NP40 buffer, and immunoprecipitated material was eluted in 5 bead volumes 
of HA-peptide (200 µg/ml), in order to avoid elution of the IgG chains from the antibody 
conjugate, which would interfere with cleavage band analysis by immunoblot. Samples were 
analyzed by immunoblot. 
Denaturing immunoprecipitation 
α-HA tag immunoprecipitation was performed as in Capotosti et al. (2011) with modifications: 
cells were lysed 24-48 h post-transfection in NP40 buffer supplemented with Roche 
Complete protease inhibitors and 10 µg/ml Pefabloc SC (AEBSF from Roche Life Science). 
The lysates were adjusted to 1% SDS and incubated at 65°C for 10 min. The SDS 
concentration was adjusted to 0.1% by dilution with NP40 buffer, and lysates were incubated 
with α-HA agarose beads (Sigma) for 1 h to overnight at 4°C. Beads were washed 
extensively in NP40 buffer, and immunoprecipitated material was eluted by boiling in one 
bead volume of 2-fold SDS sample buffer. Samples were analyzed by immunoblot.  
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Immunoblot and antibodies 
For immunoblot analysis, nitrocellulose membranes were incubated for 60 min with 5 ml of 
LI-COR blocking buffer, followed by incubation with the relevant antibodies in 50% LI-COR 
blocking buffer and 50% PBST (PBS containing 0.1% Tween 20), as described below, at 4°C 
over night. The membranes were washed four times and incubated with the appropriate 
secondary antibodies (dilution 1:10,000) in 50% LI-COR blocking buffer and 50% PBST at 
room temperature for 45 min. The membranes were extensively washed in PBS containing 
0.5% Tween20 and scanned with an Odyssey infrared imager (LI-COR). Quantification of 
bands on immunoblots was performed using the LI-COR Image Quant quantification 
software. 
 Antibodies used to detect GST–HCF-1rep1, GST–POUrep2, O-GlcNAc and OGT 
were as follows: rabbit polyclonal α-GST (1-109; Santa Cruz) used at 1:1000, mouse 
monoclonal α-HA-epitope (12CA5; Field et al., 1988) used at 1:1000, mouse monoclonal 
(RL2) α-O-GlcNAc (Abcam) used at 1:3000, mouse monoclonal α-T7 (Novagen) used at 
1:5000, and rabbit polyclonal α-OGT (H-300; Santa Cruz) used at 1:1000. 
Quantification of bands on immunoblots was performed using the LI-COR Image 
Quant quantification software and visualized using GraphPad Prism version 6.0e. 
Sample preparation for O-GlcNAcylation analysis by liquid chromatography tandem 
mass spectrometry (LC-MS/MS) 
Sample preparation for O-GlcNAcylation analysis by LC-MS/MS was performed as in 
Capotosti et al. (2011) with modifications. HA-tagged GST–HCF-1rep1 plasmid expression 
vectors with wild-type or with E10A, E10D, E10Q and T17-22A mutated HCF-1PRO repeats 
were transfected into eight 15 cm dishes of HEK 293 cells for 48 hours. Cells were lysed in 8 
ml NP40 buffer supplemented with 1mM PMSF, 10 µM PUGNAc and Roche Complete 
protease inhibitors. The lysates were adjusted to 1% SDS and incubated at 65°C for 10 min. 
The SDS concentration was adjusted to 0.1% by dilution with NP40 buffer, and lysates were 
incubated with α-HA agarose beads overnight at 4°C. Immunoprecipitated material was 
eluted with HA-peptide as described above and the resulting elute concentrated using 
Amicon concentration tubes (Milipore). For proteomic analysis, see below. 
O-GlcNAcylation analysis by LC-MS/MS 
For the O-GlcNAcylation analysis, purified proteins were resolved by SDS-PAGE and stained 
with Coomassie Blue. Gel bands were excised from SDS-PAGE gel and in-gel digested with 
sequencing-grade trypsin (Promega, Madison, WI, USA) as described (Shevchenko et al., 
1996; Wilm et al., 1996). Extracted peptides were then cleaved with Glu-C endoproteinase 
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(Sigma-Aldrich, St. Louis, MO, USA). Data-dependent LC-MS/MS analyses were carried out 
on a hybrid linear trap LTQ-Orbitrap XL (Thermo Scientific) mass spectrometer interfaced to 
a nanocapillary HPLC equipped with a C18 reversed-phase column (Thermo Scientific), 
using CID (collision induced dissociation) mode for MS/MS fragmentation. MS/MS spectra 
were analyzed using Mascot 2.4 software (Matrix Science, London, UK). Mascot was set up 
to search a custom-built database containing the sequences of the HCF constructions and of 
contaminants (enzymes, keratins, etc.). Semi-specific cleavage at K, R (not before P), and at 
E, D were used as the enzyme definition. Mascot was searched with a fragment ion mass 
tolerance of 0.50 Da, a parent ion tolerance of 10 ppm, and allowing two missed cleavages. 
Iodoacetamide and propionamide derivatives of cysteine, deamidation of asparagine and 
glutamine, phosphorylation of serine and threonine, oxidation of methionine, and addition of 
acetylhexosamine (HexNAc) to serine and threonine were specified in Mascot as variable 
modifications. O-HexNAc modified and phosphorylated residues were considered confident if 
the ion score for the identified peptide was superior to 23 with a site localization score 
(Mascot Delta Score) higher than 70% and potential if the ion score was between 14 and 22 
or localization score between 50 and 70 %. 
Molecular dynamics simulations 
Molecular Dynamics (MD) simulations were performed using stochastic boundary conditions 
(SBC; Brooks et al., 1988), after solvating the systems with a 24 Å radius sphere of TIP3P 
water molecules, centered on the mutated residue. A 4 Å wide restrained buffer region, 
coupled to a heat bath using the Langevin equation of motion and a 250 ps-1 friction constant 
(Brooks and Karplus, 1989), was used. Protein atoms outside the buffer region were held 
fixed. The water molecules were kept within the sphere by the use of a solvent boundary 
potential (Brooks and Karplus, 1983) and a friction constant of 62 ps-1 was applied to the 
water oxygens (Brooks and Karplus, 1989). After energy minimization, the system was 
gradually heated and equilibrated at 300 K during 220 ps, while restraints initially applied on 
the heavy atoms were progressively removed. The MD production run, during which all 
atoms in the reaction region were unconstrained, was performed at 300 K for 2 ns. All 
molecular modeling calculations were performed starting from the high-quality crystal 
structure of the human OGT bound to the peptide from HCF-1PRO repeat 2 (1-26) E10Q and 
UDP-5SGlcNAc (PDB code 4N3B). This experimental structure was preferred to the lower-
quality experimental structure with E10 and UDP-GlcNAc (PDB code 4N3C) to perform 
molecular modeling calculations. Before MD simulations, the 5S sulfur atom was replaced by 
an oxygen atom, while the Q10 residue of the HCF-1PRO repeat 2 was replaced by a E, D or 
A residue using the UCSF chimera program (Pettersen et al., 2004). 
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For the calculation of residue contributions to the binding-free energy, the role of each 
residue on the HCF-1–OGT binding free energy was estimated according to the MM-GBSA 
approach (Gohlke et al., 2003; Zoete et al., 2005; Zoete and Michielin, 2007), using the GB-
MV2 implicit solvent model (Lee et al., 2003; Lee et al., 2002). This method allows the 
decomposition of the total binding free energy into residue contributions. The contribution of 
each residue of interest was calculated and averaged over 500 frames regularly extracted 
along a 2 ns SBC MD simulations centered on it. 
Periodic-boundary MD simulations were carried out with GROMACS Version 4.6.5 
(Bjelkmar et al., 2010; Hess et al., 2008), using the all-atom CHARMM27 force field 
(MacKerell et al., 1998; Mackerell et al., 2004) and the TIP3P water model (Jorgensen et al., 
1983). Electrostatic interactions were calculated with the Ewald particle-mesh method 
(Essmann et al., 1995) with a grid spacing of 1.2 Å and a spline interpolation of order 4. A 
cutoff of 10 Å was applied for the real-space direct sum part of the Ewald sum, and a cutoff 
of 14 Å for the van der Waals interactions. Dispersion corrections were applied to the energy. 
Bonds involving hydrogen atoms were constrained using the P-LINCS algorithm (Hess et al., 
2008). The system was coupled to a barostat (Berendsen et al., 1984) with a relaxation time 
of 1 ps. The solute and the solvent were separately coupled to two thermostats (Bussi et al., 
2007), each with a relaxation time of 0.2 ps. The time integration step was set to 2 fs, the 
temperature to 300 K, and the pressure to 1 bar. A cubic simulation cell with an edge length 
of 120 Å was used to prevent direct interactions between periodic images, resulting about 
170,000 atoms per system. Sodium atoms were added to neutralize each system. Initial 
structures were optimized, heated from 0 to 300 K over a period of 0.1 ns, equilibrated for a 
further 0.9 ns restraining each solute non-hydrogen atom to its original position, and finally 
equilibrated for 0.5 ns without restraints before data collection. For each system, 8 
simulations were carried out for a total of 40 ns of production time, saving coordinates every 
0.05 ns. 
OGT simulations in complex with HCF-1-derived peptides were based on the X-ray 
structure 4N3B (Lazarus et al., 2013), replacing UDP-5SGlcNAc with UDP-GlcNAc and 
glutamine 10 with glutamate. When replacing glutamine 10 by glutamate, it was observed 
that neutralizing its carboxylate group was necessary to obtain a stable OGT–HCF-1 
complex. The added proton formed a stable hydrogen bond with the backbone oxygen of 
OGT glycine 654. 
Molecular graphics were performed with the UCSF Chimera visualization software 
(Pettersen et al., 2004) or the PyMOL (Schrodinger, 2010) software v1.5.0.3 enhanced for 
Mac OS X. 
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Appendix 
 
 
Figure Appendix-1: Serine and threonine density in the HCF-1 amino acid sequence 867-1071. 
The ratio of serines and threonines per position in a sliding window of 10 amino acids (aa) is shown. 
Analysis and figure by Dr. Viviane Praz (member of the Herr laboratory). 
 
Position on the sequence
Se
rin
e 
an
d 
Th
re
on
in
e 
ra
tio
 (w
in
do
w 
of
 1
0 
aa
)
Serine and Threonine density 
HCF-1rep1 sequence 867-1071
I II III rep1 IV
  
148 
Table Appendix-1: In vitro and in vivo activities of selected HCF-1 recombinant constructs. 
 
HCF-1 mutants were analyzed in multiple independent experiments with similar results unless marked by an asterisk. Cleavage activities were evaluated as 
enhanced (++++), moderate (+++), low (++), at detection level (+) or no cleavage detectable (–). (*), the experiment was performed only once; N/D, not 
determined. 
in vitro OGT binding TPR mutants in vitro OGT bindingin vitro in vitro
 D554H / H558D OGT bindingin vivoin vitroconstructs short name cleavage TPR 5N-5A TPR ∆1–6 TPR ∆1–8 TPR ∆1–9
no cofactorcleavage O-GlcNAcylation cleavage O-GlcNAcylation UDP-GlcNAc no cofactor D554H / H558D UDP-GlcNAc no cofactor  UDP-GlcNAc
I. II. III. rep1. IV FL +++ +++ +++ +++ ++ +++ +++ +++ ++ + (*) N/D N/D N/D
II. III. rep1. IV ∆ I +++ +++ +++ ++ – N/D N/D N/D N/D N/D N/D N/D N/D
I. III. rep1. IV ∆ II ++ (+) ++ (+) – N/D N/D N/D N/D N/D N/D N/D N/D
I. II. rep1. IV ∆ III ++ +++ ++++ +++ ++ N/D N/D N/D N/D N/D N/D N/D N/D
with  PRO rep1. IV ∆ I.II.III + – (+) – (+) (+) + N/D N/D N/D N/D N/D N/D
I. rep1. IV + I ++ + ++ (+) ++ ++ ++ ++++ N/D N/D N/D N/D N/D
II. rep1. IV + II ++++ ++++ ++++ +++ ++++ ++++ ++++ ++++ +++ N/D N/D N/D N/D
III. rep1. IV + III ++ – + – – – + – – N/D N/D N/D N/D
I. II. III. rep1  ∆ IV +++ +++ + (*) +++ (*) – + N/D +++ N/D N/D N/D N/D N/D
II. rep1. II. rep1. (+) +++ (+) (*) +++ (*) ++ +++ N/D +++ ++ N/D N/D N/D N/D
rep1. II. IV + II_C – ++ (+) ++++ +++ N/D N/D N/D N/D N/D N/D N/D
rep1. II. IV / E10A + II_C/E10A – ++ – +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D
Region II II. rep1. II. IV + II_N/C – + – (*) N/D ++ +++ N/D N/D N/D N/D N/D N/D N/D
4 
ho
ur
s 
cl
ea
va
ge
mutants I. CK-II. III. rep1. IV CK-II N/D N/D + (*) +++ (*) N/D N/D N/D N/D N/D N/D N/D N/D N/D
II_scrambled. rep1. IV + II_scramb. (+) + (+) (*) ++ (*) N/D +++ N/D N/D N/D N/D N/D N/D N/D
III. rep1. II. IV + III_N/II_C + (*) +++++ (*) N/D N/D N/D ++ (*) N/D N/D N/D N/D N/D N/D N/D
II-a.rep1.IV + II-a +++ +++ (+) ++ N/D N/D N/D N/D N/D N/D N/D N/D N/D
II-b.rep1.IV + II-b ? ? + ++ N/D N/D N/D N/D N/D N/D N/D N/D N/D
Region III III_scrambled. rep1. IV + III_scramb. ++ N/D N/D N/D N/D (+) N/D N/D N/D N/D N/D N/D N/D
mutants HdaA. rep1. IV + HdaA ++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. IV ∆ PRO – N/D – +++ N/D N/D - N/D N/D N/D N/D N/D N/D
II. IV II_IV – N/D – N/D +++ +++ - +++ +++ N/D ++ ++ –
without PRO II II_alone – N/D – N/D ++ ++ - (+) + (+) (*) – – –
II_scrambled + II_scramb_alone – N/D N/D N/D N/D + N/D N/D N/D – (*) N/D N/D N/D
III III_alone – N/D N/D N/D N/D - N/D N/D N/D – (*) N/D N/D N/D
  n
o 
cl
ea
va
ge
IV IV – N/D – N/D – N/D - N/D N/D N/D N/D N/D N/D
POUs. rep2. POUh POUrep2 (+) – (–) (*) N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
POU domain POUs. II. rep2. POUh +II POUrep2 N/D +++ +++ (*) N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
mutants POUs. III. rep2. POUh +III POUrep2 N/D (+) (+) (*) N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV FL FL +++ +++ +++ +++ ++ +++ +++ +++ ++ N/D N/D N/D N/D
I. II. III. rep1. IV E10A E10A – +++ – ++ ++++ ++++ N/D +++ N/D N/D N/D N/D N/D
I. II. III. rep1. IV E10D E10D – +++ – +++ ++++ ++++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV E10Q E10Q – +++ – +++ ++++ ++++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV E10S E10S – +++ – ++ ++++ ++++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV P7A P7A + +++ +++ +++ + UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV P8A P8A (+) +++ (–) ++ ++ UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV C9A C9A + +++ ++ +++ ++ UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV T11A T11A ++ +++ +++ ++ +++ UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV H12A H12A +++ +++ +++ ++ ++ UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV H12G H12G ++ +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV H12P H12P + +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV E13A E13A ++ +++ +++ +++ ++ UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV E13G E13G + +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
 PRO I. II. III. rep1. IV E13P E13P + +++ +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
16
 h
ou
rs
 c
le
av
ag
e
mutants I. II. III. rep1. IV H12P/E13P H12P/E13P + +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV H12G / E13G H12G/E13G + +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV T14A T14A (–) N/D N/D N/D (+) UDP: ++ N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV T14N T14N (–) N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV T14S T14S (–) N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. III. rep1. IV T17-22A T17-22A – +++ – +++ (+) +++ N/D +++ N/D N/D N/D N/D N/D
I. II. III. rep1. IV T17-22A / E10A T17-22A/E10A – +++ N/D N/D N/D N/D N/D +++ N/D N/D N/D N/D N/D
II. III. rep1. IV / E10A ∆ I/E10A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. III. rep1. IV / E10A ∆ II/E10A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. II. rep1. IV / E10A ∆ III/E10A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
I. rep1. IV / E10A + I/E10A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
II. rep1. IV /E10A + II/E10A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
III. rep1. IV / E10A + III/E10A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
rep1. IV/E10A ∆ I.II.III/E10A – – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
rep1. IV / E10S ∆ I.II.III/E10S – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
rep1. IV / T17-22A ∆ I.II.III/T17-22A – – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
rep1. IV / E10A/T17-22A ∆ I.II.III/E10A/T17-22A – N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D N/D
II. rep1. IV / T17-22A + II_T17-22A – ++++ N/D N/D ++ N/D N/D N/D N/D + (*) N/D N/D N/D
HCF-1 Taspase HCF-1 ∆PRO MLL ∆PRO MLL N/D N/D +++ +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D
mutants HCF-1 ∆PRO MLL mut ∆PRO MLL mut N/D N/D – +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D
 in
 v
iv
o
HCF-1 wild-type HCF-1 FL HCF-1 N/D N/D +++ +++ N/D N/D N/D N/D N/D N/D N/D N/D N/D
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The article by Lazarus et al. (2013) was first published in Science and is attached below or 
accessible in Pubmed (PMID: 24311690).  
 
Lazarus, M.B., Jiang, J., Kapuria, V., Bhuiyan, T., Janetzko, J., Zandberg, W.F., Vocadlo, 
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HCF-1 Is Cleaved in the Active Site
of O-GlcNAc Transferase
Michael B. Lazarus,1,4*† Jiaoyang Jiang,1*‡ Vaibhav Kapuria,2 Tanja Bhuiyan,2 John Janetzko,4
Wesley F. Zandberg,3 David J. Vocadlo,3,5 Winship Herr,2§ Suzanne Walker1§
Host cell factor–1 (HCF-1), a transcriptional co-regulator of human cell-cycle progression,
undergoes proteolytic maturation in which any of six repeated sequences is cleaved by the
nutrient-responsive glycosyltransferase, O-linked N-acetylglucosamine (O-GlcNAc) transferase
(OGT). We report that the tetratricopeptide-repeat domain of O-GlcNAc transferase binds the
carboxyl-terminal portion of an HCF-1 proteolytic repeat such that the cleavage region lies in the
glycosyltransferase active site above uridine diphosphate–GlcNAc. The conformation is similar
to that of a glycosylation-competent peptide substrate. Cleavage occurs between cysteine and
glutamate residues and results in a pyroglutamate product. Conversion of the cleavage site
glutamate into serine converts an HCF-1 proteolytic repeat into a glycosylation substrate.
Thus, protein glycosylation and HCF-1 cleavage occur in the same active site.
O-linked N-acetylglucosamine (O-GlcNAc)transferase (OGT) is a Ser/Thr (S/T) gly-cosyltransferase that O-GlcNAcylates nu-
clear and cytoplasmic proteins, thus influencing
their activity, localization, and overall function
(1–3). Because OGTactivity is sensitive to uridine
diphosphate (UDP)–GlcNAc concentrations, OGT
is proposed to regulate cellular responses to
nutrient status (4–6). Human HCF-1 is a transcrip-
tional coregulator involved in regulating cell-
cycle progression (7, 8). In an unusual proteolytic
maturation process (9–11), any of six centrally lo-
cated 20 to 26 amino acid sequence repeats called
HCF-1PRO repeats (Fig. 1A) are cleaved by OGT
in the presence of UDP-GlcNAc (12), providing
a link between cell-cycle progression and nutrient
levels. TheHCF-1PRO repeats contain two essential
regions for proteolysis: a threonine-rich region
proposed to be an OGT-binding site and the cleav-
age site, which contains a conserved Cys-Glu-Thr
(CET) sequence (10, 11).
OGT can cleave a fragment of HCF-1, called
HCF-1rep1, which contains the first HCF-1PRO
repeat plusN-terminal HCF-1 sequences contain-
ing several O-GlcNAc sites (12) (Fig. 1A). To
elucidate the cleavage process, we first analyzed
the effect of amino acid substitutions in OGT
(Fig. 1B and fig. S1) and the HCF-1PRO repeat
(Fig. 1C) on cleavage and glycosylation. Three
OGT active site residues implicated in S/T gly-
cosylation were evaluated: K842, which is in-
volved in binding and activation of UDP-GlcNAc
for glycosyl-transfer; H498, which contacts the
C2-N-acetyl group of UDP-GlcNAc; and H558,
which contacts a backbone carbonyl of glycosyl-
ation substrates (13–17). Substitution ofK842with
methionine prevented S/T glycosylation upstream
of the proteolytic repeat aswell as cleavagewithin
the repeat region. Substitution of H498 or H558
with alanine decreased S/T glycosylation but had
a negligible effect on the extent of cleavage after
16 hours. K842 is an essential residue for gly-
cosylation (14, 15), and its importance in cleav-
age suggests that UDP-GlcNAc is involved in the
cleavage mechanism.
Next, we tested substitutions in the proteolytic
repeat of HCF-1rep1. We previously showed that
alanine substitution of glutamate E10 leads to
loss of cleavage (11, 12). To probe the role of E10
in more detail, we substituted it with glutamine
(E10Q), aspartate (E10D), and serine (E10S). All
three substitutions blocked cleavage (Fig. 1C), in-
dicating that the chemical nature of the glutamate
residue is critical for OGT-mediated HCF-1PRO-
repeat cleavage. In contrast, the C9 position
can tolerate alanine and serine substitution (12)
(fig. S2).
Because S/T glycosylation upstream of the
cleavage site in HCF-1rep1 complicates study of
the cleavage requirements, we identified a cleav-
age substrate consisting of the first three proteo-
lytic repeats (HCF3R, Fig. 1A), which did not
undergo substantial glycosylation. No cleavage
products were observed when HCF3R was incu-
bated with OGTalone or in the presence of UDP,
but several products were observed in reactions
containing bothOGTandUDP-GlcNAc (Fig. 2A).
These products did not form if HCF3R was in-
cubated with a K842A OGTmutant incapable of
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catalyzing glycosylation (13, 16) or when wild-
type OGTwas pretreated with 1.5 equivalents of
a previously described inhibitor that covalently
inactivates the enzyme by cross-linking the active
site (18). Cleavage was also inhibited if UDPwas
added to reactions containing OGT and UDP-
GlcNAc (fig. S3A) but accelerated by adding al-
kaline phosphatase, which destroys UDP. Because
intact UDP-GlcNAc, but not UDP, promoted
HCF3R cleavage, we tested cleavage in the pres-
enceofUDP-5SGlcNAc, an isostereofUDP-GlcNAc
that adopts the same conformation within the
active site, yet is resistant to glycosylation and
hydrolysis (14, 19). Almost no peptide cleavage
was observed (Fig. 2A and fig. S3B), implying
that the UDP-GlcNAc does not simply fulfill a
structural function but must react for HCF3R
cleavage to occur. Consistent with this proposal,
UDP-5SGlcNAc was found to inhibit cleavage
of HCF-1rep1 when added to reactions contain-
ing UDP-GlcNAc (fig. S3C).
We next examined the cleavage products
using liquid chromatography–mass spectrometry
(LC-MS). Previous analysis of products isolated
from cells concluded that cleavage occurs at the
E-T peptide bond of the CET sequence (10, 11),
but none of the four products we observed had
masses consistent with E-Tcleavage (Fig. 2B and
fig. S4). Instead, they were consistent with cleav-
age at the preceding C-E bond except that all the
C-terminal fragments were 18 daltons lower in
mass than expected.We hypothesized that the 18-
dalton difference resulted from generation of an
N-terminal pyroglutamate. Indeed, cleavage of a
simplified HCF3R substrate possessing a single
active HCF-1PRO repeat (HCF3R-EAA) led to the
production of one dehydrated C-terminal product
(Fig. 2C and fig. S5). Pyroglutamate amino-
peptidase (PGAP) treatment reduced the mass
of this product by 111 daltons, corresponding to
loss of pyroglutamate (Fig. 2C and fig. S6). The
earlier proposed cleavage site was probably mis-
identified because N-terminal pyroglutamates are
resistant to the Edman sequencing method used
in those studies, and cellular PGAPs likely pro-
cessed some cleavage products (10, 11).
To gain additional insight into how OGT
cleaves HCF-1, we solved crystal structures of
OGT-HCF-1PRO-repeat complexes (tables S1 and
S2).We solved a 1.8 Å structure of OGTcontain-
ing UDP and a 16 amino acid peptide comprising
the threonine-rich region of the HCF-1PRO repeat
(Fig. 3, A and B). We also solved a 1.9 Å struc-
ture with UDP and a full HCF-1PRO repeat con-
taining an E10A mutation, but density was only
observed for the threonine-rich portion of the
repeat (Fig. 3C and fig. S7). These two structures
show the threonine-rich peptide bound in an ex-
tended conformation along the channel formed
by the tetratricopeptide-repeat (TPR) domain
(13, 20, 21) of OGT (Fig. 3B and fig. S7). Five
conserved asparagine residues within the TPR
domain form a series of interactions, four being
bidentate, with the amides of alternating residues
along the peptide backbone (Fig. 3C). A lysine
side chain also contacts the peptide backbone.
Four aspartates of OGT form hydrogen bonds to
the threonine side chains of the HCF-1 repeat. The
binding mode in the crystal structures is con-
sistent with mutational data demonstrating the
importance of the OGT asparagines (Fig. 3D
and fig. S8) and the conserved HCF-1PRO-repeat
threonines (12) (Figs. 3E and 1C) for both cleav-
age and binding.
Because intact UDP-GlcNAc is required for
OGT-catalyzed cleavage of HCF-1PRO-repeats,
we thought the UDP-5SGlcNAc analog might
stabilize density for a full repeat. Indeed, we ob-
tained a structure of OGTwith UDP-5SGlcNAc
and a 26 amino acid peptide corresponding to
HCF-1PRO rep2, but with an E10Q substitution.
In this structure, the C-terminal threonine-rich re-
gion binds to the TPR domain as described above,
and the N-terminal cleavage region is now visible
(Fig. 4A) and forms an extensive binding inter-
face with UDP-5SGlcNAc (Fig. 4B). A structure
containing UDP-GlcNAc and a wild-type repeat
confirms the binding mode of the E10Q peptide
(fig. S9). Remarkably, the cleavage region binds in
a mode almost identical to that of a glycosylation-
competent peptide substrate (14), and residue 10
aligns perfectly with the glycosyl acceptor amino
acid (Fig. 4C). The structures suggested that an
Fig. 1. Effect of mutations in OGT and
HCF-1 constructs on cleavage and glyco-
sylation. (A) (Top) Schematic of HCF-1 show-
ing the six proteolytic repeats (rep1 to rep6) with the amino
acid identities of a representative pro repeat shown. The
conserved residues are shown in yellow, with the E10 glu-
tamate essential for cleavage shown in red. The repeats are
subdivided into cleavage and threonine-rich regions (12).
Site-specific proteolysis by OGT leads to the formation of HCF-
1N and HCF-1C subunits. (Bottom ) Schematic of HCF-1 constructs used in this
study. Glutathione S-transferase (GST)–HCF-1rep1 contains the first HCF-1PRO
repeat and surrounding sequences fused to GST. Several S/T glycosylation sites
are found in the HCF-1rep1 construct as schematized. The HCF3R construct
contains only the first three HCF-1PRO repeats fused to an N-terminal His-tag.
(B) Comparative cleavage and glycosylation activities of wild-type (WT) OGT
and several catalytic domain mutants. GST–HCF-1rep1 was incubated in the
absence (lane 1) or presence of WT OGT (lane 2) or the indicated mutants
(lanes 3 to 5). HCF-1rep1 cleavage was detected by Western blot analysis with
antibody to GST, and HCF-1rep1 glycosylation was detected with antibody to
O-GlcNAc (RL2). (C) Cleavage activities of WT andmutant HCF-1rep1 constructs.
WT GST–HCF1rep1 (lanes 1 and 2) or a threonine-rich region mutant (T17-22A;
lanes 3 and 4) or the indicated E10 cleavage site mutants (E10A, E10Q, E10D,
and E10S; lanes 5 to 12) were incubated in the absence (–) or presence (+) of
WT OGT as described in the supplementary materials. Cleavage was detected
as in (B).
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E10Smutation, which prevents cleavage (Fig. 1D),
would be glycosylated at residue 10. Indeed, un-
like HCF3R-EAA, the E10S analog (HCF3R-
SAA) was glycosylated effectively (Fig. 4D and
fig. S10). Thus, the identity of the amino acid at
position 10 of an HCF-1PRO repeat—glutamate
or serine—can dictate whether OGT cleaves or
glycosylates the substrate.
Previous hypotheses suggested that OGTcon-
tains a dedicated protease active site or acts as a
coprotease to template HCF-1 autocatalysis (12).
Instead, OGT promotes cleavage of the HCF-
1PRO repeat using the same catalytic region as for
glycosylation. The threonine-rich region of the
HCF-1PRO repeat binds in the channel formed
by the TPR domain of OGT, stabilized by the
contacts described above. The cleavage region
threads into the active site and binds over UDP-
GlcNAc in the same conformation that a glyco-
sylation substrate would, with the glutamate side
chain positioned near the anomeric carbon of the
sugar. Because a pyroglutamate product is formed,
and spontaneous cyclization of N-terminal gluta-
mates is kinetically very slow (22), the glutamate
side chain is likely activated by formation of an
ester species as part of the cleavage mechanism.
We speculate that the glutamate side chain traps
a transient oxocarbenium ion formed within the
active site, producing a glutamyl ester that can
undergo intramolecular attack, leading ultimately
to formation of the N-terminal pyroglutamate. We
note that pyroglutamates are proposed species in
other biological phenomena (23). Possible mech-
anisms for cleavage proceeding from a glutamyl
ester are suggested (fig. S11). Although direct phys-
ical evidence for a glutamyl-sugar intermediate
has yet to be obtained, glycosylation of the gluta-
mate side chain before cleavage is consistent with
the structural data, the strict requirement for glu-
tamate at the cleavage site, the formation of a
pyroglutamate product, and the observation that
cleavage of HCF-1PRO repeats requires UDP-
GlcNAc and depends on an OGT residue, K842,
which is essential for catalyzing glycosylation.
These studies provide insight into two im-
portant aspects of OGT function. First, they pro-
vide a view of a peptide bound to OGT’s TPR
domain, which is thought to play a central role in
substrate selection (20, 21, 24, 25). The structures
reported suggest that some glycosylation substrates
may bind in a manner similar to the HCF-1PRO
repeats, with the glycosylation site separated by
several residues from a C-terminal recognition
motif that binds in the channel formed by the
TPR domain. Adaptor proteins that recruit gly-
cosylation substrates to OGT might also contain
threonine-rich recognition motifs. Second, they
suggest an unprecedented mechanism of proteol-
ysis in which OGT uses UDP-GlcNAc as a co-
substrate in a cleavage reaction that takes place in
the active site for glycosylation. Indeed, we show
that two very different posttranslational protein
modifications—proteolysis and addition of a sugar
residue—can occur in the same active site, with
the outcome determined by the identity of a single
amino acid in the substrate.
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Fig. 2. HCF-1PRO-repeat cleavage results in formation of a pyrogluta-
mate product. (A) Cleavage of HCF3R requires UDP-GlcNAc. HCF3R was
incubated with WT OGT (lanes 2 to 6), with K842A OGT (lane 7) or with OGT
treated with a previously reported (18) covalent inhibitor BZX2 (lane 8), in the
presence of UDP (lane 3), UDP-GlcNAc (lanes 4, 5, 7, and 8), or UDP-5SGlcNAc
(5S) (lane 6). Alkaline phosphatase (AP) was added to some reactions, as in-
dicated. Cleavage products were separated by SDS–polyacrylamide gel elec-
trophoresis (SDS-PAGE) and stained with Coomassie Blue. (B) LC-MS analysis of
untreated HCF3R (black) and HCF3R cleavage products (red) after incubation
with OGT and UDP-GlcNAc shows unexpected mass peaks. Detected and pre-
dicted MS peaks for different cleavage products are tabulated. (C) Mutation of
E10 to alanine in the cleavage region of the second and third HCF-1PRO repeats
produces a construct, HCF3R-EAA, containing only a single cleavable repeat.
Pyroglutamate (pyroGlu) aminopeptidase removed a 111-dalton fragment from
the HCF3R-EAA C-terminal cleavage product, confirming the formation of
pyroglutamate in the cleavage reaction.
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Fig. 4. HCF-1 cleavage takes place in the
glycosyltransferase active site ofOGT. (A)
Overall structure of the OGT:UDP-5SGlcNAc:
HCF-1-E10Q1-26 complex. The HCF-1 peptide
is shown as spheres in cyan, with the UDP-
5SGlcNAc in yellow. (B) Close-up view of the
two substrate analogs shown in yellow in the
OGT active site. The entire cleavage region
can be seen, and the C-E10Q-T residues are
annotated. The anomeric carbon of UDP-
5SGlcNAc is indicated (C1). (C) Overlay of
the substrate analogs from the OGT:UDP-
5SGlcNAc:HCF-1 peptide complex (yellow) and
the previously reported (14) OGT:UDP-5SGlcNAc:
CKIIA complex (cyan). CKII is a well-characterized
OGT glycosylation substrate. The E10Q side
chain of the HCF-1 peptide is shown as trans-
parent just after the b carbon. (D) Mutating
E10 to S in anHCF-1PRO repeat converts a cleav-
age substrate (HCF3R-EAA) into a glycosyla-
tion substrate (HCF3R-SAA), which is defective
in cleavage. (Left) Cleavage products of HCF3R-
EAA and HCF3R-SAA were separated by SDS-
PAGE and stained with Coomassie Blue. (Right)
Glycosylation of WT and mutant HCF3R sub-
strateswas carried out with 14C-UDP-GlcNAc and
analyzed by PAGE. Full gels are shown in fig. S10.
Fig. 3. The threonine-rich regionof theHCF-1PRO repeat binds in the channel
formedby the TPRdomain ofOGT. (A) Overall structure of the OGT:UDP:HCF-111-26
peptide complex. A 16-residue peptide comprising the threonine-rich region of
HCF-1PRO repeat 2 (THETGTTNTATTATSN) was cocrystallized with UDP and a previously described (13)
N-terminally truncated OGT construct (hOGT4.5) and refined to 1.8 Å. The OGT catalytic domain (red)
and TPR domain (gray), along with the HCF-111-26 peptide (cyan) and UDP (yellow), are shown. (B)
Close-up view of OGT-peptide interactions. The electron density around the visible portion of HCF-111-26 is shown as an FO-FC difference map contoured at 3s. The
peptide is shown in cyan. OGT side chains that contact the peptide backbone are shown in yellow, and OGT side chains that contact HCF-1 peptide side chains are
shown in magenta. (C) Schematic of contacts between OGT side chains and the threonine-rich region of the HCF-1PRO repeat 2 from the complex of OGT:UDP:
HCF-1-E10A1-26. OGT side chains are numbered and colored as in (B). (D) Mutations in the TPR domain of OGT (5N-5A) inhibit cleavage. Cleavage and
glycosylation of GST–HCF-1rep1 were assayed, as in Fig. 1C, in the absence (lane 1) or presence (lane 2) of WT OGT or the 5N-5A TPR-domain mutant in which
Asn residues 322, 356, 390, 424, and 458 are mutated to alanine (lane 3). (E) OGT does not bind effectively in vitro to an HCF-1PRO repeat mutant containing
mutations in the threonine-rich region (T17–22A). WT (lane 2) and mutant (lanes 1, 3, and 4) GST–HCF-1rep1 substrates were tested for OGT binding in the
presence of UDP-GlcNAc using an OGT-directed pull-down assay. Antibodies to GST and T7 were used to detect GST–HCF-1rep1 (top) and OGT (bottom),
respectively, by Western blotting. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K,
Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
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Crosstalk Between Microtubule
Attachment Complexes Ensures
Accurate Chromosome Segregation
Dhanya K. Cheerambathur, Reto Gassmann,* Brian Cook, Karen Oegema, Arshad Desai†
The microtubule-based mitotic spindle segregates chromosomes during cell division. During
chromosome segregation, the centromeric regions of chromosomes build kinetochores that
establish end-coupled attachments to spindle microtubules. Here, we used the Caenorhabditis
elegans embryo as a model system to examine the crosstalk between two kinetochore protein
complexes implicated in temporally distinct stages of attachment formation. The kinetochore
dynein module, which mediates initial lateral microtubule capture, inhibited microtubule binding
by the Ndc80 complex, which ultimately forms the end-coupled attachments that segregate
chromosomes. The kinetochore dynein module directly regulated Ndc80, independently of
phosphorylation by Aurora B kinase, and this regulation was required for accurate segregation.
Thus, the conversion from initial dynein-mediated, lateral attachments to correctly oriented,
Ndc80-mediated end-coupled attachments is actively controlled.
The four-subunit Ndc80 complex, whoseNdc80 subunit harbors direct microtubule-binding activity, is the central component
of the microtubule end-coupled attachments that
segregate chromosomes on mitotic spindles (1, 2).
In metazoans, initial lateral capture of microtu-
bules by dynein motors localized to kinetochores
kinetically accelerates the formation of end-coupled
attachments and ensures their correct orientation
(3–7). How kinetochores transition from an ini-
tial laterally bound state to the final end-coupled
state is unclear.
The kinetochore dynein module is composed
of the three-subunit RZZ (Rod-Zw10-Zwilch)
complex, which recruits dynein to kinetochores
via Spindly (Fig. 1A) (7–9). Formation of end-
coupled microtubule attachments was assessed
during the first division of the Caenorhabditis
elegans embryo by visualizing chromosome dy-
namics (Fig. 1B) and by quantifying the kinet-
ics of spindle pole separation (Fig. 1C) (10, 11).
Removal of Spindly (SPDL-1 in C. elegans) was
nearly equivalent to removal of NDC-80 (Fig 1,
B and C). As expected (7, 12), the failure to es-
tablish end-coupled attachments resulting from
SPDL-1 depletion was suppressed by codepletion
of RZZ (Fig. 1B); the double inhibition exhibited
only the mild delay in end-coupled attachment for-
mation expected for loss of kinetochore dynein.
Thus, RZZ inhibits the formation of NDC-80–
mediated microtubule attachments, and relief of
this inhibition requires SPDL-1.
Aurora B kinase inhibits microtubule binding
of Ndc80 by phosphorylating its basic tail (13–15).
To determine whether RZZ inhibits NDC-80 by
promoting Aurora B–mediated phosphorylation
of NDC-80, we created an RNA interference
(RNAi)–resistant transgenic system (fig. S1, A and
B) to replace endogenous NDC-80 with transgene-
encoded NDC-80WT or a phosphorylation-resistant
NDC-804A mutant (fig. S1, C and D) (13). NDC-
80WT and NDC-804A mutants both rescued the
severe chromosome segregation defect and em-
bryonic lethality of NDC-80 depletion (Fig 1D and
fig. S1, E and F). Furthermore, NDC-80WT and
NDC-804Awere equally sensitive to inhibition by
RZZ—after SPDL-1 depletion, both exhibited se-
vere chromosome segregation (Fig. 1D) and pole
separation (fig. S1G) defects indicative of a fail-
ure to form end-coupled attachments. Thus, Aurora
B–mediated phosphorylation of the NDC-80
tail is not required for RZZ to inhibit NDC-80–
mediated end-coupled attachments.
We next tested if the RZZ complex directly in-
teracts with NDC-80 and inhibits its microtubule-
binding activity. ROD-1 has an N-terminal b-propeller
domain that binds to ZwilchZWL-1 followed by an ex-
tended a solenoid that binds Zw10CZW-1 (Fig. 2A)
(16). The N-terminal b-propeller domain of ROD-1
and the N-terminal microtubule-binding region
of NDC-80 interacted in a yeast two-hybrid as-
say (Fig. 2B and fig. S2A). Deletion of the ba-
sic tail of NDC-80 abolished its interaction with
ROD-1 without affecting binding to its Nuf2HIM-10
partner; by contrast, mimicking an Aurora B–
phosphorylated NDC-80 tail by mutation of four
target sites to aspartic acid (4D) did not affect
the ROD-1 interaction (Fig. 2B). Binding assays
with a partially reconstituted RZZ complex com-
posed of the N terminus of ROD-1 and ZwilchZWL-1
(termed RNZ) confirmed a direct tail-dependent
interaction between RNZ and NDC-80 (Fig. 2B).
To test if the ROD-1–NDC-80 interaction regu-
lates NDC-80 microtubule binding, we used re-
constituted C. elegans NDC-80 complex (fig. S2B)
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Materials and Methods 
Bacterial protein expression 
The GST–HCF-1rep1 fusion construct encoding HCF-1 amino acids 867-1071 
was purified as described(12). This construct was mutated using QuickChange site-
directed mutagenesis (Stratagene) to obtain GST–HCF-1rep1 with mutated HCF-
1rep1PRO-repeats: E10A, E10D, E10Q, E10S and T17-22A. These constructs were 
subsequently synthesized and purified from E. coli BL21(DE3) using IMAC. 
Recombinant human ncOGT was likewise synthesized as a fusion protein in BL21(DE3) 
cells with N-terminal T7 and 8-His tags as described(26) with minor modifications: 
Starter cultures were grown at 37°C after diluting an overnight culture 1 to 250 in fresh 
kanamycin supplemented LB media. Cells were grown to an A600 of 1.1, after which they 
were transferred to 16°C for 30  min. They were then induced with 0.2  mM IPTG and 
grown overnight at 16°C for 16  h. The bacteria were pelleted and re-suspended in lysis 
buffer (20  mM Tris, pH 7.4, 250  mM NaCl, 0.5% NP40 supplemented with 1  mM PMSF 
and 0.1  mg/ml lysozyme) for 30 min on ice. The lysate was then sonicated 6 times for 10 
s and centrifuged at 14,000 RPM in an SS-34 rotor for 1 h at 4°C. Imidazole was added 
to the supernatant to a final concentration of 40  mM before the lysate was incubated with 
Ni-NTA agarose superflow resin (Qiagen) overnight at 4°C, which was prewashed with 
TBS + 40  mM imidazole for nickel affinity purification. The flow through was removed 
and the resin washed with 3 column volumes of lysis buffer supplemented with 50  mM 
imidazole. The protein was then eluted with PBS supplemented with 250  mM imidazole. 
To concentrate the eluate, Amicon concentration tubes (Millipore) were used. The 
concentrated protein was dialyzed against PBS supplemented with 1 mM DTT overnight 
at 4°C. The concentrated dialyzed protein was supplemented with 1 mM DTT and stored 
at -80°C until needed. To generate mutants of OGT, we used site-directed mutagenesis 
(Agilent technologies) to create catalytic domain (K842M, H498A, H558A) and the 
multi-asparagine (N322A, N356A, N390A, N424A, N458A) mutants. The mutants were 
verified by sequencing. 
HCF-1rep1 cleavage and glycosylation assay 
For a typical in vitro cleavage/glycosylation assay, bacterially purified GST–
HCF-1rep1 (2 µg) was incubated with purified OGT (1 µg) in the presence or absence of 
UDP-GlcNAc (1 mM, unless otherwise noted) as described earlier(9) at 37°C overnight. 
HCF-1rep1 cleavage and glycosylation were examined by performing SDS-PAGE 
followed by western blotting to detect HCF-1rep1 cleavage (anti-GST) and HCF-1 
glycosylation (anti-O-GlcNAc). 
CKII glycosylation assay 
CKII glycosylation assay was performed by incubating CKII (NEB, 2500 U) with 
1 µg of recombinant human ncOGT (WT or mutant) in the presence of 1 mM UDP-
GlcNAc. The reaction was incubated at 37°C for 90 min, and the extent of CKII 
glycosylation was assessed by western blotting using anti-O-GlcNAc antibody.  
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Antibodies 
Antibodies used to detect GST–HCF-1rep1, O-GlcNAc and OGT were as 
follows: rabbit polyclonal anti-GST (1-109) (Santa Cruz), mouse monoclonal (RL2) anti-
O-GlcNAc (Abcam) and mouse monoclonal anti-T7 (Novagen). Casein kinase IIα 
antibody (1AD9) was obtained from Santa Cruz biotech.  
In vitro HCF-1–OGT binding assay 
20 µl of a slurry of anti-T7 antibody-conjugated beads (polyclonal from goat, 
Abcam) were incubated with PBS containing 5% (w/v) bovine serum albumin (BSA) for 
1 h at 4°C to decrease non-specific binding of GST–HCF-1rep1 to the agarose beads. 
Subsequently, the beads were washed extensively in PBS followed by 0.5 % NP40 buffer 
as described(27). For the OGT-pulldown, 2.5 µg GST–HCF-1rep1 and 5 µg OGT were 
pre-incubated in the presence of 5 mM DTT and 1 mM UDP-GlcNAc in a rotating 
incubator for 1 h at 20°C. After incubation, 9% of the reaction was taken as an input-
control for the OGT-pulldown. The washed anti-T7 agarose beads were added to the 
reaction, and the volume was increased to 500 µl using NP40 buffer and the suspension 
incubated for 1 h at 20°C. The beads were washed in NP40 buffer three times for 5 min at 
room temperature, and the OGT/GST–HCF-1rep1 complexes were eluted by boiling for 5 
min in 20 µl of 2x SDS sample buffer. 
Purification and crystallization 
Human OGT4.5 was prepared as previously described(13). All peptides for 
crystallization were purchased (Biomatik, ≥95% purity, HPLC). A summary of the 
peptides and their sequences is listed in table S1 below. All complexes were prepared by 
incubating OGT4.5 at 7 mg/ml with nucleotide-sugar (1 mM) and peptide (3 mM). UDP-
5SGlcNAc was synthesized as previously described(14, 19). All crystals were grown 
with the hanging drop method by combining 2 µl protein complex with 1 µl reservoir 
solution. Crystals for the C-terminal fragment of HCF-1 were grown with reservoir 
consisting of 1.5 M potassium sodium tartrate and 0.1 M Tris pH 8.5. The 
OGT:UDP:HCF-1-E10A complex crystals were obtained with reservoir consisting of 
0.88 M potassium phosphate dibasic and 0.72 M potassium phosphate monobasic. 
Crystals of the complex containing OGT and UDP-5SGlcNAc and the E10Q peptide 
were grown with reservoir solution consisting of 1.4 M sodium malonate pH 7.0 and 0.1 
M Bis-Tris Propane pH 7.0. Crystals of the complex of OGT with UDP-GlcNAc and the 
wild-type peptide were grown in 0.86 M potassium phosphate dibasic and 0.86 M sodium 
phosphate monobasic. Crystals were grown at room temperature and cryoprotected in 
solutions consisting of the reservoir solution plus 28% glycerol or xylitol and flash frozen 
in liquid nitrogen. 
Data collection, structure determination, and refinement 
All data were collected at NSLS beamline X29 or X25 at Brookhaven National 
Laboratory. Data was processed using iMosflm(28) and scaled with Scala(29). The 
previously determined OGT-UDP-CKII ternary complex (3PE4) was used as a search 
model for molecular replacement in this work, using Phaser(30). The models were 
subsequently refined using Phenix(31), with rigid body refinement and multiple rounds of 
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simulated annealing, minimization, atomic displacement parameter (ADP or B-factor) 
refinement and TLS refinement (determined using the TLSMD server(32, 33)), with 
interspersed manual adjustments using Coot(34). Geometric restraints for UDP-GlcNAc 
or UDP-5SGlcNAc were generated using Phenix Elbow(35), and these restraints were 
used throughout refinement. All structural figures were made with Pymol(36). 
Crystallization software installation support was provided by SBGrid(37). 
HCF3R and OGT constructs 
The HCF3R construct (residues 1006-1130) was amplified from a cDNA library 
(Promega) and cloned into a modified N-terminal 8-His pET47b vector (EMD). Full 
length OGT constructs were purified as previously described(13). To generate mutants of 
HCF3R, an HCF3R-AAA construct (containing alanines in all three E10 sites) was 
synthesized by overlap extension PCR to get around the problems of repeating nucleotide 
sequences, using primers designed with DNAworks(38). The HCF3R-AAA insert was 
also cloned into an 8-His pET47b vector. Mutations were then made in this vector using 
QuickChange mutagenesis. The constructs were subsequently expressed and purified 
from E. coli using IMAC.  
The DNA sequence of the HCF3R-AAA insert is: 
CCGGGTACCGTTACCCTGGTTTGCTCTAACCCGCCGTGCGCTACCCACGAAACCGGTACCACCAA
CACCGCTACCACCACCGTTGTTGCTAACCTGGGTGGTCACCCGCAGCCGACCCAGGTTCAGTTCGTTTGCG
ACCGTCAGGAAGCTGCTGCTTCTCTGGTTACCTCTACCGTTGGTCAGCAGAATGGTAGCGTGGTCCGAGTC
TGTTCGAATCCTCCCTGTGCAACACACGAGACGGGCACGACGAATACGGCCACAACGGCCACCTCCAACAT
GGCTGGACAACATGGATGTTCTAATCCTCCTTGTGCTACTCATGAAACTGGAACTACTAATACTGCTACTA
CTGCTATGTCTTCTGTTGGAGCTAATTAA 
HCF3R cleavage assays 
Purified His-HCF3R constructs were incubated in 20 µl reactions with PBS pH 
7.4 buffer and 1 mM THP for 5 h at 37°C in the presence or absence of OGT constructs 
and different reagents as specified in the figures. For reactions described in Figure 2, the 
concentrations were: 200 µM HCF3R; 2.5µM wild-type or K842A ncOGT; 100 U/ml 
alkaline phosphatase (NEB) supplemented with 20 mM MgCl2; 1 mM UDP-GlcNAc, 
UDP-5SGlcNAc, and UDP; 3.75 µM BZX inhibitor (Compound 2) (18). For Figure 4 
and for the cysteine mutants, reagent concentrations were: 100 µM HCF3R, 2.67 µM 
ncOGT and 0.1 U (100 U/mL) calf-alkaline phosphatase (NEB) in 10 µl TBS pH 7.4 with 
20 mM MgCl2 and 1 mM UDP-GlcNAc except for the 14C cleavage, which used a 1 mM 
mixture of UDP-GlcNAc with 14C/12C (1:3), as specified. After incubation at 37oC, the 
reaction were quenched by 1:1 addition of 2x SDS loading buffer and the products were 
separated on a 4-20% Tris-Glycine SDS-PAGE gel and detected either by Coomassie 
staining or autoradiography. 
LC-MS detection of cleavage products 
Purified His-HCF3R (100 µM) was incubated with 2.5 µM ncOGT and 1 mM 
UDP-GlcNAc using the same reaction conditions specified above, except that incubation 
time was only 1 h. The reaction products were separated using an Agilent 6520 LC-
QTOF system equipped with a Phenomenex Gemini-NX C18 column (5 µm, 110 Å, 50 x 
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2.00 mm), pre-equilibrated with 6% acetonitrile and 0.1% aqueous formic acid at a flow 
rate of 0.4 ml/min with a linear gradient of 6–60% buffer B (90% acetonitrile and 0.1% 
aqueous formic acid) over 20 min after desalting for 10 min with 6% buffer B. The data 
was analyzed using Agilent MassHunter software. 
Pyroglutamate aminopeptidase treatment of HCF-1 cleavage products 
Purified HCF3R-EAA (100 µM) was incubated in reaction buffer with alkaline 
phosphatase at 37°C overnight as described above to generate cleaved products. Pfu 
pyroglutamate aminopeptidase (Takara Bio) was then added to the reaction at 12.5 U/L 
and the incubation was continued at 37ºC for another 5 h to cleave the pyroglutamate. 
The reaction products were tested on Q-TOF LC-MS as described above. 
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Supplementary Figures 
 
 
 
Fig. S1. Cleavage vs. Glycosylation by OGT. (A) GST–HCF-1rep1 was incubated with 
WT human OGT or its mutants (K842M, H498A, H558A) in the presence of UDP-
GlcNAc for indicated time periods. HCF-1rep1 cleavage and glycosylation were 
examined by western blotting as described in Materials and Methods. (B) CKII was 
incubated in the presence of WT OGT or the specified mutants and UDP-GlcNAc, as 
described in Materials and Methods. The glycosylation of CKII was examined by western 
blotting using O-GlcNAc antibody (RL2).  
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Fig. S2. The C9 cysteine is not essential for HCF-1 pro-repeat cleavage. We tested 
serine and alanine substitutions of the cysteine at the cleavage site in the HCF3R-EAA 
construct. Both substitutions weakened but did not abolish the cleavage, consistent with 
previous work on the cysteine to alanine substitution(12). 
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Fig. S3. HCF-1rep1 cleavage requires UDP-GlcNAc. (A) HCF3R was incubated with 
OGT (lanes 2-5) in the presence of UDP-GlcNAc (lane 2), UDP (lane 3), both (lane 4), or 
neither of them (lane 5). Alkaline phosphatase (AP) was added to reaction 5, as indicated. 
In reaction 6, HCF3R was incubated with UDP-GlcNAc alone. Cleavage products were 
separated by SDS-PAGE and stained with Coomassie Blue. (B) GST–HCF-1rep1 
(precursor HCF-1) was incubated with WT human OGT in the absence or presence of 
increasing concentrations of UDP-GlcNAc or its inhibitory analogue UDP-5SGlcNAc. 
The reaction was incubated for 16 h at 37°C and HCF-1rep1 cleavage and glycosylation 
were examined by western blotting as described in Materials and Methods. HCF-1rep1 
cleavage and glycosylation were observed only when UDP-GlcNAc was present in the 
reaction. (C) A competition assay between UDP-GlcNAc and its analogue UDP-
5SGlcNAc was performed by incubating GST–HCF-1rep1 (precursor HCF-1) with WT 
human OGT in the presence of UDP-GlcNAc alone (0.5 mM) or in combination with 
varying concentrations of UDP-5SGlcNAc (0.05-1.0 mM). The reaction was incubated 
for 16 h at 37°C and HCF-1 cleavage and glycosylation were examined by western 
blotting as described in Materials and Methods. The presence of UDP-5SGlcNAc 
inhibited HCF-1 proteolysis. 
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Fig. S4. LC-MS detection of HCF3R cleavage products. OGT was incubated with 
either HCF3R and UDP-GlcNAc (red) or with HCF3R alone as a control (black). The 
detected MS peaks are summarized in the table in Figure 2B.  
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Fig. S5. LC-MS analysis of HCF3R-EAA cleavage. (A) HCF3R-EAA construct and the 
numbering of detected mass peaks. (B) Total Ion Chromatogram (TIC) of the cleavage 
products from the incubation of HCF3R-EAA, OGT, and UDP-GlcNAc (red), HCF3R-
EAA alone as a control (black). (C) The detected MS peaks for HCF3R-EAA cleavage. 
(D) Table summarizing the detected mass peaks from HCF3R-EAA cleavage. 
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Fig. S6. Treatment of HCF3R-EAA cleavage products with PyGlu aminopeptidase 
removes a pyroglutamate from the C-terminal fragment. The HCF3R-EAA cleavage 
products in the absence of PyGlu aminopeptidase are shown in black (6 and 7) and those 
in the presence of PyGlu aminopeptidase are shown in purple (6’ and 7’). The MS data 
are summarized in the table in Figure 2C. Loss of 111 Da from the C-terminal fragment 
(7) to produce 7’ confirms formation of an N-terminal PyGlu during cleavage. 
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Fig. S7. Interactions between the TPR domain of OGT with the HCF-1PRO repeat 
E10A peptide. The 26-residue full HCF-1 repeat containing the E10A mutation was 
crystallized with hOGT4.5 and UDP. Compared with the structure shown in Figures 3A 
and 3B, two additional residues (23 and 24) are now visible, both of which make contacts 
with the TPRs of OGT. A schematic of the interactions in this structure is shown in 
Figure 3C. The HCF-1 peptide is shown in cyan, with the N-terminus of the peptide 
labeled as residue E13 and the C-terminus as residue T24. The OGT TPRs are shown as 
gray cylindrical helices. OGT side chains that make contacts to the HCF-1 peptide 
backbone are colored in yellow; and OGT side chains that contact HCF-1 side chains are 
colored in violet. 
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Fig. S8. The 5N-5A OGT mutant is defective in binding to HCF-1rep1. (A) 
Glycosylation of CKII is minimally affected by the 5N-5A mutations in the TPR domain 
of OGT. CKII (2500 U) was incubated in the presence of WT human OGT or 5N-5A 
OGT and CKII glycosylation was examined as described above. (B) In vitro binding 
assay to study GST–HCF-1rep1 interaction with WT human OGT and 5N-5A OGT was 
performed as described in Materials and Methods.  
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Fig. S9. Crystal structure of the wild-type HCF-1PRO repeat peptide bound to OGT 
with UDP-GlcNAc. The structure for the native complex is nearly identical to the ternary 
complex of OGT with UDP-5SGlcNAc and the HCF-1PRO repeat E10Q peptide (0.185 Å 
rmsd). We note that the density for the GlcNAc is poorer in this complex, which may be 
related to the reactivity of UDP-GlcNAc. 
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Fig. S10. A single amino acid substitution converts HCF-1 from a cleavage substrate 
into a glycosylation substrate of OGT. Full-size versions of the gels shown in Figure 
4D. (A) Coomassie stained SDS-PAGE gel of HCF3R constructs. Only the EAA with 
UDP-GlcNAc is cleaved. (B) Autoradiogram of HCF3R constructs incubated with OGT 
and 14C-UDP-GlcNAc. Only HCF3R-SAA is glycoslyated by OGT. 
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Fig. S11. Possible mechanisms for OGT cleavage of HCF-1. We speculate that 
cleavage occurs after formation of a glutamyl-sugar intermediate. After this initial step 
there are several ways this could proceed to cleavage. We outline 3 possible mechanisms 
here. Mechanisms 2 and 3 involve the C9 cysteine of the HCF-1PRO repeat through the 
formation of thioester intermediates. Other biological mechanisms with peptide backbone 
cleavage involve cysteines or pyroglutamate(23, 39). However, the fact that the C9 
cysteine residue is not essential for cleavage of HCF-1 (fig. S2 and ref. 12) supports the 
first mechanism, although other mechanisms are possible. 
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Supplementary Tables 
 
Table S1. Peptides used for crystallization in this study. 
 
 Peptide 1 
Name HCF-111-26 
Sequence THETGTTNTATTATSN 
  
 Peptide 2 
Name HCF-1-E10A1-26 
Sequence VRVCSNPPCATHETGTTNTATTATSN 
  
 Peptide 3 
Name HCF-1-E10Q1-26 
Sequence VRVCSNPPCQTHETGTTNTATTATSN 
  
 Peptide 4 
Name HCF-11-26 
Sequence VRVCSNPPCETHETGTTNTATTATSN 
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Table S2. X-ray Data collection and refinement statistics for crystal structures. 
 
 OGT:UDP: 
HCF-111-26  
Complex 
OGT:UDP: 
HCF-1-E10A1-26 
Complex 
OGT:UDP-
5SGlcNAc: HCF-1-
E10Q1-26  Complex 
OGT:UDP-GlcNAc: 
HCF-11-26  Complex 
Data 
collection 
    
Space group P3221 P6122 P6122 P6122 
Cell 
dimensions   
    
    a, b, c (Å) 101.17 101.17 
131.73 
98.93 98.93 
367.02 
98.91 98.91 364.93 98.88 98.88 
365.93 
    a, b, g  (°)  90.00 90.00 
120.00 
90.00 90.00 
120.00 
90.00 90.00 120.00 90.00 90.00 
120.00 
Resolution 
(Å) 
35.00 - 1.76 
(1.86 - 1.76) 
47.76 - 1.88 
(1.98 - 1.88) 
55.55 - 2.17 (2.29 - 
2.17) 
77.56 - 2.55 (2.69 
- 2.55) 
Rsym or Rmerge 0.093 (0.628) 0.087 (0.599) 0.123 (0.762) 0.151 (0.807) 
I / sI 9.1 (2.1) 7.3 (2.1) 11.5 (2.0) 6.0 (2.1) 
Completeness 
(%) 
99.6 (100.0) 95.0 (96.1) 99.9 (99.5) 96.1 (92.7) 
Redundancy 5.1 (5.2) 3.8 (3.8) 7.6 (4.7) 3.0 (3.1) 
     
Refinement     
Resolution 
(Å) 
33.12 - 1.76 45.86 - 1.88 49.59 - 2.17 62.51-2.55 
No. 
reflections 
77299 82481 56713 33941 
Rwork / Rfree 0.1872 / 0.2158 0.2158 / 0.2239  0.1922 / 0.2228 0.1837 / 0.2261 
No. atoms     
    Protein 5598 5610 5670 5663 
    Ligand/ion 25 25 39 39 
    Water 551 148 124 102 
B-factors     
    Protein 25.89 38.85 50.67 50.04 
    Ligand/ion 17.23 23.22 38.27 58.34 
    Water 35.53 33.51 46.78 45.21 
R.m.s. 
deviations 
    
    Bond 
lengths (Å) 
0.005 0.002 0.003 0.003 
    Bond 
angles (°) 
0.899 0.72 0.73 0.749 
*Values in parentheses are for highest-resolution shell. 
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